

CITATION REPORT

List of articles citing

Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia

DOI: [10.1182/blood.v94.6.1848](https://doi.org/10.1182/blood.v94.6.1848)
Blood, 1999, 94, 1848-1854.

Source: <https://exaly.com/paper-pdf/30045079/citation-report.pdf>

Version: 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2247	Mature B-cell leukemias. 171-190		
2246	Frequent occurrence of deletions and duplications during somatic hypermutation: implications for oncogene translocations and heavy chain disease. 1998 , 95, 2463-8		288
2245	Mutational Status of Ig VH Genes Provides Clinically Valuable Information in B-Cell Chronic Lymphocytic Leukemia. <i>Blood</i> , 1999 , 94, 1837-1839	2.2	48
2244	Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia. <i>Blood</i> , 1999 , 94, 1840-1847	2.2	2015
2243	Bibliography. Current world literature. Hematologic malignancies. 2000 , 7, B73-124		
2242	Clinical relevance of immunoglobulin mutation analysis. 2000 , 12, 395-402		6
2241	Lymphomas: complexity, not chaos. 2000 , 12, 379-82		2
2240	Chronic lymphocytic leukemia. 2000 , 7, 223-34		84
2239	Update on the biology of chronic lymphocytic leukemia. 2000 , 12, 22-9		66
2238	MUM1: a step ahead toward the understanding of lymphoma histogenesis. 2000 , 14, 563-6		62
2237	Identification of three subgroups of B cell chronic lymphocytic leukemia based upon mutations of BCL-6 and IgV genes. 2000 , 14, 811-5		42
2236	Historical aspects of chronic lymphocytic leukaemia. 2000 , 111, 1023-1034		
2235	Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia. 2000 , 111, 230-238		
2234	Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia. 2000 , 111, 608-617		
2233	Biology of chronic lymphocytic leukemia. 2000 , 4, 5-21		54
2232	Morphological and immunophenotypic features of chronic lymphocytic leukemia. 2000 , 4, 22-47		82
2231	Genetic features of B-cell chronic lymphocytic leukemia. 2000 , 4, 48-72		49

2230	New Concepts in the Pathogenesis, Diagnosis, Prognostic Factors and Clinical Presentation of Chronic Lymphocytic Leukemia. 2000 , 4, 103-117		7
2229	Hematopoietic Stem-Cell Transplantation for B-Cell Chronic Lymphocytic Leukemia: Current Status. 2000 , 4, 167-178		5
2228	[Small cell B-cell lymphomas: guidelines for differential diagnosis]. 2000 , 21, 147-61		3
2227	A more favourable clinical course of lymphoma relapsing after high-dose therapy: evidence of tumour heterogeneity?. 2000 , 17, 229-32		
2226	Somatic mutation of bcl-6 genes can occur in the absence of VH mutations in chronic lymphocytic leukemia. <i>Blood</i> , 2000 , 95, 3534-3540	2.2	39
2225	Salivary gland mucosa-associated lymphoid tissue lymphoma immunoglobulin VH genes show frequent use of V1-69 with distinctive CDR3 features. <i>Blood</i> , 2000 , 95, 3878-3884	2.2	104
2224	HFE polymorphism and accurate diagnosis of C282Y hereditary hemochromatosis carriers. <i>Blood</i> , 2000 , 95, 2453-2455	2.2	2
2223	Immunoglobulin V genes and CD38 expression in CLL. <i>Blood</i> , 2000 , 95, 2455-2457	2.2	137
2222	Expression of Ig- λ (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion. <i>Blood</i> , 2000 , 95, 2725-2727	2.2	12
2221	Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. <i>Blood</i> , 2000 , 96, 377-379	2.2	108
2220	High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. <i>Blood</i> , 2000 , 96, 1505-1511	2.2	135
2219	Neue Methoden in Diagnostik und Therapie: Kostensteigerung oder Kostenverminderung?. 2000 , 45-47		
2218	Biclonal chronic lymphocytic leukemia. 2000 , 113, 798-804		24
2217	Aberrant B cell receptor signaling from B29 (Igbeta, CD79b) gene mutations of chronic lymphocytic leukemia B cells. 2000 , 97, 5504-9		29
2216	Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. 2000 , 97, 10209-13		188
2215	When and how to treat chronic lymphocytic leukemia. 2000 , 343, 1799-801		106
2214	The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. 2000 , 79, 157-73		82
2213	Histological and immunoglobulin VH gene analysis of interfollicular small lymphocytic lymphoma provides evidence for two types. 2000 , 157, 1063-70		27

2212	White cells 2: impact of understanding the molecular basis of haematological malignant disorders on clinical practice. 2000 , 355, 1447-53		4
2211	Genomic aberrations and survival in chronic lymphocytic leukemia. 2000 , 343, 1910-6		2573
2210	CD40 ligand in CLL pathogenesis and therapy. <i>Leukemia and Lymphoma</i> , 2000 , 37, 461-72	1.9	46
2209	Lymphoid neoplasms. 2001 , 14, 609-30		6
2208	Achieving optimal outcomes in chronic lymphocytic leukaemia. 2001 , 61, 593-611		14
2207	CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2001 , 98, 181-6	2.2	348
2206	Adhesion molecule expression in CD5-negative/CD10-negative chronic B-cell leukemias: comparison with non-Hodgkin's lymphomas and CD5-positive B-cell chronic lymphocytic leukemia. 2001 , 32, 66-73		12
2205	Secondary ocular involvement in systemic "memory" B-cell lymphocytic leukemia. 2001 , 108, 1289-95		21
2204	How immunology is reshaping clinical disciplines: the example of haematology. 2001 , 358, 49-55		13
2203	CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2001 , 42, 109-14	1.9	72
2202	Immunophenotypic analysis of leukocytes in disease. 2001 , 138-164		
2201	Gene expression profiling in lymphoid malignancies. 2001 , 162-186		
2200	Chronic lymphocytic leukemia: case-based session. 2001 , 2001, 140-56		16
2199	Ordered recombination of immunoglobulin light chain genes occurs at the IGK locus but seems less strict at the IGL locus. <i>Blood</i> , 2001 , 97, 1001-8	2.2	59
2198	V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. <i>Blood</i> , 2001 , 97, 1023-6	2.2	161
2197	Common Germinal-Center B-Cell Origin of the Malignant Cells in Two Composite Lymphomas, Involving Classical Hodgkin's Disease and Either Follicular Lymphoma or B-CLL. 2001 , 7, 285-292		71
2196	Pathology and cytogenetics. 2001 , 12-18		
2195	Small lymphocytic lymphoma and its variants. 2001 , 141-153		

2194 Aktuelle Therapieergebnisse und Perspektiven mit Bendamustin. **2001**, 24, 1-2

2193 CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. *Blood*, **2001**, 97, 1892-4 2.2 112

2192 CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia. *Blood*, **2001**, 97, 1902-3.2 70

2191 Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol. *Blood*, **2001**, 97, 1929-36 2.2 19

2190 Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. *Blood*, **2001**, 97, 2777-83 2.2 280

2189 Survival of leukemic B cells promoted by engagement of the antigen receptor. *Blood*, **2001**, 98, 3050-7 2.2 162

2188 Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. *Blood*, **2001**, 98, 781-6 2.2 50

2187 Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing. *Blood*, **2001**, 98, 1174-81 2.2 70

2186 Clinical significance of CD38 expression in chronic lymphocytic leukemia. *Blood*, **2001**, 98, 2633-9 2.2 216

2185 The occurrence and significance of V gene mutations in B cell-derived human malignancy. **2001**, 83, 81-116 82

2184 Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. **2001**, 25, 1268-76 111

2183 Tumours of the Immune System. **2001**,

2182 Chronic lymphocytic leukaemia. **2001**, 1, 350-3

2181 Absence of clonal chromosomal relationship between concomitant B-CLL and multiple myeloma--a report on two cases. **2001**, 80, 474-8 30

2180 Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. **2001**, 115, 854-61 163

2179 Molecular abnormalities in B-cell chronic lymphocytic leukaemia. **2001**, 23, 139-48 4

2178 Pathology of lymphoma progression. **2001**, 38, 285-306 43

2177 Peripheral blood CD38 expression predicts survival in B-cell chronic lymphocytic leukemia. **2001**, 25, 927-32 45

2176	Lack of allelic exclusion and isotype switching in B cell chronic lymphocytic leukemia. 2001 , 68, 295-7		4
2175	New aspects on the pathogenesis, diagnostic procedures, and therapeutic management of chronic lymphocytic leukemia. 2001 , 73, 32-8		13
2174	Immunoglobulin variable region structure and B-cell malignancies. 2001 , 73, 47-53		5
2173	Molecular single-cell analysis of Hodgkin- and Reed-Sternberg cells harboring unmutated immunoglobulin variable region genes. 2001 , 81, 289-95		24
2172	Immunoglobulin lambda isotype gene rearrangements in B cell malignancies. 2001 , 15, 121-7		17
2171	Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive and -negative diffuse large B cell lymphoma. 2001 , 15, 452-7		21
2170	Molecular heterogeneity of splenic marginal zone lymphomas: analysis of mutations in the 5' non-coding region of the bcl-6 gene. 2001 , 15, 628-34		24
2169	Human CD38: a (r)evolutionary story of enzymes and receptors. 2001 , 25, 1-12		212
2168	The classification of lymphomas and leukemias. 2001 , 135-136, 653-64		10
2167	Telomerase regulation and telomere dynamics in germinal centers. <i>European Journal of Haematology</i> , 2001 , 67, 309-17	3.8	40
2166	Laboratory, morphologic, and immunophenotypic correlates of surface immunoglobulin heavy chain isotype expression in B-cell chronic lymphocytic leukemia. 2001 , 116, 905-12		8
2165	Association of CD38 antigen expression with other prognostic parameters in early stages of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2001 , 42, 1315-21	1.9	5
2164	Towards a molecular classification of hematolymphoid neoplasms: where are we now? Where are we going?. 2001 , 49, 1323-4		4
2163	Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cells. 2001 , 166, 95-102		59
2162	Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. 2001 , 194, 1639-47		882
2161	Somatic hypermutation and B-cell lymphoma. 2001 , 356, 73-82		26
2160	Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. 2001 , 194, 1625-38		731
2159	Absence of somatic hypermutation of immunoglobulin heavy chain variable region genes in precursor B-lymphoblastic lymphoma: a study of four cases in childhood and adolescence. 2001 , 116, 673-82		15

2158	Immunoglobulin heavy chain variable region (VH) genes of B cell chronic lymphocytic leukemia cells from lymph nodes show somatic mutations and intraclonal diversity irrespective of follicular dendritic cell network. <i>Leukemia and Lymphoma</i> , 2001 , 42, 499-506	1.9	7
2157	CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1855-8	1.9	34
2156	Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia. 2002 , 86, 31-5		37
2155	Chronic lymphocytic leukemia B cells can undergo somatic hypermutation and intraclonal immunoglobulin V(H)DJ(H) gene diversification. 2002 , 196, 629-39		78
2154	The configuration of the immunoglobulin genes in B cell chronic lymphocytic leukemia. 2002 , 16, 973-84		39
2153	Cleaved lymphocytes in chronic lymphocytic leukemia: a detailed retrospective analysis of diagnostic features. <i>Leukemia and Lymphoma</i> , 2002 , 43, 555-64	1.9	6
2152	Chronic lymphocytic leukemia. 2002 , 2002, 193-213		54
2151	B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. 2002 , 16, 911-9		109
2150	Lack of somatic hypermutation of IG V(H) genes in lymphoid malignancies with t(2;14)(p13;q32) translocation involving the BCL11A gene. 2002 , 16, 937-9		26
2149	Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. 2002 , 16, 985-92		87
2148	Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. 2002 , 29, 817-23		80
2147	CD5-induced apoptosis of B cells in some patients with chronic lymphocytic leukemia. 2002 , 16, 44-52		30
2146	CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. 2002 , 16, 30-5		181
2145	Immunoglobulin diversification in B cell malignancies: internal splicing of heavy chain variable region as a by-product of somatic hypermutation. 2002 , 16, 636-44		7
2144	The role of soluble CD23 in distinguishing stable and progressive forms of B-chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2002 , 43, 549-54	1.9	22
2143	ATM mutations in sporadic lymphoid tumours. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1563-71	1.9	66
2142	Immunophenotype does not correlate with lymph node histology in chronic lymphocytic leukemia/small lymphocytic lymphoma. 2002 , 26, 624-9		28
2141	Molecular diagnosis of lymphoid malignancies by gene expression profiling. 2002 , 9, 333-8		51

2140	Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. <i>Blood</i> , 2002 , 100, 635-9	2.2	263
2139	The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signaling for apoptosis. <i>Blood</i> , 2002 , 100, 3068-76	2.2	44
2138	Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. <i>Blood</i> , 2002 , 99, 300-9	2.2	121
2137	B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. <i>Blood</i> , 2002 , 99, 4087-93	2.2	259
2136	CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. <i>Blood</i> , 2002 , 99, 1023-9	2.2	512
2135	Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. <i>Blood</i> , 2002 , 99, 1299-304	2.2	138
2134	Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 99, 2262-4	2.2	263
2133	Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. <i>Blood</i> , 2002 , 99, 2562-8	2.2	202
2132	The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. <i>Blood</i> , 2002 , 99, 2977-84	2.2	168
2131	Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 100, 4671-5	2.2	47
2130	V(H) gene analysis of splenic marginal zone lymphomas reveals diversity in mutational status and initiation of somatic mutation in vivo. <i>Blood</i> , 2002 , 100, 2659-61	2.2	36
2129	Do B-cell chronic lymphocytic leukemia patients with Ig VH3-21 genes constitute a new subset of chronic lymphocytic leukemia?. <i>Blood</i> , 2002 , 100, 1097-8; author reply 1098-9	2.2	11
2128	Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. <i>Blood</i> , 2002 , 100, 2289-90	2.2	184
2127	CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not. <i>Blood</i> , 2002 , 100, 1100-1	2.2	40
2126	Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 100, 4609-14	2.2	407
2125	Erratum for vol. 100, p. 1404. <i>Blood</i> , 2002 , 100, 2291-2291	2.2	
2124	Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. 2002 , 16, 993-1007		197
2123	Gene expression profiling of lymphoid malignancies. 2002 , 53, 303-18		101

2122	Splenic marginal zone lymphomas appear to originate from different B cell types. 2002 , 161, 81-8		49
2121	Multicolor-FICTION: expanding the possibilities of combined morphologic, immunophenotypic, and genetic single cell analyses. 2002 , 161, 413-20		73
2120	VIII International Conference on Malignant Lymphoma: June 12-15, 2002, Lugano, Switzerland. 2002 , 3, 139-44		
2119	Monitoring disease in lymphoma and CLL patients using molecular techniques. 2002 , 15, 179-95		11
2118	Chronic lymphocytic leukaemia: a model for investigating potential new targets for the therapy of indolent lymphomas. 2002 , 15, 563-75		5
2117	Chronic Lymphocytic Leukemia. 2002 , 1, 127-143		
2116	Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 100, 1404-9	2.2	197
2115	A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2002 , 43, 2179-89	1.9	37
2114	Malignant B cells and antigenic receptor: necessity or habit?. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1383-90.9		2
2113	Chronic lymphocytic leukaemia: one cell, two diseases?. 2002 , 360, 184-6		3
2112	Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia. 2002 , 360, 1935-9		82
2111	The P2X7 receptor of CLL lymphocytes-a molecule with a split personality. 2002 , 360, 1898-9		17
2110	Most immunoglobulin heavy chain switch mu rearrangements in B-cell chronic lymphocytic leukemia are internal deletions. 2002 , 518, 119-23		10
2109	Practical evaluation and management of cutaneous lymphoma. 2002 , 46, 325-57; quiz, 358-60		71
2108	Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. <i>Blood</i> , 2002 , 100, 1177-1184	2.2	424
2107	V H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 100, 1410-1416	2.2	633
2106	Clonal relation in a case of CLL, ALCL, and Hodgkin composite lymphoma. <i>Blood</i> , 2002 , 100, 1425-1429	2.2	67
2105	Advances in classification and therapy of indolent B-cell malignancies. 2002 , 29, 98-104		17

2104	Clinical translation of gene expression profiling in lymphomas and leukemias. 2002 , 29, 258-63		39
2103	The clinical significance of CD8+ T cell subset abnormalities in common human malignancies. 2002 , 2, 141-154		
2102	Somatic hypermutation and V(H) gene usage in mantle cell lymphoma. <i>European Journal of Haematology</i> , 2002 , 68, 217-24	3.8	72
2101	Refining prognostic factors in chronic lymphocytic leukemia. 2002 , 6, 335-49; discussion 449-50		8
2100	B-chronic lymphocytic leukemia: practical aspects. 2002 , 20, 103-46		37
2099	Significance of phosphotyrosine proteins, Bcl-2 and p53 for apoptosis in resting B-chronic lymphocytic leukemia (CLL) cells. 2002 , 97, 344-8		7
2098	Mutation analysis of IgVH gene in B-cell chronic lymphocytic leukemia. 2002 , 22, 177-9, 182		
2097	No V(H) somatic hypermutation was detected in B-cells of a patient with macroglobulinemia due to splenic marginal zone lymphoma. 2002 , 76, 453-9		3
2096	Cytogenetic and FISH studies in myelodysplasia, acute myeloid leukemia, chronic lymphocytic leukemia and lymphoma. 2002 , 76 Suppl 2, 65-74		9
2095	[Pathogenesis and biology of leukemias]. 2002 , 43, 1179-89		0
2094	Chronic lymphocytic leukaemia: one disease or two?. 2002 , 81, 299-303		55
2093	Diagnostik und Therapie der chronisch-lymphatischen Leukämie. 2002 , 8, 708-720		
2092	CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. 2002 , 116, 142-50		92
2091	Symposium 6B: Unusual features of the bone marrow. 2002 , 41, 93-112		1
2090	Spontaneous clinical regression in chronic lymphocytic leukaemia. 2002 , 116, 341-345		28
2089	Quantification improves the prognostic value of CD38 expression in B-cell chronic lymphocytic leukaemia. 2002 , 118, 755-61		28
2088	Revised guideline on immunophenotyping in acute leukaemias and chronic lymphoproliferative disorders. 2002 , 24, 1-13		73
2087	Telomere length and heavy-chain T mutation status in familial chronic lymphocytic leukemia. 2002 , 26, 791-4		18

2086	MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). 2002 , 93, 685-94		24
2085	Immunoglobulin light chain gene rearrangements display hierarchy in absence of selection for functionality in precursor-B-ALL. 2002 , 16, 1448-53		20
2084	Do CLL B cells correspond to naive or memory B-lymphocytes? Evidence for an active Ig switch unrelated to phenotype expression and Ig mutational pattern in B-CLL cells. 2002 , 16, 2438-46		34
2083	Lymphoid malignancies: the dark side of B-cell differentiation. 2002 , 2, 920-32		310
2082	Quantitative analysis of Cyclin D1 and CD23 expression in mantle cell lymphoma and B-chronic lymphocytic leukemia. 2002 , 26, 809-15		13
2081	What are we learning from familial chronic lymphocytic leukemia?. 2002 , 26, 779-80		5
2080	DNA microarray analysis in malignant lymphomas. 2003 , 82, 323-32		20
2079	The classification of lymphomas: a new beginning or the end of an era?. 2003 , 30 Suppl 1, S13-8		2
2078	Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. <i>European Journal of Haematology</i> , 2003 , 70, 373-8	3.8	37
2077	Surface antigen expression and correlation with variable heavy-chain gene mutation status in chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2003 , 70, 53-9	3.8	20
2076	Richter syndrome in B-cell chronic lymphocytic leukemia. 2003 , 53, 195-203		31
2075	More extensive genetic alterations in unmutated than in hypermutated cases of chronic lymphocytic leukemia. 2003 , 37, 417-20		14
2074	Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia. 2003 , 97, 1914-9		23
2073	Thymic function and immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia patients. 2003 , 107, 958-61		8
2072	Pan B-cell markers are not redundant in analysis of chronic lymphocytic leukemia (CLL). 2003 , 56, 30-42		18
2071	Ex vivo drug and irradiation sensitivities in hypermutated and unmutated forms of chronic lymphocytic leukemia cells. 2003 , 27, 337-41		8
2070	Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. 2003 , 120, 452-6		57
2069	Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia. 2003 , 120, 1017-25		38

2068	Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. 2003 , 121, 287-95	176
2067	Mechanism of action of purine analogues in chronic lymphocytic leukaemia. 2003 , 121, 692-702	61
2066	The P2X7 receptor gene polymorphism 1513 A-->C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemia. 2003 , 123, 66-71	36
2065	Role of the microenvironment in chronic lymphocytic leukaemia. 2003 , 123, 380-8	143
2064	Anti-idiotype vaccines. 2003 , 123, 770-81	25
2063	Prolegomenon for chronic lymphocytic leukaemia. 2003 , 58, 588-600	7
2062	A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. 2003 , 17, 323-7	44
2061	Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. 2003 , 17, 133-7	46
2060	IL-4 and interferon gamma regulate expression of inducible nitric oxide synthase in chronic lymphocytic leukemia cells. 2003 , 17, 442-50	34
2059	Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. 2003 , 17, 841-8	165
2058	Incomplete DJH rearrangements of the IgH gene are frequent in multiple myeloma patients: immunobiological characteristics and clinical implications. 2003 , 17, 1398-403	31
2057	P2X7 polymorphism and chronic lymphocytic leukaemia: lack of correlation with incidence, survival and abnormalities of chromosome 12. 2003 , 17, 2097-100	40
2056	Unsolved issues in CLL biology and management. 2003 , 17, 2385-91	33
2055	B Cell Chronic Lymphocytic Leukemia. 2003 , 987, 302-304	
2054	Chronic lymphocytic leukemia (B-CLL) occurring with human immunodeficiency virus (HIV) infection: implications. 2003 , 27, 853-7	6
2053	The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype. 2003 , 27, 765-74	21
2052	Classification systems for acute and chronic leukaemias. 2003 , 16, 561-82	29
2051	Variations in ATM protein expression during normal lymphoid differentiation and among B-cell-derived neoplasias. 2003 , 163, 423-32	31

2050	Splenic marginal zone lymphoma with villous lymphocytes shows on-going immunoglobulin gene mutations. 2003 , 162, 681-9		34
2049	ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. 2003 , 348, 1764-75		1093
2048	B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. 2003 , 21, 841-94		294
2047	ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. 2003 , 17, 2426-34		179
2046	New insights into EBV-associated post-transplant lymphoproliferative disease. 2003 , 361, 192-3		4
2045	Towards molecular diagnosis and targeted therapy of lymphoid malignancies. 2003 , 40, 296-307		21
2044	[Genetic changes in chronic lymphocytic leukemia]. 2003 , 51, 366-74		2
2043	Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). <i>Blood</i> , 2003 , 101, 6-14	2.2	486
2042	Update in the pathologic features of mature B-cell and T/NK-cell leukemias. 2003 , 20, 180-95		2
2041	B-cell chronic lymphocytic leukaemia: a polymorphic family unified by genomic features. 2003 , 4, 505-14		25
2040	Molecular diagnosis of the hematologic cancers. 2003 , 348, 1777-85		162
2039	Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. <i>Blood</i> , 2003 , 102, 1035-41	2.2	70
2038	Correlation between cell size and CD38 expression in chronic lymphocytic leukaemia. <i>Leukemia and Lymphoma</i> , 2003 , 44, 797-800	1.9	18
2037	Monocyte-derived dendritic cells in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2003 , 44, 1267-73	1.9	5
2036	Biological and clinical heterogeneity of B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2003 , 44, 223-8	1.9	25
2035	Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. 2003 , 21, 2747-53		214
2034	Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. 2003 , 21, 3928-32		69
2033	Proteomic analysis of chronic lymphocytic leukemia subtypes with mutated or unmutated Ig V(H) genes. 2003 , 2, 1331-41		28

2032	Association between telomere length and V(H) gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications. 2003 , 88, 593-8		44
2031	Determining the clinical course and outcome in chronic lymphocytic leukemia. 2003 , 348, 1797-9		37
2030	Biology and treatment of chronic lymphocytic leukemia. 2003 , 2003, 153-75		85
2029	Chronic lymphocytic leukemia: advances in biology and therapeutics. 2003 , 15, 16-22		4
2028	Immunobiology of chronic lymphocytic leukemia. 2003 , 10, 312-8		16
2027	Role of autologous stem cell transplantation in chronic lymphocytic leukemia. 2003 , 10, 306-11		1
2026	Somatic hypermutation patterns in germinal center B cell malignancies. 2003 , 8, 319-28		7
2025	T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma. <i>Blood</i> , 2003 , 101, 4930-6	2.2	52
2024	CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes. <i>Blood</i> , 2003 , 101, 1962-9	2.2	113
2023	The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. <i>Blood</i> , 2003 , 101, 1262-9	2.2	204
2022	Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. <i>Blood</i> , 2003 , 101, 1087-93	2.2	253
2021	Features of the overexpressed V1-69 genes in the unmutated subset of chronic lymphocytic leukemia are distinct from those in the healthy elderly repertoire. <i>Blood</i> , 2003 , 101, 3082-4	2.2	60
2020	Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. <i>Blood</i> , 2003 , 101, 2748-55	2.2	68
2019	Chronic lymphocytic leukemia B cells expressing AID display dissociation between class switch recombination and somatic hypermutation. <i>Blood</i> , 2003 , 101, 4029-32	2.2	95
2018	ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. <i>Blood</i> , 2003 , 101, 4944-51	2.2	650
2017	Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. <i>Blood</i> , 2003 , 101, 4047-54	2.2	93
2016	Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. <i>Blood</i> , 2003 , 101, 4952-7	2.2	258
2015	CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. <i>Blood</i> , 2003 , 102, 2146-55	2.2	145

2014	Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone. <i>Blood</i> , 2003 , 102, 3333-9	2.2	111
2013	Lymphoid malignancies: immunophenotypic analysis. 2003 , 37, 293-353		0
2012	Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. <i>Blood</i> , 2003 , 101, 2049-53	2.2	102
2011	Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. <i>Blood</i> , 2003 , 101, 4042-6	2.2	109
2010	VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. <i>Blood</i> , 2003 , 102, 3003-9	2.2	122
2009	Divergence from the germ-line sequence in unmutated chronic lymphocytic leukemia is due to somatic mutation rather than polymorphisms. <i>Blood</i> , 2003 , 102, 3075	2.2	20
2008	A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. <i>Blood</i> , 2003 , 101, 4975-81	2.2	241
2007	High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. <i>Blood</i> , 2003 , 101, 4903-8	2.2	121
2006	Molecular detection of the G(-248)A BAX promoter nucleotide change in B cell chronic lymphocytic leukaemia. 2003 , 56, 205-9		17
2005	Immunoglobulin heavy- and light-chain repertoire in splenic marginal zone lymphoma. 2004 , 10, 89-95		37
2004	Dendritic cells from chronic lymphocytic leukemia patients are normal regardless of Ig V gene mutation status. 2004 , 10, 96-103		5
2003	Variability in the degree of expression of phosphorylated I κ B α in chronic lymphocytic leukemia cases with nodal involvement. 2004 , 10, 6796-806		35
2002	Allelotyping in B-cell chronic lymphocytic leukemia (B-CLL). <i>Leukemia and Lymphoma</i> , 2004 , 45, 887-96	1.9	1
2001	Similar humoral immunity parameters in chronic lymphocytic leukemia patients independent of VH gene mutation status. <i>Leukemia and Lymphoma</i> , 2004 , 45, 2451-4	1.9	19
2000	Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. 2004 , 101, 3118-23		339
1999	Principles of Molecular Oncology. 2004 ,		6
1998	Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. 2004 , 200, 519-25		331
1997	Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells: a meta-analysis of three microarray studies. 2004 , 20, 3166-78		99

1996	Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. 2004 , 22, 3937-49		177
1995	Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. 2004 , 76, 462-71		126
1994	Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. 2004 , 64, 9172-9		144
1993	Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia. 2004 , 9, 387-400		42
1992	Human B lymphocyte malignancies: exploitation of BLYS and APRIL and their receptors. 2005 , 8, 266-88		32
1991	A set of commercially available fluorescent in-situ hybridization probes efficiently detects cytogenetic abnormalities in patients with chronic lymphocytic leukemia. 2004 , 6, 48-53		26
1990	Clinical Significance of Cytogenetics in Multiple Myeloma and Chronic Lymphocytic Leukemia. 2004 , 35, 685-692		
1989	Abstracts. 2004 , 22, 1-111		
1988	Characterization of Incidentally Identified Minute Clonal B-Lymphocyte Populations in Peripheral Blood and Bone Marrow. 2004 , 122, 588-595		17
1987	Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. 2004 , 101, 1039-44		206
1986	Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status. <i>Leukemia and Lymphoma</i> , 2004 , 45, 2037-45	1.9	33
1985	Assessing prognosis in patients with chronic lymphocytic leukemia a quarter of a century after Rai and Binet staging systems. 2004 , 15, 1450-1		7
1984	The Natural History of CLL. 2004 , 3-54		1
1983	Chronic lymphocytic leukaemia: new biological markers for assessing prognosis. 2004 , 5, 197-201		5
1982	Treatment options in chronic lymphocytic leukemia. 2004 , 5 Suppl 1, S2-9		9
1981	CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. 2004 , 5, 145-51		43
1980	Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. 2004 , 125, 294-317		112
1979	Analysis of IgV gene mutations in B cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery. 2004 , 126, 29-42		51

1978	IgV gene intracloal diversification and clonal evolution in B-cell chronic lymphocytic leukaemia. 2006 , 133, 50-8		16
1977	Novel molecular diagnostic and therapeutic targets in chronic lymphocytic leukaemia. 2004 , 34 Suppl 2, 25-30		7
1976	Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant?. 2004 , 34, 289-97		13
1975	Tools for molecular risk-stratification for clinical purposes: CLL as a prototype. 2004 , 12, 423		4
1974	Relationship between the mutational status of VH genes and pathogenesis of diffuse large B-cell lymphoma in Richter's syndrome. 2004 , 18, 326-30		45
1973	High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia. 2004 , 18, 756-62		69
1972	Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. 2004 , 18, 747-55		119
1971	Bcl-6 mutation status provides clinically valuable information in early-stage B-cell chronic lymphocytic leukemia. 2004 , 18, 743-6		14
1970	Revisiting the definition of somatic mutational status in B-cell tumors: does 98% homology mean that a V(H)-gene is unmutated?. 2004 , 18, 882-3		18
1969	Prognostic impact of p27KIP1 expression in cyclin D1 positive lymphoproliferative disorders. 2004 , 18, 953-61		16
1968	Variant t(2;11)(p11;q13) associated with the IgK-CCND1 rearrangement is a recurrent translocation in leukemic small-cell B-non-Hodgkin lymphoma. 2004 , 18, 1705-10		42
1967	Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. 2004 , 18, 1637-45		77
1966	Methylenetetrahydrofolate reductase (MTHFR) gene 677C>T and 1298A>C polymorphisms are associated with differential apoptosis of leukemic B cells in vitro and disease progression in chronic lymphocytic leukemia. 2004 , 18, 1816-23		25
1965	Evidence of biased immunoglobulin variable gene usage in highly stable B-cell chronic lymphocytic leukemia. 2004 , 18, 1941-7		34
1964	Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. 2004 , 17, 954-61		91
1963	VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia. <i>European Journal of Haematology</i> , 2004 , 73, 407-11	3.8	10
1962	Molecular cytogenetic abnormalities in patients with concurrent chronic lymphocytic leukemia and multiple myeloma shown by interphase fluorescence in situ hybridization: evidence of distinct clonal origin. 2004 , 148, 44-8		23
1961	Functional evaluation of the role of inhibitor of apoptosis proteins in chronic lymphocytic leukemia. 2004 , 32, 556-62		20

1960	Different gene expression in immunoglobulin-mutated and immunoglobulin-unmutated forms of chronic lymphocytic leukemia. 2004 , 153, 69-72		30
1959	Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia. 2004 , 6, 348-54		8
1958	Quantitative analysis of DNA methylation in chronic lymphocytic leukemia patients. 2004 , 25, 1530-5		46
1957	The clinical significance of large cells in bone marrow in patients with chronic lymphocytic leukemia. 2004 , 100, 2167-75		13
1956	Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. 2004 , 101, 999-1008		64
1955	Albumin enhanced morphometric image analysis in CLL. 2004 , 57, 7-14		13
1954	CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes. 2004 , 109, 402-11		69
1953	Biallelic IgH rearrangements in patients with indolent lymphoproliferative disorders: molecular and practical implications. 2004 , 199, 217-26		7
1952	Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis. 2004 , 28, 845-50		24
1951	V(H)3-21 gene usage in chronic lymphocytic leukemia--characterization of a new subgroup with distinct molecular features and poor survival. <i>Leukemia and Lymphoma</i> , 2004 , 45, 221-8	1.9	32
1950	The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B-CLL). <i>Leukemia and Lymphoma</i> , 2004 , 45, 455-62	1.9	33
1949	Quantification of CD38 expression in B-cell chronic lymphocytic leukemia (B-CLL): a comparison between antibody binding capacity (ABC) and relative median fluorescence (RMF). <i>Leukemia and Lymphoma</i> , 2004 , 45, 1167-73	1.9	3
1948	Chronic lymphocytic leukemia: revelations from the B-cell receptor. <i>Blood</i> , 2004 , 103, 4389-95	2.2	322
1947	Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. <i>Blood</i> , 2004 , 104, 2499-504	2.2	200
1946	hTERT expression and prognosis in B-chronic lymphocytic leukemia. 2004 , 15, 1476-80		35
1945	Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. <i>Blood</i> , 2004 , 103, 1202-10	2.2	195
1944	CD38 autoimmunity: recent advances and relevance to human diabetes. 2004 , 27, 695-707		17
1943	Histopathology of B-cell chronic lymphocytic leukemia. 2004 , 18, 807-26, viii		6

1942	Current guidelines in defining therapeutic strategies. 2004 , 18, 881-93, ix	3
1941	Molecular genetics and its clinical relevance. 2004 , 18, 827-48, viii	16
1940	Perspectives in chronic lymphocytic leukemia biology and management. 2004 , 18, 927-43, x	3
1939	[Applications of molecular biology to care of patients with malignant hematological disease]. 2004 , 62, 401-20	1
1938	Role of auto- and allotransplantation in B-cell chronic lymphocytic leukemia. 2004 , 18, 915-26, x	11
1937	Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma. 2004 , 79, 318-25	69
1936	Current approach to diagnosis and management of chronic lymphocytic leukemia. 2004 , 79, 388-98	24
1935	Routine analysis of IgVH mutational status in CLL patients using BIOMED-2 standardized primers and protocols. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1899-904	1.9 45
1934	Mutational status of IgVH genes consistent with antigen-driven selection but not percent of mutations has prognostic impact in B-cell chronic lymphocytic leukemia. 2004 , 5, 123-6	8
1933	Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. 2004 , 64, 2424-33	120
1932	The nature and origin of the B-chronic lymphocytic leukemia cell: a tentative model. 2004 , 18, 849-62, viii	11
1931	Molecular genetic analysis in the assessment of lymphomas. 2004 , 10, 351-359	1
1930	Recent advances in understanding small B-cell leukaemias and lymphomas. 2004 , 10, 374-384	3
1929	Microenvironmental interactions and survival of CLL B-cells. <i>Leukemia and Lymphoma</i> , 2004 , 45, 2365-72	1.9 109
1928	Clinical staging and prognostic markers in chronic lymphocytic leukemia. 2004 , 18, 795-805, vii	19
1927	Molecular methods to distinguish reactive and neoplastic lymphocyte expansions and their importance in transitional neoplastic states. 2004 , 33, 196-207	40
1926	ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. 2004 , 351, 893-901	754
1925	Novel therapies for chronic lymphocytic leukemia. 2004 , 18, 137-48	26

1924	Clonal lymphocytes in persons without known chronic lymphocytic leukemia (CLL): implications of recent findings in family members of CLL patients. 2004 , 41, 192-200		15
1923	Recent advances in the molecular biology and immunobiology of chronic lymphocytic leukemia. 2004 , 41, 207-23		28
1922	The role of stem cell transplantation in chronic lymphocytic leukemia. 2004 , 41, 246-53		9
1921	ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. 2004 , 363, 105-11		465
1920	Small Lymphocytic Lymphoma. 2004 , 9, 214-220		
1919	Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells. 2004 , 9, 279-86		20
1918	Prognostic factors in B-CLL. 2004 , 11, 172-173		
1917	A National Data Base for Prostate Cancer. 2004 , 11, 172		
1916	EpsteinBarr Virus may have a role in progression of thyroid carcinoma. 2004 , 11, 173		
1915	Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. <i>Blood</i> , 2004 , 103, 291-300	2.2	88
1914	Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. <i>Blood</i> , 2004 , 103, 375-82	2.2	152
1913	Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs. <i>Blood</i> , 2004 , 103, 1855-61	2.2	38
1912	Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. <i>Blood</i> , 2004 , 104, 1428-34	2.2	115
1911	The pattern and distribution of immunoglobulin VH gene mutations in chronic lymphocytic leukemia B cells are consistent with the canonical somatic hypermutation process. <i>Blood</i> , 2004 , 103, 3490-5	2.2	63
1910	The cycling history of CLL. <i>Blood</i> , 2004 , 103, 367-367	2.2	2
1909	Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. <i>Blood</i> , 2004 , 103, 3278-81	2.2	334
1908	Utilization of Ig heavy chain variable, diversity, and joining gene segments in children with B-lineage acute lymphoblastic leukemia: implications for the mechanisms of VDJ recombination and for pathogenesis. <i>Blood</i> , 2004 , 103, 4602-9	2.2	34
1907	Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. <i>Blood</i> , 2004 , 104, 2600-2	2.2	139

1906	Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. <i>Blood</i> , 2004 , 104, 2879-85	2.2	216
1905	Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch. <i>Blood</i> , 2004 , 104, 3312-7	2.2	78
1904	CLL: to mend it or be rid of it. <i>Blood</i> , 2004 , 104, 2210-2210	2.2	
1903	Stem cell expansion: success and complexities. <i>Blood</i> , 2004 , 104, 2210-2211	2.2	5
1902	Advances in the diagnosis and classification of chronic lymphoproliferative disorders. 2004 , 121, 145-65		5
1901	Clinical Flow Cytometry. 2004 , 239-257		1
1900	New developments in the diagnosis, prognosis and treatment of chronic lymphocytic leukemia. 2005 , 17, 597-604		17
1899	Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. 2005 , 115, 1636-43		248
1898	CD38 as a prognostic marker in CLL. 2005 , 10, 39-46		45
1897	CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. <i>Blood</i> , 2005 , 105, 3042-50	2.2	161
1896	Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. <i>Blood</i> , 2005 , 105, 49-53	2.2	349
1895	Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations. <i>Blood</i> , 2005 , 105, 767-74	2.2	66
1894	ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. <i>Blood</i> , 2005 , 105, 2036-41	2.2	205
1893	Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. <i>Blood</i> , 2005 , 105, 2099-106	2.2	38
1892	Deregulated expression of the Myc cellular oncogene drives development of mouse "Burkitt-like" lymphomas from naive B cells. <i>Blood</i> , 2005 , 105, 2135-7	2.2	33
1891	Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. <i>Blood</i> , 2005 , 105, 1678-85	2.2	168
1890	Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. <i>Blood</i> , 2005 , 105, 4820-7	2.2	208
1889	The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. <i>Blood</i> , 2005 , 106, 650-7	2.2	113

1888	Lower levels of surface B-cell-receptor expression in chronic lymphocytic leukemia are associated with glycosylation and folding defects of the mu and CD79a chains. <i>Blood</i> , 2005 , 105, 2933-40	2.2	53
1887	Different isoforms of BSAP regulate expression of AID in normal and chronic lymphocytic leukemia B cells. <i>Blood</i> , 2005 , 105, 2495-503	2.2	30
1886	Distinctive gene expression pattern in VH3-21 utilizing B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2005 , 106, 681-9	2.2	38
1885	Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. <i>Blood</i> , 2005 , 105, 4807-12	2.2	110
1884	Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. <i>Blood</i> , 2005 , 106, 3175-82	2.2	189
1883	Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. <i>Blood</i> , 2005 , 106, 4389-96	2.2	182
1882	Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. <i>Blood</i> , 2005 , 105, 2007-15	2.2	76
1881	ZAP-70 staining in chronic lymphocytic leukemia. 2005 , Chapter 6, Unit 6.19		2
1880	Heterogeneous somatic hypermutation status confounds the cell of origin in hairy cell leukemia. 2005 , 29, 153-8		35
1879	Transcriptional profiling and assessment of cell lines as in vitro models for mantle cell lymphoma. 2005 , 29, 205-13		16
1878	B-chronic lymphocytic leukemia cells exert an in vitro cytotoxicity mediated by tumor necrosis factor alpha. 2005 , 29, 829-39		6
1877	Microarray-based gene expression profiling of hematologic malignancies: basic concepts and clinical applications. 2005 , 19, 223-34		39
1876	B-cell chronic lymphocytic leukemia, a clonal disease of B lymphocytes with receptors that vary in specificity for (auto)antigens. 2005 , 1062, 1-12		47
1875	Prognostic usage of V(H) gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia. 2005 , 22, 217-28		21
1874	Immunoglobulin gene analysis of mature B-cell malignancies: reconsideration of cellular origin and potential antigen involvement in pathogenesis. 2005 , 22, 327-41		25
1873	CD5+ diffuse large B-cell lymphoma consists of germline cases and hypermutated cases in the immunoglobulin heavy chain gene variable region. 2005 , 81, 58-61		4
1872	Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. 2005 , 114, 441-9		122
1871	Stem cell transplantation for chronic lymphocytic leukaemia. 2005 , 128, 145-52		25

1870	Unique gene expression and clinical characteristics are associated with the 11q23 deletion in chronic lymphocytic leukaemia. 2005 , 128, 460-71	19
1869	p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV. 2005 , 129, 53-9	30
1868	Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia. 2005 , 129, 499-510	41
1867	The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. 2005 , 130, 549-57	45
1866	Differential expression of CD 180 and IgM by B-cell chronic lymphocytic leukaemia cells using mutated and unmutated immunoglobulin VH genes. 2005 , 131, 313-9	26
1865	Comparison of flow cytometric methods for the measurement of ZAP-70 expression in a routine diagnostic laboratory. 2005 , 27, 258-66	44
1864	Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. 2005 , 36, 825-30	67
1863	Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. 2005 , 12, 773-82	128
1862	Translocation t(1;6)(p35.3;p25.2): a new recurrent aberration in "unmutated" B-CLL. 2005 , 19, 77-82	22
1861	Role of B-cell antigen receptor-associated molecules and lipid rafts in CD5-induced apoptosis of B CLL cells. 2005 , 19, 223-9	22
1860	Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. 2005 , 19, 427-34	77
1859	Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. 2005 , 19, 750-8	175
1858	Mcl-1 gene promoter insertions do not correlate with disease outcome, stage or VH gene mutation status in chronic lymphocytic leukaemia. 2005 , 19, 871-3	18
1857	Analysis of VH gene sequences using two web-based immunogenetics resources gives different results, but the affinity maturation status of chronic lymphocytic leukaemia clones as assessed from either of the resulting data sets has no prognostic significance. 2005 , 19, 741-9	7
1856	ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype. 2005 , 19, 1018-24	69
1855	Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. 2005 , 19, 1029-33	135
1854	High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. 2005 , 19, 1216-23	118
1853	T-cell ZAP-70 overexpression in chronic lymphocytic leukemia (CLL) correlates with CLL cell ZAP-70 levels, clinical stage and disease progression. 2005 , 19, 1289-91	21

1852	Gene expression profiling of chronic lymphocytic leukemia can discriminate cases with stable disease and mutated Ig genes from those with progressive disease and unmutated Ig genes. 2005 , 19, 2002-5	31
1851	Incidence of chromosomal anomalies detected with FISH and their clinical correlations in B-chronic lymphocytic leukemia. 2005 , 160, 27-34	28
1850	Mitogen induced activation, proliferation and surface antigen expression patterns in unmutated and hypermutated chronic lymphocytic leukemia cells. <i>European Journal of Haematology</i> , 2005 , 75, 34-40 ^{3,8}	3
1849	Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance. 2005 , 305, 20-32	14
1848	Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling. 2005 , 204, 113-23	28
1847	Advances in the diagnosis and treatment of chronic lymphocytic leukemia. 2005 , 23, 34-40	4
1846	High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia. 2005 , 113, 730-7	63
1845	Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. 2005 , 104, 2124-32	58
1844	The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. 2005 , 104, 2743-52	43
1843	[Basics of molecular diagnostics and therapy of malignant tumors]. 2005 , 46, 835-6, 838-42, 844-6	0
1842	Excellent response of chemotherapy-resistant B-cell-type chronic lymphocytic leukemia with meningeal involvement to rituximab. 2005 , 10, 357-61	20
1841	Genetics and molecular biology of chronic lymphocytic leukemia. 2005 , 6, 215-25	12
1840	A population-based assessment of the prognostic value of the CD19 positive lymphocyte count in B-cell chronic lymphocytic leukemia using Cox and Markov models. 2005 , 20, 993-1001	2
1839	Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. 2005 , 205, 507-13	62
1838	SAIVGeM: spreadsheet analysis of immunoglobulin VH gene mutations. 2005 , 39, 353-8	3
1837	Cytogenetics of Hematologic Neoplasms. 2005 , 365-420	1
1836	3 Allgemeine Pathogenese. 2005 ,	
1835	B-cell receptor translocation to lipid rafts and associated signaling differ between prognostically important subgroups of chronic lymphocytic leukemia. 2005 , 65, 7328-37	52

1834	Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. 2005 , 23, 3433-8		116
1833	Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. 2005 , 23, 3780-92		60
1832	What do somatic hypermutation and class switch recombination teach us about chronic lymphocytic leukaemia pathogenesis?. 2005 , 294, 71-89		15
1831	The immunoglobulin genes and chronic lymphocytic leukemia (CLL). 2005 , 110, 97-113		8
1830	Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. 2005 , 201, 1229-41		171
1829	Revisiting the role of hematopoietic stem cell transplantation in chronic lymphocytic leukemia. 2005 , 5, 875-91		
1828	Identification and assembly of V genes as idiotype-specific DNA fusion vaccines in multiple myeloma. 2005 , 113, 105-19		3
1827	The Principles of Clinical Cytogenetics. 2005 ,		25
1826	A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2005 , 46, 553-60	1.9	19
1825	Functional and prognostic role of ZAP-70 in chronic lymphocytic leukaemia. 2005 , 9, 1165-78		15
1824	TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. 2005 , 23, 3877-85		78
1823	Determining mutational status of immunoglobulin v genes in chronic lymphocytic leukemia: a useful prognostic indicator. 2005 , 115, 129-44		3
1822	Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. 2005 , 23, 3819-29		191
1821	B cell response to surface IgM cross-linking identifies different prognostic groups of B-chronic lymphocytic leukemia patients. 2005 , 174, 3749-56		49
1820	Genotypic prognostic markers. 2005 , 294, 147-64		8
1819	Immunoglobulin light chain repertoire in chronic lymphocytic leukemia. <i>Blood</i> , 2005 , 106, 3575-83	2.2	78
1818	Activation-induced cytidine deaminase and CD38 expression in B-cell chronic lymphocytic leukemia. 2005 , 6, 251-2		3
1817	Biological validation of differentially expressed genes in chronic lymphocytic leukemia identified by applying multiple statistical methods to oligonucleotide microarrays. 2005 , 7, 337-45		13

1816	Immunoglobulin mutational status detected through single-round amplification of partial V(H) region represents a good prognostic marker for clinical outcome in chronic lymphocytic leukemia. 2005 , 7, 566-74		11
1815	Lymphoma. 2005 ,		
1814	Cytogenetic testing for therapeutic indication in cancer. 2005 , 5, 23-9		
1813	ZAP-70 in B cell malignancies. <i>Leukemia and Lymphoma</i> , 2005 , 46, 1689-98	1.9	24
1812	Economic assessment on the management of chronic lymphocytic leukaemia. 2005 , 6, 1179-89		5
1811	Cyclin D expression in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2005 , 46, 1275-85	1.9	10
1810	Touch-down reverse transcriptase-PCR detection of IgV(H) rearrangement and Sybr-Green-based real-time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia. 2005 , 9, 23-34		14
1809	Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated. 2005 , 23, 1514-21		65
1808	CLL biology and prognosis. 2005 , 2005, 278-84		44
1807	Clonal proliferation of cyclin D1-positive mantle lymphocytes in an asymptomatic patient: an early-stage event in the development or an indolent form of a mantle cell lymphoma?. 2005 , 36, 1232-7		37
1806	Chronic lymphocytic leukemia: a review of some new aspects of the biology, factors influencing prognosis and therapeutic options. 2005 , 32, 85-97		16
1805	The emerging role of alemtuzumab in chronic lymphocytic leukemia. 2005 , 6, 115-21		9
1804	VH gene analysis of primary CNS lymphomas. 2005 , 228, 143-7		22
1803	A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. 2005 , 353, 1793-801		2041
1802	Multiple Myeloma. 2005 ,		1
1801	Chronic lymphocytic leukemia. 2005 , 352, 804-15		1261
1800	Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1053-61	1.9	46
1799	Recent advances in chronic lymphocytic leukemia. 2006 , 24, 302-9		5

1798	CD38 expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006 , 47, 2371-9	1.9	26
1797	Chronic lymphocytic leukemia with osteolytic Richter's syndrome mimicking myeloma bone disease shows no over-expression of DKK1. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1987-8	1.9	4
1796	Serum levels of syndecan-1 in B-cell chronic lymphocytic leukemia: correlation with the extent of angiogenesis and disease-progression risk in early disease. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1034-40	1.9	11
1795	Prognostic factors in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006 , 47, 2261-2	1.9	6
1794	11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules. <i>Leukemia and Lymphoma</i> , 2006 , 47, 231-44	1.9	25
1793	Update on risk-stratified management for chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1738-46	1.9	19
1792	Evaluation of clinical staging in chronic lymphocytic leukemia- population-based study. <i>Leukemia and Lymphoma</i> , 2006 , 47, 2505-16	1.9	13
1791	The influence of pregnancy on the development of autoimmunity in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1481-7	1.9	5
1790	Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2006 , 108, 853-61	2.2	155
1789	Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. 2006 , 24, 4634-41		208
1788	Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. 2006 , 24, 437-43		212
1787	Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. <i>Blood</i> , 2006 , 107, 2889-94	2.2	149
1786	Chronic lymphocytic leukemia: diagnosis and treatment. 2006 , 81, 1105-29		49
1785	Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance. 2006 , 4, 11		7
1784	Pathology of B-cell non-Hodgkin's lymphomas and multiple myeloma. 2006 , 131, 1-48		1
1783	Monoclonal antibody combinations in CLL: evolving strategies. 2006 , 19, 781-93		6
1782	Discovery and identification of potential biomarkers in a prospective study of chronic lymphoid malignancies using SELDI-TOF-MS. 2006 , 5, 2258-69		41
1781	Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression. 2006 , 66, 7158-66		77

1780	Hodgkin's disease variant of Richter's syndrome clonally related to chronic lymphocytic leukemia arises in ZAP-70 negative mutated CLL. 2006 , 66, 577-9		18
1779	Cloning and molecular characterization of a human recombinant IgG Fab binding to the Tat protein of human immunodeficiency virus type 1 (HIV-1) derived from the repertoire of a seronegative patient. 2006 , 43, 1363-9		3
1778	The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma. 2006 , 37, 152-9		65
1777	Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70). 2006 , 37, 1153-61		17
1776	Genomic profiling in clinical oncology. The predictive value of genomic information in cancer management. 2006 , 119, 56-61		1
1775	Classification and Histopathology of the Lymphomas. 2006 , 2-38		4
1774	Similarities and differences between the light and heavy chain Ig variable region gene repertoires in chronic lymphocytic leukemia. 2006 , 12, 300-8		18
1773	A novel gene for an old disease. <i>Blood</i> , 2006 , 107, 2594-2594	2.2	2
1772	Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. <i>Blood</i> , 2006 , 107, 2090-3	2.2	46
1771	ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). <i>Blood</i> , 2006 , 107, 3584-92	2.2	154
1770	ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications. <i>Blood</i> , 2006 , 107, 197-204	2.2	25
1769	Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. <i>Blood</i> , 2006 , 107, 742-51	2.2	230
1768	Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia. <i>Blood</i> , 2006 , 108, 1001-6	2.2	19
1767	Identification of a gene on chromosome 12q22 uniquely overexpressed in chronic lymphocytic leukemia. <i>Blood</i> , 2006 , 107, 2904-11	2.2	47
1766	In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. <i>Blood</i> , 2006 , 108, 1135-44	2.2	120
1765	FIXing hemophilia B with gene therapy. <i>Blood</i> , 2006 , 107, 2593-2594	2.2	
1764	Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. <i>Blood</i> , 2006 , 108, 3152-60	2.2	181
1763	Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. <i>Blood</i> , 2006 , 108, 2950-6	2.2	27

1762 Chronic lymphoproliferative disorders and malignant lymphoma. 93-109

1761 Chronic Lymphocytic Leukemia (CLL). **2006**,

1760 Leucémie lymphoïde chronique. **2006**, 1, 1-12

1759 Genetics, gene expression, and targeted therapies in chronic lymphocytic leukemia. **2006**, 7, 1313-27

7

1758 Role of allogeneic transplantation in low-grade lymphoma and chronic lymphocytic leukemia. **2006**, 13, 273-9

4

1757 Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia. **2006**, 13, 266-72

13

1756 Pattern and distribution of immunoglobulin VH gene usage in a cohort of B-CLL patients from a Northeastern region of Italy. **2006**, 15, 206-15

13

1755 Immunoglobulin VH genes in thymic MALT lymphoma are biased toward a restricted repertoire and are frequently unmutated. **2006**, 208, 415-22

21

1754 Proteomic analysis of malignant lymphocyte membrane microparticles using double ionization coverage optimization. **2006**, 6, 153-71

108

1753 Leucémie lymphoïde chronique: Biologie et pronostic. **2006**, 2006, 37-43

0

1752 Somatic hypermutation and VH gene usage in hairy cell leukaemia. **2006**, 133, 504-12

34

1751 Plasma as a source of mRNA for determining IgV(H) mutation status in patients with chronic lymphocytic leukaemia. **2006**, 133, 690-2

7

1750 Immunoglobulin VH somatic hypermutation in mantle cell lymphoma: mutated genotype correlates with better clinical outcome. **2006**, 19, 1498-505

26

1749 Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: the Finnish experience. **2006**, 37, 1093-8

29

1748 The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia. **2006**, 20, 77-81

29

1747 High Mda-7 expression promotes malignant cell survival and p38 MAP kinase activation in chronic lymphocytic leukemia. **2006**, 20, 498-504

33

1746 Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL. **2006**, 20, 514-20

36

1745 Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. **2006**, 20, 1080-8

53

1744	IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). 2006 , 20, 1231-7		48
1743	Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status. 2006 , 20, 1774-82		64
1742	The role of microRNAs in normal hematopoiesis and hematopoietic malignancies. 2006 , 20, 1931-6		86
1741	Distinctive immunoglobulin VH gene usage in Japanese patients with chronic lymphocytic leukemia. 2006 , 30, 272-6		21
1740	Nocodazole, a microtubule de-polymerising agent, induces apoptosis of chronic lymphocytic leukaemia cells associated with changes in Bcl-2 phosphorylation and expression. 2006 , 30, 427-36		41
1739	Is chronic lymphocytic leukemia a response to infectious agents?. 2006 , 30, 1063-4		12
1738	High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission. 2006 , 23, 359-68		4
1737	Chronische lymphatische Leukämie. 2006 , 12, 1030-1038		1
1736	Immunotherapy in chronic lymphocytic leukemia. 2006 , 55, 185-7		1
1735	Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells. 2006 , 85, 458-62		10
1734	Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: A methodological approach. 2006 , 85, 795-805		7
1733	[DNA-chips in the diagnosis of hematological malignancies]. 2006 , 47, 39-46		0
1732	Bortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations. 2006 , 8, 805-11		4
1731	New agents in chronic lymphocytic leukemia. 2006 , 7, 200-12		10
1730	New aspects of the treatment of chronic lymphocytic leukemia. 2006 , 1, 251-7		
1729	Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression. <i>European Journal of Haematology</i> , 2006 , 76, 51-7	3.8	9
1728	Mutational and methylation analysis of the cyclin-dependent kinase 4 inhibitor (p16INK4A) gene in chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2006 , 76, 230-6	3.8	13
1727	ZAP-70 mRNA quantification in B-cell chronic lymphocytic leukaemia. <i>European Journal of Haematology</i> , 2006 , 76, 294-8	3.8	32

1726	Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression. <i>European Journal of Haematology</i> , 2006 , 77, 309-17	3.8	25
1725	Burkitt t(8;14)(q24;q32) and cryptic deletion in a CLL patient: report of a case and review of literature. 2006 , 166, 12-21		12
1724	Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis. 2006 , 168, 109-19		38
1723	Genetic abnormalities and clinical outcome in chronic lymphocytic leukemia. 2006 , 171, 57-64		50
1722	Epigenetics in chronic lymphocytic leukemia. 2006 , 33, 157-66		32
1721	The origin of B-cell chronic lymphocytic leukemia. 2006 , 33, 150-6		30
1720	Initial therapy for patients with chronic lymphocytic leukemia. 2006 , 33, 202-9		16
1719	Risk stratification in chronic lymphocytic leukemia. 2006 , 33, 186-94		62
1718	Beyond detectable minimal residual disease in chronic lymphocytic leukemia. 2006 , 33, S23-8		8
1717	CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2006 , 76, 455-64	3.8	29
1716	Quantitative flow cytometry of ZAP-70 levels in chronic lymphocytic leukemia using molecules of equivalent soluble fluorochrome. 2006 , 70, 218-26		34
1715	ZAP-70 by flow cytometry: a comparison of different antibodies, anticoagulants, and methods of analysis. 2006 , 70, 235-41		26
1714	Kolmogorov-Smirnov statistical test for analysis of ZAP-70 expression in B-CLL, compared with quantitative PCR and IgV(H) mutation status. 2006 , 70, 302-8		14
1713	Use of a blocking antibody method for the flow cytometric measurement of ZAP-70 in B-CLL. 2006 , 70, 251-8		8
1712	Flow cytometry for ZAP-70: New colors for chronic lymphocytic leukemia. 2006 , 70, 201-3		6
1711	ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV(H) mutations. 2006 , 70, 284-92		31
1710	Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia. 2006 , 70, 209-13		22
1709	Clinical implications of ZAP-70 expression in chronic lymphocytic leukemia. 2006 , 70, 214-7		22

1708	Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process. 2006 , 70, 309-14	58
1707	Comparison of methods for determining zeta-chain associated protein - 70 (ZAP-70) expression in patients with B-cell chronic lymphocytic leukemia (B-CLL). 2006 , 70, 293-301	12
1706	Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis. 2006 , 70, 270-5	18
1705	A standardized ZAP-70 assay--lessons learned in the trenches. 2006 , 70, 276-83	14
1704	B lymphocytes in humans express ZAP-70 when activated in vivo. 2006 , 36, 558-69	55
1703	IGHV gene insertions and deletions in chronic lymphocytic leukemia: "CLL-biased" deletions in a subset of cases with stereotyped receptors. 2006 , 36, 1963-74	33
1702	A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia. 2006 , 207, 354-63	40
1701	The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. 2006 , 107, 1023-33	71
1700	What is the current evidence for antigen involvement in the development of chronic lymphocytic leukemia?. 2006 , 24, 7-13	11
1699	Silencing of APAF-1 in B-CLL results in poor prognosis in the case of concomitant p53 mutation. 2006 , 118, 2329-36	16
1698	New prognostic markers in CLL. 2006 , 2006, 279-84	53
1697	Molecular Genetic Abnormalities in Acute and Chronic Leukemias. 2006 , 415-436	1
1696	MicroRNA in chronic lymphocytic leukemia. 2006 , 354, 524-5; author reply 524-5	25
1695	Structural and functional features of the B-cell receptor in IgG-positive chronic lymphocytic leukemia. 2006 , 12, 1672-9	32
1694	Evolving view of the in-vivo kinetics of chronic lymphocytic leukemia B cells. 2006 , 2006, 273-8, 512	18
1693	Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. 2006 , 11, 21-30	45
1692	The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. 2006 , 17, 683-90	53
1691	Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. 2006 , 24, 2343-51	208

1690	c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications. 2006 , 66, 7801-9		31
1689	Flow-cytometric immunophenotyping of normal and malignant lymphocytes. 2006 , 44, 775-96		43
1688	Flow cytometric immunophenotyping of normal and malignant lymphocytes / Immunphänotypisierung normaler und maligner Lymphozyten mittels Durchflusszytometrie. 2006 , 30, 370-392		
1687	Immunoglobulin V(H) genes and CD38 expression analysis in B-cell chronic lymphocytic leukemia. 2006 , 116, 72-4		1
1686	A new memory CD27-IgG+ B cell population in peripheral blood expressing VH genes with low frequency of somatic mutation. 2006 , 177, 3728-36		229
1685	The biology and treatment of chronic lymphocytic leukemia. 2006 , 17 Suppl 10, x144-54		20
1684	The GNAS1 T393C polymorphism is associated with disease progression and survival in chronic lymphocytic leukemia. 2006 , 12, 5686-92		39
1683	Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia. 2006 , 6, 1787-800		3
1682	Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. 2006 , 24, 969-75		157
1681	B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. 2006 , 103, 11713-8		139
1680	Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. <i>Blood</i> , 2007 , 109, 4679-85	2.2	264
1679	The prognostic evaluation of CLLU1 expression levels in 50 Chinese patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007 , 48, 1785-92	1.9	12
1678	B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens. 2007 , 60, 627-32		6
1677	Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia. 2007 , 97, 769-77		43
1676	iHMMune-align: hidden Markov model-based alignment and identification of germline genes in rearranged immunoglobulin gene sequences. 2007 , 23, 1580-7		105
1675	Molecular diagnostics of non-Hodgkin lymphoma. 2007 , 1, 47-63		2
1674	The immunoglobulin genes: structure and specificity in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007 , 48, 1081-6	1.9	8
1673	Biomarkers and the design of clinical trials in cancer. 2007 , 1, 387-97		6

1672	A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease. 2007 , 67, 8653-61		54
1671	Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia. 2007 , 53, 1757-66		35
1670	Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. 2007 , 92, 1242-5		179
1669	Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia. 2007 , 127, 182-91		26
1668	Familial B-cell chronic lymphocytic leukemia: analysis of cytogenetic abnormalities, immunophenotypic profiles, and immunoglobulin heavy chain gene usage. 2007 , 127, 31-8		10
1667	17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis. <i>Leukemia and Lymphoma</i> , 2007 , 48, 311-20	1.9	32
1666	High-resolution oligonucleotide array-CGH pinpoints genes involved in cryptic losses in chronic lymphocytic leukemia. 2007 , 118, 8-12		49
1665	Microarray expression technology in clinical research of non-Hodgkin lymphoma. 2007 , 15, 28-35		1
1664	Cytogenetic aberrations and immunoglobulin VH gene mutations in clinically benign CD5-monoclonal B-cell lymphocytosis. 2007 , 128, 333-8		31
1663	Intracellular cytokine expression by T cells differs in ZAP-70-positive and ZAP-70-negative chronic lymphocytic leukaemia patients. 2007 , 118, 106-10		
1662	Murine models for chronic lymphocytic leukaemia. 2007 , 35, 1009-12		3
1661	ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. <i>Blood</i> , 2007 , 109, 2032-9	2.2	141
1660	Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. <i>Blood</i> , 2007 , 109, 259-70	2.2	402
1659	Progressive immunoglobulin gene mutations in chronic lymphocytic leukemia: evidence for antigen-driven intraclonal diversification. <i>Blood</i> , 2007 , 109, 1559-67	2.2	29
1658	A novel human B cell subpopulation representing the initial germinal center population to express AID. <i>Blood</i> , 2007 , 109, 2545-52	2.2	48
1657	Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells. <i>Blood</i> , 2007 , 109, 3989-97	2.2	44
1656	Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. <i>Blood</i> , 2007 , 109, 2989-98	2.2	57
1655	CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia. <i>Blood</i> , 2007 , 109, 4973-9	2.2	45

1654	Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. <i>Blood</i> , 2007 , 109, 4424-31	2.2	184
1653	IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. 2007 , 31, 1605-14		176
1652	ZAP70 expression assessed by immunohistochemistry on peripheral blood: a simple prognostic assay for patients with chronic lymphocytic leukemia. 2007 , 15, 471-6		5
1651	Anomalies chromosomiques et g�ntiques dans les h�mopathies malignes. 2007 , 2, 1-13		
1650	Regulation of CD38 in proliferating chronic lymphocytic leukemia cells stimulated with CD154 and interleukin-4. 2007 , 92, 1359-66		20
1649	Pathology of chronic lymphocytic leukemia: an update. 2007 , 11, 363-89		44
1648	Recent progress in the management of chronic lymphocytic leukemia. 2007 , 33, 710-28		30
1647	Laminin-332 (Laminin-5) is the major motility ligand for B cell chronic lymphocytic leukemia. 2007 , 26, 473-84		8
1646	Diagnostic, pronostic et traitement chez les patients avec une leuc�mie lymphoide chronique. 2007 , 22, 313-318		0
1645	Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. 2007 , 370, 230-239		610
1644	Current immunotherapeutic strategies in pancreatic cancer. 2007 , 16, 919-43, xi		7
1643	Prognostic markers in chronic lymphocytic leukaemia. 2007 , 20, 455-68		44
1642	p53 as a predictor for chemotherapy response in CLL cells. <i>Leukemia and Lymphoma</i> , 2007 , 48, 219-20	1.9	5
1641	CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. <i>Blood</i> , 2007 , 110, 3352-9	2.2	133
1640	Expression level of lipoprotein lipase and dystrophin genes predict survival in B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007 , 48, 912-22	1.9	25
1639	Microarray Technology and Cancer Gene Profiling. 2007 ,		4
1638	Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia. 2007 , 53, 204-12		47
1637	Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test. 2007 , 82, 449-53		47

1636	The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. <i>Leukemia and Lymphoma</i> , 2007 , 48, 1931-9	1.9	85
1635	Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. 2007 , 25, 799-804		296
1634	CD5 does not regulate the signaling triggered through BCR in B cells from a subset of B-CLL patients. <i>Leukemia and Lymphoma</i> , 2007 , 48, 147-57	1.9	3
1633	Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease. 2007 , 7, 1789-97		7
1632	Analysis of the immunoglobulin heavy chain variable region gene expression in Iranian patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007 , 48, 109-16	1.9	17
1631	The changing face of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007 , 48, 2283-4	1.9	2
1630	Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology. 2007 , 9, 546-55		20
1629	Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL). 2007 , 20, 469-77		14
1628	Update on Genomic Profiling in Chronic Lymphocytic Leukemia. 2007 , 1, 217-222		
1627	The Role of MicroRNAs in Chronic Lymphocytic Leukemia. 2007 , 1, 287-291		
1626	Chronic Lymphocytic Leukemia: How to Assess Prognosis in 2007. 2007 , 1, 162-167		1
1625	Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. 2007 , 149, 231-5		49
1624	FISH panels for hematologic malignancies. 2007 , 118, 284-96		30
1623	Genetic alteration associated with chronic lymphocytic leukemia. 2007 , 118, 310-9		12
1622	The normal counterpart to the chronic lymphocytic leukemia B cell. 2007 , 20, 385-97		26
1621	Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia. 2007 , 20, 439-53		58
1620	Differential diagnosis in chronic lymphocytic leukaemia. 2007 , 20, 367-84		23
1619	The role of stem-cell transplantation in chronic lymphocytic leukemia risk-adapted therapy. 2007 , 20, 529-43		8

1618	Stem-cell transplantation in chronic lymphocytic leukaemia. 2007 , 20, 513-27	8
1617	Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. 2007 , 20, 545-56	25
1616	The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia. 2007 , 20, 415-24	32
1615	[Chronic lymphocytic leukaemia: an autoimmune disorder? Prognostic factors and the current view of pathogenesis]. 2007 , 148, 867-78	0
1614	The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells. 2007 , 92, 349-56	34
1613	Management of Haematological Malignancies. 2007 ,	1
1612	Lymph Nodes. 2007 ,	
1611	Preclinical assessment of curcumin as a potential therapy for B-CLL. 2007 , 82, 23-30	58
1610	Igbeta(CD79b) mRNA expression in chronic lymphocytic leukaemia cells correlates with immunoglobulin heavy chain gene mutational status but does not serve as an independent predictor of clinical severity. 2007 , 82, 712-20	4
1609	Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. 2007 , 82, 787-91	33
1608	Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. 2007 , 82, 1063-70	41
1607	IgVH gene mutation status and genomic imbalances in chronic lymphocytic leukaemia with increased prolymphocytes (CLL/PL). 2007 , 25, 90-5	1
1606	High rate of centrosome aberrations and correlation with proliferative activity in patients with untreated B-cell chronic lymphocytic leukemia. 2007 , 121, 978-83	11
1605	Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia. 2007 , 121, 1984-93	50
1604	Comparative analysis of ZAP-70 expression and Ig VH mutational status in B-cell chronic lymphocytic leukemia. 2007 , 72, 96-102	13
1603	National standardization of ZAP-70 determination by flow cytometry: the French experience. 2007 , 72, 103-8	18
1602	CD5 provides viability signals to B cells from a subset of B-CLL patients by a mechanism that involves PKC. 2007 , 31, 183-93	20
1601	V(H)3-48 and V(H)3-53, as well as V(H)3-21, gene rearrangements define unique subgroups in CLL and are associated with biased lambda light chain restriction, homologous LCDR3 sequences and poor prognosis. 2007 , 31, 231-4	14

1600	Chronic lymphocytic leukemia patients with a V1-69 gene rearrangement do not have inferior survival with respect to patients that express other unmutated V(H) genes. 2007 , 31, 245-8	8
1599	Is "leukemia" an appropriate label for all patients who meet the diagnostic criteria of chronic lymphocytic leukemia?. 2007 , 31, 273-5	14
1598	Progressive disease in chronic lymphocytic leukemia is correlated with the DNA methylation index. 2007 , 31, 773-7	10
1597	Use of IGJ and IGHD gene mutations in analysis of immunoglobulin sequences for the prognosis of chronic lymphocytic leukemia. 2007 , 31, 1247-52	10
1596	Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells. 2007 , 26, 1166-77	66
1595	Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. 2007 , 7, 750-62	387
1594	Fetal B-cell lymphopoiesis and the emergence of B-1-cell potential. 2007 , 7, 213-9	113
1593	The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. 2007 , 21, 110-20	125
1592	Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. 2007 , 21, 12-7	297
1591	ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. 2007 , 21, 1-3	181
1590	ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor. 2007 , 21, 102-9	31
1589	Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. 2007 , 21, 207-14	257
1588	Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. 2007 , 21, 697-705	40
1587	Highly purified CD38+ and CD38- sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin. 2007 , 21, 687-96	46
1586	A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation. 2007 , 21, 1532-44	77
1585	Comparison of a quantitative PCR method with FISH for the assessment of the four aneuploidies commonly evaluated in CLL patients. 2007 , 21, 1460-3	25
1584	Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine. 2007 , 21, 1715-22	76
1583	The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. 2007 , 21, 1885-91	83

1582	Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation. 2007 , 21, 1984-91	47
1581	Sequence analysis proves clonal identity in five patients with typical and blastoid mantle cell lymphoma. 2007 , 20, 1-7	40
1580	Molecular genetic analysis of haematological malignancies II: Mature lymphoid neoplasms. 2007 , 29, 229-60	21
1579	Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?. 2007 , 136, 379-92	21
1578	Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. 2007 , 137, 355-63	84
1577	Trisomy 19 is associated with trisomy 12 and mutated IGHV genes in B-chronic lymphocytic leukaemia. 2007 , 138, 217-20	35
1576	CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia. 2007 , 138, 721-32	54
1575	Bi-clonal disease in patients with chronic lymphocytic leukaemia as detected by analysing IGHV mutation status. 2007 , 139, 507-9	1
1574	Combined factors V and VIII deficiency (F5F8D) in a Chinese family due to compound heterozygosity for nonsense mutations of the LMAN1 gene. 2007 , 139, 509-11	7
1573	Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis. 2007 , 139, 672-86	63
1572	Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes. 2007 , 139, 744-52	20
1571	Discordance of ZAP-70 in patients with chronic lymphocytic leukemia. 2008 , 30, 36-40	2
1570	Immunoglobulin variable region gene analysis to the autoantibody-secreting B cells from tumors in association with paraneoplastic autoimmune multiorgan syndrome. 2007 , 46, 1146-54	12
1569	From normal to clonal B cells: Chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity. 2007 , 7, 127-31	39
1568	Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells. 2007 , 7, 102-8	61
1567	Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemia. 2007 , 174, 57-60	14
1566	p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia. 2007 , 179, 36-44	15
1565	Pathophysiologic mechanisms of chronic lymphocytic leukemia and their application to therapy. 2007 , 35, 134-6	7

1564	Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response. 2007 , 35, 1527-37	55
1563	Zap-70 and CD38 as predictors of IgVH mutation in CLL. 2007 , 83, 459-61	6
1562	The use of scoring systems in patients with haematological malignancy. 2007 , 95, 47-51	1
1561	Expression of soluble CD27 and interleukins-8 and -10 in B-cell chronic lymphocytic leukemia: correlation with disease stage and prognosis. 2007 , 24, 29-40	23
1560	Prognostic factors in chronic lymphocytic leukemia. 2007 , 2, 49-55	10
1559	Chronic lymphocytic leukemia: biology and current treatment. 2007 , 9, 345-52	8
1558	Plasmablastic lymphoma of head and neck: report of two new cases and correlation with c-myc and IgVH gene mutation status. 2007 , 1, 150-5	11
1557	Chronic lymphocytic leukemia. 2007 , 64, 234-46	73
1556	Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia. 2008 , 57, 1705-10	14
1555	Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration. 2008 , 87, 891-8	12
1554	Chronisch lymphatische Leukämie (CLL). 2008 , 3, 81-91	
1553	Eradication of minimal residual disease in chronic lymphocytic leukemia. 2008 , 3, 54-60	2
1552	Chronische lymphatische Leukämie. 2008 , 3, 26-37	
1551	miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. 2008 , 215, 13-20	100
1550	Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 2008 , 112, 119-28	78
1549	Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. 2008 , 113, 1933-52	74
1548	Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia. 2008 , 113, 897-906	29
1547	Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. 2008 , 113, 2110-8	62

1546	Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia. 2008 , 26, 247-51	34
1545	Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. 2008 , 123, 1190-5	138
1544	Fc receptor-like 1-5 molecules are similarly expressed in progressive and indolent clinical subtypes of B-cell chronic lymphocytic leukemia. 2008 , 123, 2113-9	29
1543	Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. 2008 , 47, 781-93	54
1542	Redundant role for Zap70 in B cell development and activation. 2008 , 38, 1721-33	17
1541	Chronic lymphocytic leukemia patients exposed to ionizing radiation due to the Chernobyl NPP accident--with focus on immunoglobulin heavy chain gene analysis. 2008 , 32, 535-45	21
1540	Controversies in the front-line management of chronic lymphocytic leukemia. 2008 , 32, 679-88	8
1539	Distinctive IgVH gene segments usage and mutation status in Chinese patients with chronic lymphocytic leukemia. 2008 , 32, 1491-8	43
1538	New prognostic markers in chronic lymphocytic leukemia. 2008 , 22, 211-9	107
1537	The most frequent t(14;19)(q32;q13)-positive B-cell malignancy corresponds to an aggressive subgroup of atypical chronic lymphocytic leukemia. 2008 , 22, 2123-7	40
1536	Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients. 2008 , 22, 1882-90	23
1535	Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia. 2008 , 22, 2184-92	8
1534	Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells. 2008 , 27, 2445-55	56
1533	A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. 2008 , 40, 1204-10	294
1532	Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis. 2008 , 41, 239-44	16
1531	Many human immunoglobulin heavy-chain IGHV gene polymorphisms have been reported in error. 2008 , 86, 111-5	50
1530	Efficient gene transfer in CLL by mRNA electroporation. 2008 , 22, 323-9	19
1529	Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. 2008 , 22, 330-8	158

1528	The BCL-2 promoter (-938C>A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia. 2008 , 22, 339-43		6
1527	Determination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia - long-term follow up of patients with different percentages of mutations. 2008 , 140, 320-3		34
1526	Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. 2008 , 141, 36-40		65
1525	The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. 2008 , 141, 615-21		84
1524	Advances in the understanding of mantle cell lymphoma. 2008 , 142, 149-65		134
1523	MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis. 2008 , 142, 36-44		65
1522	Analysis of a large multi-generational family provides insight into the genetics of chronic lymphocytic leukemia. 2008 , 142, 238-45		24
1521	High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia. 2008 , 143, 54-9		17
1520	Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. 2008 , 264, 549-62		131
1519	Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR. <i>European Journal of Haematology</i> , 2008 , 81, 100-6	3.8	4
1518	Biallelic deletion 13q14.3 in patients with chronic lymphocytic leukemia: cytogenetic, FISH and clinical studies. <i>European Journal of Haematology</i> , 2008 , 81, 94-9	3.8	26
1517	Human B cell subsets. 2008 , 98, 151-224		62
1516	Molecular genetic characterization reveals new subsets of mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1042-9	1.9	28
1515	Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. 2008 , 359, 575-83		447
1514	Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2008 , 49, 49-56	1.9	146
1513	Targeted Cancer Therapy. 2008 ,		6
1512	Human leukocyte antigen class II allele association to disease progression in Iranian patients with chronic lymphocytic leukemia. 2008 , 69, 666-74		8
1511	Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma. 2008 , 45, 1567-72		44

1510	[Chronic lymphocytic leukaemia: current management]. 2008 , 29, 424-35		2
1509	ZAP70 in chronic lymphocytic leukaemia. 2008 , 40, 1654-8		6
1508	Predominantly post-transcriptional regulation of activation molecules in chronic lymphocytic leukemia: the case of transferrin receptors. 2008 , 41, 203-9		4
1507	Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. <i>Blood</i> , 2008 , 111, 1524-33	2.2	263
1506	Lack of the leukocyte-associated Ig-like receptor-1 expression in high-risk chronic lymphocytic leukaemia results in the absence of a negative signal regulating kinase activation and cell division. 2008 , 22, 980-8		38
1505	Molecular diagnostics in chronic lymphocytic leukemia - pathogenetic and clinical implications. <i>Leukemia and Lymphoma</i> , 2008 , 49, 864-73	1.9	36
1504	Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. <i>Blood</i> , 2008 , 111, 5446-56	2.2	2531
1503	Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 112, 975-80	2.2	568
1502	Chronic lymphocytic leukaemia. 2008 , 371, 1017-29		235
1501	Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease?. 2008 , 26, 4497-503		161
1500	Usefulness of Risk Stratification in the Treatment of Patients with Chronic Lymphocytic Leukemia. 2008 , 2, 46-54		
1499	Indolent lymphomas other than follicular and marginal zone lymphomas. 2008 , 22, 903-40, viii		5
1498	Current Treatment for Chronic Lymphocytic Leukemia. 2008 , 2, 230-236		0
1497	The genetics of cancer survivorship. 2008 , 22, 257-69, vi-vii		2
1496	Chronic Lymphocytic Leukemia: An Amazing Time Given the Development of New Combination Therapies and New Agents, but Still No Cure, and a Need to Focus on Patient-Specific Treatment Options. 2008 , 2, 221-222		
1495	Clinical application of array-based comparative genomic hybridization for the identification of prognostically important genetic alterations in chronic lymphocytic leukemia. 2008 , 12, 271-80		18
1494	Overview of lymphoma diagnosis and management. 2008 , 46, 175-98, vii		69
1493	First-Line Treatment in Chronic Lymphocytic Leukemia: A Risk-Stratified Approach. 2008 , 2, 121-127		

1492	Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 111, 1584-93	2.2	103
1491	Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL. <i>Leukemia and Lymphoma</i> , 2008 , 49, 2108-15	1.9	43
1490	Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1879-86	1.9	12
1489	Humoral immune responses against the immature laminin receptor protein show prognostic significance in patients with chronic lymphocytic leukemia. 2008 , 180, 6374-84		14
1488	ZAP-70 mRNA expression provides clinically valuable information in early-stage chronic lymphocytic leukemia. 2008 , 93, 1422-4		5
1487	Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. 2008 , 14, 396-404		173
1486	Mutated IgHV1-69 gene usage represents a distinct subgroup associated with indolent disease in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2008 , 49, 763-8	1.9	6
1485	Translocation t(2;8)(p12;q24) in two patients with B Cell chronic lymphocytic leukemia. 2008 , 120, 232-6		4
1484	Plasmablastic lymphoma with small lymphocytic lymphoma: clinico-pathologic features, and review of the literature. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1999-2002	1.9	11
1483	Clonal relationship between Hashimoto thyroiditis and thyroid lymphoma. 2008 , 61, 438-44		44
1482	Prognostic factors in chronic lymphocytic leukemia. 2008 , 19 Suppl 4, iv51-3		18
1481	Chronic lymphocytic leukaemia: a short overview. 2008 , 19 Suppl 7, vii320-5		26
1480	Serum thrombopoietin compared with ZAP-70 and immunoglobulin heavy-chain gene mutation status as a predictor of time to first treatment in early chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2008 , 49, 62-7	1.9	3
1479	Chronic lymphocytic leukemia with mutated IgVH1-69 usage: a distinct CLL subgroup with more indolent behavior?. <i>Leukemia and Lymphoma</i> , 2008 , 49, 648-9	1.9	1
1478	Peripheral blood lymphocytosis--what is the threshold for further investigation?. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1659-61	1.9	2
1477	Monoclonal B-cell lymphocytosis--a frequent premalignant condition. 2008 , 359, 638-40		5
1476	Molecular profiling in CLL. 2008 , 444-9		21
1475	Novel epigenetic targets in lymphoproliferative disorders. 2008 , 8, 378-91		4

1474	Biologic prognostic markers and their application in clinical trials and management of chronic lymphocytic leukaemia patients. 2008 , 2, 101-12		1
1473	Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukaemia. 2008 , 7, 174-9		24
1472	Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method. 2008 , 93, 215-23		30
1471	Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. 2008 , 7, 3810-4		66
1470	CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. 2008 , 93, 1575-9		66
1469	Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. <i>Blood</i> , 2008 , 111, 3137-44	2.2	39
1468	The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. <i>Blood</i> , 2008 , 111, 846-55	2.2	254
1467	Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 111, 865-73	2.2	197
1466	Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 111, 2246-52	2.2	117
1465	Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 112, 1923-30	2.2	254
1464	Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 112, 1993-2003	2.2	83
1463	CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. <i>Blood</i> , 2008 , 111, 5173-81	2.2	173
1462	Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis. <i>Blood</i> , 2008 , 111, 1625-33	2.2	28
1461	Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. <i>Blood</i> , 2008 , 112, 188-95	2.2	180
1460	Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 111, 2790-6	2.2	25
1459	The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. <i>Blood</i> , 2008 , 112, 1443-52	2.2	90
1458	The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. <i>Blood</i> , 2008 , 111, 4681-9	2.2	128
1457	A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. <i>Blood</i> , 2008 , 111, 3838-48	2.2	210

1456	BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. <i>Blood</i> , 2008 , 112, 782-92	2.2	108
1455	Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. <i>Blood</i> , 2008 , 111, 5101-8	2.2	62
1454	CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome?. <i>Blood</i> , 2008 , 111, 5646-53	2.2	63
1453	FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 112, 179-87	2.2	44
1452	Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 112, 4665-74	2.2	50
1451	EnABLING the immune synapse. <i>Blood</i> , 2008 , 112, 3	2.2	
1450	Ligandless receptors find a role. <i>Blood</i> , 2008 , 112, 2-3	2.2	1
1449	Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. <i>Blood</i> , 2008 , 112, 3807-17	2.2	189
1448	Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. <i>Blood</i> , 2008 , 112, 5122-9	2.2	127
1447	Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia. 2008 , 93, 14-9		15
1446	Getting the diagnosis right in NHL: role of immunohistochemistry and molecular diagnostic testing. 2008 , 6, 422-7		2
1445	Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells. 2008 , 93, 413-22		39
1444	Somatic hypermutation signature in B-cell low-grade lymphomas. 2008 , 93, 1186-94		11
1443	Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. 2008 , 14, 665-74		153
1442	Chronic lymphocytic leukemia: "Cinderella" is becoming a star. 2009 , 15, 67-9		9
1441	Gene Expression and Serum Cytokine Profiling of Low Stage CLL Identify WNT/PCP, Flt-3L/Flt-3 and CXCL9/CXCR3 as Regulators of Cell Proliferation, Survival and Migration. 2009 , 2009, 453634		17
1440	BCL2-938C>A polymorphism and disease progression in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1837-42	1.9	12
1439	The molecular basis of familial chronic lymphocytic leukemia. 2009 , 94, 606-9		13

1438	Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009 , 50, 2061-70	1.9	34
1437	Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. 2009 , 27, 763-9		45
1436	Bone Marrow. 2009 , 1536-1593		
1435	Chronic lymphocytic leukemia With t(2;14)(p16;q32) involves the BCL11A and IgH genes and is associated with atypical morphologic features and unmutated IgVH genes. 2009 , 131, 663-70		27
1434	Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. 2009 , 27, 3959-63		109
1433	Apoptosis of B-cell chronic lymphocytic leukemia cells induced by a novel BH3 peptidomimetic. 2009 , 8, 263-71		17
1432	NF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia. 2009 , 5, 1027-37		26
1431	Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation. 2009 , 94, 752-6		35
1430	The interface of Medicare coverage decision-making and emerging molecular-based laboratory testing. 2009 , 11, 225-31		8
1429	A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene. 2009 , 69, 5210-7		37
1428	Chronic lymphocytic leukemia. 2009 , 105-112		
1427	Bendamustine therapy in chronic lymphocytic leukemia. 2009 , 10, 1687-98		1
1426	Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. 2009 , 69, 5424-32		141
1425	Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. 2009 , 15, 4415-22		155
1424	Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. 2009 , 27, 3808-14		125
1423	Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine. <i>European Journal of Haematology</i> , 2009 , 82, 133-42	3.8	10
1422	In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis. <i>European Journal of Haematology</i> , 2009 , 83, 22-34	3.8	4
1421	Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2009 , 83, 320-7	3.8	39

1420	Inactivation of p53 and amplification of MYCN gene in a terminal lymphoblastic relapse in a chronic lymphocytic leukemia patient. 2009 , 189, 53-8	5
1419	T-cell CD38 expression in B-chronic lymphocytic leukaemia. 2009 , 27, 82-9	6
1418	The role of stem cell transplantation in the management of chronic lymphocytic leukaemia. 2009 , 27, 53-60	8
1417	Validation of a new prognostic index for patients with chronic lymphocytic leukemia. 2009 , 115, 363-72	64
1416	Chronic lymphocytic leukemia: treatment options for patients with refractory disease. 2009 , 115, 3830-41	10
1415	Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia. 2009 , 76, 385-93	27
1414	Chronic lymphocytic leukemia: new concepts and emerging therapies. 2009 , 10, 16-32	7
1413	Prognostic factors in low-grade non-Hodgkin lymphomas. 2009 , 4, 202-10	11
1412	Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia. 2009 , 11, 353-9	1
1411	IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide. 2009 , 88, 1215-21	23
1410	La leucémie lymphoïde chronique en 2009: quelles avancées clinico-biologiques?. 2009 , 2009, 12-15	1
1409	Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia. 2009 , 9, 1197-206	19
1408	Peripheral blood CD27+ IgG+ B cells rapidly proliferate and differentiate into immunoglobulin-secreting cells after exposure to low CD154 interaction. 2009 , 128, e353-65	23
1407	Characterization of immunoglobulin heavy and light chain gene expression in chronic lymphocytic leukemia and related disorders. 2009 , 100, 671-7	11
1406	Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia. 2009 , 100, 2346-53	24
1405	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. 2009 , 144, 492-506	100
1404	Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. 2009 , 146, 44-53	46
1403	The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. 2009 , 146, 64-75	120

1402	Gene expression signature of chronic lymphocytic leukaemia with Trisomy 12. 2009 , 39, 568-75	28
1401	Expression level of lipoprotein lipase in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors. 2009 , 31, 552-9	8
1400	miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes. 2009 , 89, 708-16	87
1399	The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. 2009 , 23, 117-24	167
1398	Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. 2009 , 23, 686-97	154
1397	Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. 2009 , 23, 1062-72	85
1396	The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. 2009 , 23, 2034-41	84
1395	Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis. 2009 , 23, 2281-9	33
1394	Hypermutation in mantle cell lymphoma does not indicate a clinical or biological subentity. 2009 , 22, 416-25	26
1393	Use of similar immunoglobulin VH gene segments by MALT lymphomas of the ocular adnexa. 2009 , 22, 833-8	22
1392	Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. 2009 , 31, 97-105	19
1391	Prognostic irrelevance of HLA-G in B-cell chronic lymphocytic leukemia. 2009 , 31, 327-37	19
1390	Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. 2009 , 33, 368-76	19
1389	CD38 as a prognostic factor in Chinese patients with chronic lymphocytic leukaemia. 2009 , 33, 237-43	25
1388	Further evidence that antigen selection shapes the Ig repertoire in CLL. 2009 , 33, 363-5	
1387	Characterization of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Shanghai, China: molecular and cytogenetic characteristics, IgV gene restriction and hypermutation patterns. 2009 , 33, 1599-603	11
1386	Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. 2009 , 23, 25-47	92
1385	Treatment of elderly patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009 , 50, 171-8	1.9 87

1384	Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia. 2009 , 11, 25-34		39
1383	Gene expression profiling in chronic lymphocytic leukaemia. 2009 , 22, 211-22		18
1382	Facteurs pronostiques utiles dans l'évaluation personnalisée d'un patient avec une leucémie lymphoïde chronique (LLC). 2009 , 24, 1-8		
1381	[B-chronic lymphocytic leukemia: epidemiological study and comparison of MDACC and GIMENA prognostic indexes]. 2009 , 133, 161-6		8
1380	Analysis of chronic lymphocytic leukemia transcriptomic profile: differences between molecular subgroups. <i>Leukemia and Lymphoma</i> , 2009 , 50, 68-79	1.9	17
1379	Encyclopedia of Cancer. 2008 , 292-292		
1378	Current and emerging treatments for chronic lymphocytic leukaemia. 2009 , 69, 2415-49		33
1377	Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. 2009 , 7, 76		31
1376	BCL6: somatic mutations and expression in early-stage chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009 , 50, 773-80	1.9	12
1375	Encyclopedia of Cancer. 2008 , 287-287		
1374	B-cell clones as early markers for chronic lymphocytic leukemia. 2009 , 360, 659-67		265
1373	Transcriptional profiling of chronic lymphocytic leukemia: is there still more to learn?. <i>Leukemia and Lymphoma</i> , 2009 , 50, 10-1	1.9	
1372	Drug induction apoptosis assay as predictive value of chemotherapy response in patients with B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009 , 50, 593-603	1.9	9
1371	The negative prognostic significance of positive direct antiglobulin test in Chinese patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1482-7	1.9	14
1370	CpG island methylation patterns in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009 , 50, 419-26	1.9	22
1369	Monoclonal B-cell lymphocytosis: definitions and natural history. <i>Leukemia and Lymphoma</i> , 2009 , 50, 493-7	1.9	10
1368	Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1261-8	1.9	60
1367	How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet. 2009 , 94, 1135-50		36

1366	Molecular and cellular mechanisms of CLL: novel therapeutic approaches. 2009 , 6, 405-18		122
1365	Management of chronic lymphocytic leukemia: an update. 2009 , 6, 271-278		
1364	Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). <i>Blood</i> , 2009 , 113, 1294-303	2.2	86
1363	Predicting clinical outcome in CLL: how and why. 2009 , 421-9		47
1362	One step closer to universal influenza epitopes. 2009 , 7, 687-90		13
1361	Molecular diagnosis of hematopoietic and lymphoid neoplasms. 2009 , 23, 903-33		8
1360	The leukemias of mature lymphocytes. 2009 , 23, 843-71		7
1359	Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. 2009 , 94, 654-62		53
1358	Cryptochrome-1 expression: a new prognostic marker in B-cell chronic lymphocytic leukemia. 2009 , 94, 280-4		15
1357	Evidence for the significant role of immunoglobulin light chains in antigen recognition and selection in chronic lymphocytic leukemia. <i>Blood</i> , 2009 , 113, 403-11	2.2	61
1356	B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. <i>Blood</i> , 2009 , 113, 4188-96	2.2	91
1355	The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)-like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring. <i>Blood</i> , 2009 , 114, 26-32	2.2	107
1354	Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. <i>Blood</i> , 2009 , 113, 3168-71	2.2	73
1353	microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. <i>Blood</i> , 2009 , 113, 5237-45	2.2	204
1352	Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells. <i>Blood</i> , 2009 , 114, 3615-24	2.2	35
1351	VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. <i>Blood</i> , 2009 , 114, 4687-95	2.2	118
1350	Aberrant splicing of the E-cadherin transcript is a novel mechanism of gene silencing in chronic lymphocytic leukemia cells. <i>Blood</i> , 2009 , 114, 4179-85	2.2	34
1349	Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. <i>Blood</i> , 2009 , 114, 4696-702	2.2	95

1348	In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2009 , 114, 4832-42	2.2	111
1347	Extensive intraclonal diversification in a subgroup of chronic lymphocytic leukemia patients with stereotyped IGHV4-34 receptors: implications for ongoing interactions with antigen. <i>Blood</i> , 2009 , 114, 4460-8	2.2	58
1346	Karyotype-specific microRNA signature in chronic lymphocytic leukemia. <i>Blood</i> , 2009 , 114, 3872-9	2.2	159
1345	B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. <i>Blood</i> , 2009 , 114, 1029-37 ^{2.2}		196
1344	Chronic Lymphocytic Leukemia. 119-130		
1343	Gene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA. 2009 , 94, 790-9		27
1342	The basis and rational use of molecular genetic testing in mature B-cell lymphomas. 2010 , 17, 333-58		7
1341	Most morphologic features in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) do not reliably predict underlying FISH genetics or immunoglobulin heavy chain variable region somatic mutational status. 2010 , 18, 119-27		4
1340	Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia. 2010 , 95, 102-9		24
1339	High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors. 2010 , 95, 1519-25		40
1338	Distinct gene expression profiles in subsets of chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors. 2010 , 95, 2072-9		29
1337	Thalidomide enhances cyclophosphamide and dexamethasone-mediated cytotoxicity towards cultured chronic lymphocytic leukaemia cells. 2010 , 24, 1315-21		3
1336	Genetic lesions in chronic lymphocytic leukemia: what's ready for prime time use?. 2010 , 95, 12-5		13
1335	The normal IGHV1-69-derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL. <i>Blood</i> , 2010 , 115, 71-7	2.2	74
1334	Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins. <i>Blood</i> , 2010 , 115, 581-91	2.2	83
1333	Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. <i>Blood</i> , 2010 , 115, 296-305	2.2	112
1332	Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. <i>Blood</i> , 2010 , 115, 4497-506	2.2	152
1331	Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia. <i>Blood</i> , 2010 , 115, 3726-36	2.2	40

1330	Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. <i>Blood</i> , 2010 , 115, 3907-15	2.2	143
1329	Surface IgM of CLL cells displays unusual glycans indicative of engagement of antigen in vivo. <i>Blood</i> , 2010 , 115, 4198-205	2.2	47
1328	High expression of AID and active class switch recombination might account for a more aggressive disease in unmutated CLL patients: link with an activated microenvironment in CLL disease. <i>Blood</i> , 2010 , 115, 4488-96	2.2	69
1327	Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. <i>Blood</i> , 2010 , 116, 1479-88	2.2	145
1326	The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the EBTCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. <i>Blood</i> , 2010 , 116, 4894-905 ²	2.2	113
1325	The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells. 2010 , 95, 1136-43		25
1324	Immunoregulatory roles for fc receptor-like molecules. 2011 , 350, 89-104		29
1323	Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. <i>Leukemia and Lymphoma</i> , 2010 , 51, 822-38	1.9	8
1322	Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. <i>Blood</i> , 2010 , 116, 584-92	2.2	46
1321	Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. 2010 , 89, 1115-24		26
1320	Expression of multidrug resistance-associated ABC transporters in B-CLL is independent of ZAP70 status. 2010 , 136, 403-10		9
1319	p53 protein overexpression in bone marrow biopsies from chronic lymphocytic leukaemia is associated with TP53 deletion and resistance to fludarabine. 2010 , 3, 61-68		3
1318	Challenges in the frontline treatment of patients with chronic lymphocytic leukemia. 2010 , 5, 45-51		3
1317	CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells. 2010 , 20, 416-23		26
1316	The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia. 2010 , 20, 391-9		37
1315	CLL-like monoclonal B-cell lymphocytosis: are we all bound to have it?. 2010 , 20, 384-90		44
1314	Genetic variation and risk of chronic lymphocytic leukaemia. 2010 , 20, 363-9		13
1313	Antigens in chronic lymphocytic leukemia--implications for cell origin and leukemogenesis. 2010 , 20, 400-9		59

1312	Where is the biology of CLL leading us?. 2010 , 20, 361-2		4
1311	An unbalanced t(15;18)(q21-q22;p11) as the sole cytogenetic aberration in a patient with B-cell chronic lymphocytic leukemia. 2010 , 200, 65-9		1
1310	The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. 2010 , 17, 28-40		662
1309	CD154 expression triggered by purine analogues in vitro: Correlation with treatment response and autoimmune events in chronic lymphocytic leukemia. 2010 , 38, 165-73		2
1308	Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia. 2010 , 38, 1167-77		12
1307	IGHV3-21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2010 , 84, 109-16	3.8	7
1306	The clinical and biological features of a series of immunophenotypic variant of B-CLL. <i>European Journal of Haematology</i> , 2010 , 85, 120-9	3.8	11
1305	Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters. 2010 , 49, 851-9		40
1304	Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. 2010 , 116, 4777-87		91
1303	Telomeres and telomerase in normal and malignant B-cells. 2010 , 28, 157-67		10
1302	Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL). 2010 , 78 Suppl 1, S19-23		71
1301	Non-CLL-like monoclonal B-cell lymphocytosis in the general population: prevalence and phenotypic/genetic characteristics. 2010 , 78 Suppl 1, S24-34		33
1300	ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients. 2010 , 85, 494-8		23
1299	Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia. 2010 , 34, 335-9		9
1298	Lipoprotein lipase is differentially expressed in prognostic subsets of chronic lymphocytic leukemia but displays invariably low catalytical activity. 2010 , 34, 301-6		27
1297	ZAP-70 intron1 DNA methylation status: determination by pyrosequencing in B chronic lymphocytic leukemia. 2010 , 34, 800-8		20
1296	Increased trisomy 12 frequency and a biased IgVH 3-21 gene usage characterize small lymphocytic lymphoma. 2010 , 34, 580-4		11
1295	The proliferative response to CpG-ODN stimulation predicts PFS, TTT and OS in patients with chronic lymphocytic leukemia. 2010 , 34, 1189-94		23

1294	Percentage of smudge cells determined on routine blood smears is a novel prognostic factor in chronic lymphocytic leukemia. 2010 , 34, 892-8	26
1293	Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia. 2010 , 24, 135-41	11
1292	Primary cutaneous B-cell lymphoma is associated with somatically hypermutated immunoglobulin variable genes and frequent use of VH1-69 and VH4-59 segments. 2010 , 162, 611-8	19
1291	Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cell-origin of ALL subgroups - a UKALLXII study. 2010 , 148, 394-401	7
1290	Ribosome-associated nucleophosmin 1: increased expression and shuttling activity distinguishes prognostic subtypes in chronic lymphocytic leukaemia. 2010 , 148, 534-43	11
1289	Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease. 2010 , 148, 754-9	14
1288	Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia. 2010 , 150, 637-9	8
1287	The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies. 2010 , 151, 167-78	28
1286	Engagement of CD31 delivers an activating signal that contributes to the survival of chronic lymphocytic leukaemia cells. 2010 , 151, 252-64	11
1285	Recruitment of PKC-beta1 to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70. 2010 , 24, 141-52	34
1284	Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. 2010 , 24, 512-20	166
1283	Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. 2010 , 24, 788-97	117
1282	Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia. 2010 , 24, 877-81	17
1281	Intraclonal diversification of immunoglobulin light chains in a subset of chronic lymphocytic leukemia alludes to antigen-driven clonal evolution. 2010 , 24, 1317-24	42
1280	Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. 2010 , 42, 132-6	196
1279	From pathogenesis to treatment of chronic lymphocytic leukaemia. 2010 , 10, 37-50	438
1278	A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients. 2010 , 5, e12780	24
1277	Telomere length, molecular cytogenetic findings, and immunophenotypic features in previously untreated patients with B-chronic lymphocytic leukemia. 2010 , 57, 215-21	2

1276 Molecular pathology of leukemia. 1-25

1275	The spectrum of use of rituximab in chronic lymphocytic leukemia. 2010 , 3, 227-46	4
1274	First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. 2010 , 3, 53-67	14
1273	Allogeneic hematopoietic cell transplantation in the treatment of chronic lymphocytic leukemia: why and when?. 2010 , 2, e2010018	1
1272	A single tube, four-color flow cytometry assay for evaluation of ZAP-70 and CD38 expression in chronic lymphocytic leukemia. 2010 , 133, 708-17	8
1271	Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion. 2010 , 16, 5641-53	46
1270	High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia. 2010 , 134, 472-7	30
1269	Assessment of peripheral blood and bone marrow cells apoptosis caused by purine analogues in patients with chronic lymphocytic leukemia in correlation with parameters of disease progression. 2010 , 123, 171-8	2
1268	Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks. 2010 , 16, 835-47	63
1267	Novel insights into the biology of CLL. 2010 , 2010, 70-6	25
1266	Modifying akt signaling in B-cell chronic lymphocytic leukemia cells. 2010 , 70, 7336-44	18
1265	Standard of care and novel treatments for chronic lymphocytic leukemia. 2010 , 67, 1813-24	2
1264	Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior. 2010 , 95, 1526-33	126
1263	Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. 2010 , 5, 499-508	92
1262	Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignancies. 2010 , 9, 4884-92	12
1261	Expression and prognostic assessment of dipeptidyl peptidase IV and related enzymes in B-cell chronic lymphocytic leukemia. 2010 , 10, 180-9	18
1260	Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010 , 51, 95-106	1.9 13
1259	Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression. 2010 , 23, 1518-23	19

1258	Identification of human idiotype-specific T cells in lymphoma and myeloma. 2011 , 344, 193-210	10
1257	The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience. 2010 , 95, 464-9	31
1256	Prognostic markers and stratification of chronic lymphocytic leukemia. 2010 , 2010, 77-81	31
1255	Biological diversity and risk-adapted treatment of chronic lymphocytic leukemia. 2010 , 95, 1441-3	9
1254	MicroRNA in chronic lymphocytic leukemia: transitioning from laboratory-based investigation to clinical application. 2010 , 203, 127-33	26
1253	Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. 2010 , 95, 1705-12	102
1252	Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells. 2010 , 8, 23	15
1251	High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival. 2010 , 12, 328-34	31
1250	Clinical laboratory analysis of immunoglobulin heavy chain variable region genes for chronic lymphocytic leukemia prognosis. 2010 , 12, 244-9	5
1249	Multiplex ligation-dependent probe amplification versus multiprobe fluorescence in situ hybridization to detect genomic aberrations in chronic lymphocytic leukemia: a tertiary center experience. 2010 , 12, 197-203	22
1248	Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. 2010 , 16, 587-99	47
1247	Molecular Diagnostics and Cytogenetic Testing. 2010 , 61-95	
1246	Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. 2010 , 251-261	
1245	[Chronic lymphocytic leukemia]. 2010 , 135, 172-8	4
1244	Low-penetrance susceptibility to hematological malignancy. 2010 , 20, 245-50	7
1243	Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). 2010 , 23, 71-84	51
1242	An overview of chronic lymphocytic leukaemia biology. 2010 , 23, 21-32	21
1241	Diagnostic issues in chronic lymphocytic leukaemia (CLL). 2010 , 23, 3-20	33

1240	Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells. 2010 , 23, 33-45		43
1239	Activation-induced cytidine deaminase splicing patterns in chronic lymphocytic leukemia. 2010 , 44, 262-7		15
1238	TP53 mutation and survival in chronic lymphocytic leukemia. 2010 , 28, 4473-9		430
1237	Immunoglobulin heavy chain V-D-J gene rearrangement and mutational status in Uruguayan patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010 , 51, 2070-8	1.9	8
1236	Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. 2010 , 376, 1164-74		1471
1235	Rituximab in chronic lymphocytic leukemia. 2010 , 47, 156-69		29
1234	How I treat CLL up front. <i>Blood</i> , 2010 , 115, 187-97	2.2	154
1233	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Monoclonal B-Cell Lymphocytosis. 2010 , 3, 907-31		3
1232	NF-kappaB as a therapeutic target in chronic lymphocytic leukemia. 2010 , 14, 275-88		37
1231	Molecular analysis of genetic markers for non-Hodgkin lymphomas. 2010 , Chapter 10, Unit 10.14.1-25		
1230	Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1829-36	1.9	55
1229	Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis. <i>Leukemia and Lymphoma</i> , 2011 , 52, 15-23	1.9	8
1228	Immunoglobulin class switch recombination in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1398-400	1.9	3
1227	Allogeneic hematopoietic cell transplant with fludarabine-based reduced-intensity conditioning as treatment for advanced chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2011 , 52, 719-23	1.9	5
1226	Insight into the behavior of hairy cell leukemia by immunogenetic analysis. <i>Leukemia and Lymphoma</i> , 2011 , 52 Suppl 2, 103-7	1.9	5
1225	TOSO is overexpressed and correlated with disease progression in Chinese patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2011 , 52, 72-8	1.9	8
1224	Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. 2011 , 29, 2223-9		207
1223	B-cell receptor signaling in chronic lymphocytic leukemia. <i>Blood</i> , 2011 , 118, 4313-20	2.2	281

1222	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. 2011 , 475, 101-5	1206
1221	Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies. 2011 , 20, 1167-74	18
1220	Encyclopedia of Cancer. 2011 ,	29
1219	IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. 2011 , 25, 828-37	53
1218	Encyclopedia of Cancer. 2011 , 404-404	
1217	Cancer Immunology and Immunotherapy. 2011 ,	1
1216	Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. 2011 , 208, 1389-401	483
1215	Hematopathology. 2011 ,	
1214	Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. 2011 , 37, 3-10	77
1213	Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate. 2011 , 204, 77-83	37
1212	Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70-. 2011 , 208, 67-80	467
1211	The Syk kinase as a therapeutic target in leukemia and lymphoma. 2011 , 20, 623-36	38
1210	Advances in the clinical staging of chronic lymphocytic leukemia. 2011 , 57, 1771-2	7
1209	MFI ratio estimation of ZAP-70 in B-CLL by flow cytometry can be improved by considering the isotype-matched antibody signal. 2011 , 33, 194-200	6
1208	Phase précoce de la leucémie lymphoïde chronique (LLC) et concept de lymphocytose B monoclonale (MBL). 2011 , 2011, 47-53	
1207	Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. <i>Blood</i> , 2011 , 118, 2530-40	2.2 175
1206	Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. 2011 , 29, 2703-8	76
1205	Encyclopedia of Cancer. 2011 , 485-485	

1204	Genetics of chronic lymphocytic leukemia. 2011 , 31, 649-58, ix		6
1203	Carbonyl group serum levels are associated with CD38 expression in patients with B chronic lymphocytic leukemia. 2011 , 44, 1487-90		14
1202	Torque teno virus 10 isolated by genome amplification techniques from a patient with concomitant chronic lymphocytic leukemia and polycythemia vera. 2011 , 17, 1338-48		10
1201	Intraclonal cell expansion and selection driven by B cell receptor in chronic lymphocytic leukemia. 2011 , 17, 834-9		5
1200	Mutation pattern of paired immunoglobulin heavy and light variable domains in chronic lymphocytic leukemia B cells. 2011 , 17, 1188-95		9
1199	Zeta Chain-Associated Protein-70 Expression is a Prognostic Tool in Mature and Precursor B-Cell Neoplasm. 2011 , 2, 40-46		
1198	The chronic lymphoid leukemias. 2011 , 407-418		1
1197	Analysis of CD38 and ZAP70 mRNA expression among cytogenetic subgroups of Iranian chronic-lymphocytic-leukemia patients. 2011 , 10, 2415-23		2
1196	P53 and microRNAs in chronic lymphocytic leukemia. 2011 , 2, 8		1
1195	DNA Repair Deficiency Associated with Hematological Neoplasms. 2011 ,		1
1194	MDR-1 gene polymorphisms G2677T and C3435T in a case of Hodgkin's variant of Richter's syndrome. 2011 , 2, 379-381		2
1193	Bendamustine for patients with B cell lymphoid malignancies. 2011 ,		0
1192	Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia. 2011 , 6, e24313		35
1191	Biased use of the IGHV4 family and evidence for antigen selection in Chlamydomphila psittaci-negative ocular adnexal extranodal marginal zone lymphomas. 2011 , 6, e29114		18
1190	Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. <i>Blood</i> , 2011 , 117, 1781-91	2.2	190
1189	c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells. <i>Blood</i> , 2011 , 117, 2414-22	2.2	32
1188	LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients. <i>Blood</i> , 2011 , 117, 4076-84	2.2	28
1187	Deregulation of Aiolos expression in chronic lymphocytic leukemia is associated with epigenetic modifications. <i>Blood</i> , 2011 , 117, 1917-27	2.2	30

1186	CCL3 (MIP-1 β) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2011 , 117, 1662-9	2.2	98
1185	Evidence of canonical somatic hypermutation in hairy cell leukemia. <i>Blood</i> , 2011 , 117, 4844-51	2.2	27
1184	Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. <i>Blood</i> , 2011 , 118, 3051-61	2.2	102
1183	A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia. <i>Blood</i> , 2011 , 118, e1-15	2.2	20
1182	HCL: insights into biology. <i>Blood</i> , 2011 , 117, 4682-3	2.2	
1181	IRF4 mutations in chronic lymphocytic leukemia. <i>Blood</i> , 2011 , 118, 2827-9	2.2	50
1180	Enhanced levels of both the membrane-bound and soluble forms of IgM Fc receptor (Fc β R) in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2011 , 118, 4902-9	2.2	24
1179	CD38 and chronic lymphocytic leukemia: a decade later. <i>Blood</i> , 2011 , 118, 3470-8	2.2	153
1178	Inflammation, the microenvironment and chronic lymphocytic leukemia. 2011 , 96, 353-5		18
1177	Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. 2011 , 96, 1121-7		159
1176	LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia. 2011 , 96, 1153-60		39
1175	Non-Hodgkin's lymphomas. 2011 , 9, 484-560		47
1174	Chlorambucil for the treatment of patients with chronic lymphocytic leukaemia, or small lymphocytic lymphoma. 2011 ,		1
1173	Small cell variant of mantle cell lymphoma is an indolent lymphoma characterized by bone marrow involvement, splenomegaly, and a low Ki-67 index. 2011 , 102, 1734-41		16
1172	Cyclin D2 is overexpressed in proliferation centers of chronic lymphocytic leukemia/small lymphocytic lymphoma. 2011 , 102, 2103-7		25
1171	B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage. 2011 , 153, 3-14		21
1170	Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals. 2011 , 153, 199-211		51
1169	CD180 functions in activation, survival and cycling of B chronic lymphocytic leukaemia cells. 2011 , 153, 486-98		16

1168	13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia. 2011 , 25, 489-97		93
1167	Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL. 2011 , 25, 1459-66		29
1166	Immunoglobulin sequence analysis and prognostication in CLL: guidelines from the ERIC review board for reliable interpretation of problematic cases. 2011 , 25, 979-84		59
1165	A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment. 2011 , 25, 1268-77		39
1164	Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice. <i>European Journal of Haematology</i> , 2011 , 87, 130-7	3.8	14
1163	Unlocking the secrets of immunoglobulin receptors in mantle cell lymphoma: implications for the origin and selection of the malignant cells. 2011 , 21, 299-307		13
1162	Searching for surrogates for IGHV mutations in chronic lymphocytic leukemia. 2011 , 35, 1432-5		8
1161	MicroRNAs in chronic lymphocytic leukemia. 2011 , 90, 173-8		9
1160	Therapeutic management of chronic lymphocytic leukaemia: state of the art and future perspectives. 2011 , 80, 100-13		3
1159	Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. 2011 , 20, 246-59		203
1158	Prognostic factors in chronic lymphocytic leukemia-what do we need to know?. 2011 , 8, 38-47		128
1157	Diagnostic moléculaire des hémopathies lymphoïdes matures. 2011 , 13, 537-541		
1156	Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia. 2011 , 90, 173-83		32
1155	Genomic screening by 454 pyrosequencing identifies a new human IGHV gene and sixteen other new IGHV allelic variants. 2011 , 63, 259-65		50
1154	Cluster analysis of immunophenotypic data: the example of chronic lymphocytic leukemia. 2011 , 134, 137-44		17
1153	Immunologic aspects of monoclonal B-cell lymphocytosis. 2011 , 49, 269-80		10
1152	The autocrine motility factor receptor is overexpressed on the surface of B cells in Binet C chronic lymphocytic leukemia. 2011 , 28, 1542-8		2
1151	MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis. 2011 , 28, 1549-54		18

1150	Telomeres and prognosis in patients with chronic lymphocytic leukaemia. 2011 , 93, 74-82	21
1149	New insights into the pathobiology of chronic lymphocytic leukemia. 2011 , 4, 149-163	0
1148	High prevalence of adverse prognostic genetic aberrations and unmutated IGHV genes in small lymphocytic lymphoma as compared to chronic lymphocytic leukemia. 2011 , 4, 189-197	1
1147	Chronic lymphocytic leukemia: an update on biology and treatment. 2011 , 13, 379-85	14
1146	Evaluation of chronic lymphocytic leukemia by oligonucleotide-based microarray analysis uncovers novel aberrations not detected by FISH or cytogenetic analysis. 2011 , 4, 25	14
1145	Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling. 2011 , 50, 263-74	22
1144	13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. 2011 , 50, 633-43	57
1143	Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization to detect chromosomal abnormalities in chronic lymphocytic leukemia: a comparative study. 2011 , 50, 726-34	16
1142	Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. 2011 , 117, 2163-9	42
1141	B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia. 2011 , 117, 1891-900	27
1140	Methodological comparison of two anti-ZAP-70 antibodies. 2011 , 80, 300-8	8
1139	Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlation. 2011 , 80, 309-17	8
1138	Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. 2011 , 29, 91-9	24
1137	Hairy cell leukaemia: biological and clinical overview from immunogenetic insights. 2011 , 29, 55-66	30
1136	Mutation analysis of the TNFAIP3 (A20) tumor suppressor gene in CLL. 2011 , 128, 1747-50	15
1135	High expression of the immature laminin receptor protein correlates with mutated IGVH status and predicts a favorable prognosis in chronic lymphocytic leukemia. 2011 , 35, 721-9	9
1134	CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. 2011 , 35, 750-6	53
1133	Prognostic significance of serum immunoglobulin paraprotein in patients with chronic lymphocytic leukemia. 2011 , 35, 1060-5	21

1132	Association between single nucleotide polymorphism-genotype and outcome of patients with chronic lymphocytic leukemia in a randomized chemotherapy trial. 2011 , 96, 1496-503		13
1131	Lenalidomide in the treatment of chronic lymphocytic leukemia. 2011 , 20, 273-86		7
1130	Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1873-81	1.9	12
1129	Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. 2011 , 96, 1161-9		74
1128	Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies. <i>Leukemia and Lymphoma</i> , 2011 , 52, 374-86	1.9	1
1127	Multi-parameter prognostication in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1823-4	1.9	
1126	Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia. 2011 , 6, 188-94		50
1125	Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. 2011 , 29, 4088-95		105
1124	Chronic lymphocytic leukemia with t(14;19)(q32;q13) is characterized by atypical morphologic and immunophenotypic features and distinctive genetic features. 2011 , 135, 686-96		30
1123	Molecular Pathology of Chronic Lymphocytic Leukemia. 2011 , 255-291		
1122	Unraveling the molecular pathogenesis of chronic lymphocytic leukemia: dissecting a microRNA regulatory network. 2011 , 305, 95-7		4
1121	Relevance of IgVH gene somatic hypermutation and interphase cytogenetics in lymphomatous presentation of chronic lymphocytic leukemia/small lymphocytic lymphoma. 2011 , 19, 563-9		2
1120	Clinical Laboratory Method for Detection of IGHV Mutation Status in Patients with CLL Validated by Igbblast and IMGT/V-QUEST. 2011 , 11, 17-25		
1119	Cancer stem cells of differentiated B-cell malignancies: models and consequences. <i>Cancers</i> , 2011 , 3, 1566-79		4
1118	The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia. 2011 , 5, 45-53		7
1117	A pathobiological role of the insulin receptor in chronic lymphocytic leukemia. 2011 , 17, 2679-92		27
1116	Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1425-34	1.9	11
1115	Choosing first-line therapy for chronic lymphocytic leukemia. 2011 , 11, 1379-90		13

1114	Antigens. 2011 , 1-157		0
1113	Update on therapy of chronic lymphocytic leukemia. 2011 , 29, 544-50		88
1112	Current strategies for the diagnosis and management of chronic lymphocytic leukemia (CLL), with a focus on poor-risk CLL: A review. 2011 , 28, 86-96		
1111	Lymphomas: its gene expression profiling. 2011 , 7, 393-8		2
1110	Relationship between advanced oxidation protein products, advanced glycation end products, and S-nitrosylated proteins with biological risk and MDR-1 polymorphisms in patients affected by B-chronic lymphocytic leukemia. 2012 , 30, 20-6		30
1109	Immunoglobulin gene repertoire in chronic lymphocytic leukemia: insight into antigen selection and microenvironmental interactions. 2012 , 4, e2012052		14
1108	Recent advances in chronic lymphocytic leukemia. 2012 , 49, 137-43		7
1107	Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial. 2012 , 47, 542-8		31
1106	Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. 2012 , 72, 5307-16		195
1105	Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 2136-42	1.9	90
1104	Small lymphocytic lymphoma and chronic lymphocytic leukemia: are they the same disease?. 2012 , 18, 396-403		36
1103	Gene expression profiling identifies ARSD as a new marker of disease progression and the sphingolipid metabolism as a potential novel metabolism in chronic lymphocytic leukemia. 2011 , 11, 15-28		16
1102	Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 218-24	1.9	10
1101	Protein phosphatase-2A activation is a critical step for enzastaurin activity in chronic lymphoid leukemia cells. <i>Leukemia and Lymphoma</i> , 2012 , 53, 966-72	1.9	8
1100	Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subset-biased global DNA methylation profiles. 2012 , 7, 1435-42		29
1099	Prognostic factors in CLL. 2012 , 1, S29-30		4
1098	The times they are a-changin': prognostic markers in the new era of BCR-targeting therapies for CLL. 2012 , 6, 49-57		3
1097	Chronic lymphocytic leukemia: treatment of relapse. 2012 , 1, S31-2		1

1096	Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. 2012 , 188, 6071-83		60
1095	Chronic Lymphocytic Leukemia. 2012 , 85-101		
1094	State-of-the-Art Management of Patients Suffering from Chronic Lymphocytic Leukemia. 2012 , 6, 165-78		1
1093	Advances in the diagnosis and management of lymphoma. 2012 , 29		1
1092	The role of B cell receptor stimulation in CLL pathogenesis. 2012 , 18, 3335-55		12
1091	Microenvironmental interactions in chronic lymphocytic leukemia: hints for pathogenesis and identification of targets for rational therapy. 2012 , 18, 3323-34		11
1090	Editorial: the importance of rational chemotherapy of chronic lymphocytic leukemia. 2012 , 18, 3321-2		
1089	Clinical and laboratory prognostic indicators in chronic lymphocytic leukemia. 2012 , 19, 18-25		28
1088	Prognostic markers in chronic lymphocytic leukemia. 2012 , 76-86		
1087	The initial approach to patients with chronic lymphocytic leukemia diagnosed in day-to-day practice. 2012 , 1, 47-55		
1086	Dysfunctional $\gamma\delta$ T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. <i>Blood</i> , 2012 , 120, 3271-9	2.2	40
1085	Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia. <i>Blood</i> , 2012 , 119, 1726-36	2.2	49
1084	Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells. <i>Blood</i> , 2012 , 119, 170-9	2.2	77
1083	Enhanced outgrowth of EBV-transformed chronic lymphocytic leukemia B cells mediated by coculture with macrophage feeder cells. <i>Blood</i> , 2012 , 119, e35-44	2.2	11
1082	The IGHV1-69/IGHJ3 recombinations of unmutated CLL are distinct from those of normal B cells. <i>Blood</i> , 2012 , 119, 2106-9	2.2	8
1081	NOTCH1 mutations in CLL associated with trisomy 12. <i>Blood</i> , 2012 , 119, 329-31	2.2	168
1080	Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice. <i>Blood</i> , 2012 , 120, 1027-38	2.2	47
1079	Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. <i>Blood</i> , 2012 , 119, 2854-62	2.2	236

1078	Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT. <i>Blood</i> , 2012 , 119, 6278-87	2.2	66
1077	T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients. <i>Blood</i> , 2012 , 120, 2438-49	2.2	13
1076	Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. <i>Blood</i> , 2012 , 120, 2639-49	2.2	51
1075	CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. 2012 , 97, 279-87		21
1074	Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. <i>Blood</i> , 2012 , 120, 3501-9	2.2	107
1073	Molecular pathogenesis of chronic lymphocytic leukemia. 2012 , 122, 3432-8		124
1072	Molecular characterization of chronic lymphocytic leukemia patients with a high number of losses in 13q14. 2012 , 7, e48485		29
1071	IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions. <i>Blood</i> , 2012 , 120, 4802-11	2.2	42
1070	Predicting survival in chronic lymphocytic leukemia. 2012 , 12, 393-403		15
1069	Studies of Rearrangements and Somatic Hypermutation of IGHV Genes in Chronic Lymphocytic Leukemia. 2012 , 429-442		
1068	[Bone marrow histology from the clinical point of view]. 2012 , 33, 490-5		1
1067	Nowe markery prognostyczne przewlekłej białaczki limfocytowej badane metodą immunofenotypizacji. 2012 , 43, 271-276		
1066	Surface profiles for subclassification of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1046-56	1.9	10
1065	KIBRA gene methylation is associated with unfavorable biological prognostic parameters in chronic lymphocytic leukemia. 2012 , 7, 211-5		27
1064	Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. <i>Blood</i> , 2012 , 119, 4467-75	2.2	289
1063	Distinct cellular pathways select germline-encoded and somatically mutated antibodies into immunological memory. 2012 , 209, 2079-97		190
1062	Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. <i>Blood</i> , 2012 , 120, 843-6	2.2	63
1061	Optimal management of older patients with chronic lymphocytic leukemia: some facts and principles guiding therapeutic choices. 2012 , 26, 15-23		13

1060	Chronic lymphocytic leukemia. 2012 , 58, 153-67		20
1059	Cellular origin and pathophysiology of chronic lymphocytic leukemia. 2012 , 209, 2183-98		178
1058	Signaling pathways activated by the B-cell receptor in chronic lymphocytic leukemia. 2012 , 5, 341-8		20
1057	Targeting the B cell receptor pathway in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 2362-70	1.9	68
1056	Phenotypic complexity of T regulatory subsets in patients with B-chronic lymphocytic leukemia. 2012 , 25, 246-59		26
1055	Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL. 2012 , 16, 2074-84		7
1054	Genetics in chronic lymphocytic leukemia. 2012 , 16-24		
1053	Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype. 2012 , 181, 1879-88		24
1052	The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia. 2012 , 12, 132-7		15
1051	IGHV3-21 gene frequency in a Swedish cohort of patients with newly diagnosed chronic lymphocytic leukemia. 2012 , 12, 201-6		10
1050	Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia. 2012 , 12, 252-60		10
1049	Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice. 2012 , 9, S85-S92		5
1048	Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results. 2012 , 36, 1134-40		
1047	Molecular Profiling Methods in the Diagnosis of Hematologic Disorders. 2012 , 244-266		
1046	Comprehensive assessment of prognostic factors predicting outcome in Chinese patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide. 2012 , 29, 2102-10		3
1045	Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1023-31	1.9	28
1044	Chronische lymphatische Leukämie. 2012 , 18, 1115-1119		0
1043	Myeloma and Leukemia. 2012 , 509-529		

1042	Bone Marrow Lymphoid Infiltrates. 2012,		1
1041	Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia. 2012, CD009045		4
1040	Molecular Aspects of Hematologic Malignancies. 2012,		2
1039	Methylation of tumor suppressor microRNAs: lessons from lymphoid malignancies. 2012, 12, 755-65		14
1038	Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study. <i>Leukemia and Lymphoma</i> , 2012, 53, 1743-8	1.9	14
1037	HS1, a Lyn kinase substrate, is abnormally expressed in B-chronic lymphocytic leukemia and correlates with response to fludarabine-based regimen. 2012, 7, e39902		25
1036	Lymphoproliferative Disorders in Patients with Systemic Lupus Erythematosus. 2012,		
1035	Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors. 2012, 18, 1281-91		56
1034	Lipoprotein lipase: a new prognostic factor in chronic lymphocytic leukaemia. 2012, 16, 474-9		1
1033	The Biological Relevance of ZAP-70 in CLL. 2012,		
1032	Predicting clinical outcome in B-chronic lymphocytic leukemia. 2012, 394-8		1
1031	Mouse Models of Chronic Lymphocytic Leukemia. 2012,		2
1030	Upper respiratory tract colonization by gram-negative rods in patients with chronic lymphocytic leukemia: analysis of risk factors. 2012, 2012, 617218		3
1029	Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. 2012, 97, 849-53		9
1028	Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. 2011, 44, 47-52		752
1027	Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. <i>Blood</i> , 2012, 119, 521-9	2.2	337
1026	Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 2105-15	1.9	4
1025	Molecular genetic characterization of lymphoma: application to cytology diagnosis. 2012, 40, 542-55		20

1024	Next generation RNA-sequencing in prognostic subsets of chronic lymphocytic leukemia. 2012 , 87, 737-40		21
1023	Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. 2012 , 30, 2483-91		100
1022	Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. 2012 , 97, 56-63		43
1021	Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia. 2012 , 21, 409-23		3
1020	RNA-based markers as prognostic factors in chronic lymphocytic leukemia. 2012 , 5, 69-79		8
1019	Unexpectedly high frequency of European parentage in Venezuelan patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 235-41	1.9	4
1018	Pathogenesis of human B cell lymphomas. 2012 , 30, 565-610		307
1017	IGHV gene rearrangements as outcome predictors for CLL patients: experience of Ukrainian group. 2012 , 29, 1093-101		8
1016	Immunological aspects in chronic lymphocytic leukemia (CLL) development. 2012 , 91, 981-96		32
1015	Detection methods of ZAP-70 in chronic lymphocytic leukemia. 2012 , 12, 69-77		13
1014	Defining the prognosis of early stage chronic lymphocytic leukaemia patients. 2012 , 156, 499-507		38
1013	A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis. 2012 , 40, 197-206.e1		14
1012	Pathologic and molecular genetic features of chronic lymphocytic leukemia. 2012 , 39, 74-9		11
1011	Single-institution long-term outcomes for patients receiving nonmyeloablative conditioning hematopoietic cell transplantation for chronic lymphocytic leukemia and follicular lymphoma. <i>European Journal of Haematology</i> , 2012 , 89, 151-9	3.8	6
1010	In non-follicular lymphoproliferative disorders, IGH/BCL2-fusion is not restricted to chronic lymphocytic leukaemia. 2012 , 158, 489-98		18
1009	Clinical utility of molecular and flow cytometric markers in chronic lymphocytic leukaemia. 2012 , 42, 137-46		2
1008	Combined normal donor and CLL: Single tube ZAP-70 analysis. 2012 , 82, 67-77		4
1007	Improved flow cytometric detection of ZAP-70 in chronic lymphocytic leukemia using experimentally optimized isotypic control antibodies. 2012 , 82, 78-84		9

1006	Telomere/telomerase interplay in virus-driven and virus-independent lymphomagenesis: pathogenic and clinical implications. 2012 , 32, 233-53	27
1005	Mantle cell lymphoma displays a homogenous methylation profile: a comparative analysis with chronic lymphocytic leukemia. 2012 , 87, 361-7	11
1004	Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?. 2012 , 7, 3-12	13
1003	B cell receptor signaling in chronic lymphocytic leukemia. 2013 , 34, 592-601	207
1002	Antigen selection in B-cell lymphomas--tracing the evidence. 2013 , 23, 399-409	32
1001	Lymphoma. 2013 ,	1
1000	Complete haplotype sequence of the human immunoglobulin heavy-chain variable, diversity, and joining genes and characterization of allelic and copy-number variation. 2013 , 92, 530-46	150
999	Cancer Genomics. 2013 ,	4
998	Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications. 2013 , 27, 207-35	67
997	MBL versus CLL: how important is the distinction?. 2013 , 27, 251-65	9
996	Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia. 2013 , 27, 329-39	7
995	B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities. 2013 , 32, 377-96	4
994	NOTCH1 mutations influence survival in chronic lymphocytic leukemia patients. 2013 , 13, 274	23
993	The genomic landscape of chronic lymphocytic leukemia: clinical implications. 2013 , 11, 124	26
992	Chronic Lymphoid Leukaemias and Exfoliating Lymphoma. 2013 , 100-151	
991	Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. 2013 , 27, 173-206	73
990	GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia. 2013 , 8, 22-7	35
989	Chronic lymphocytic leukemia: inception to cure: are we there?. 2013 , 29, 1-10	4

988	Novel Molecular Acquisitions in Leukemias. 2013 , 453-493		
987	Very low levels of surface CD45 reflect CLL cell fragility, are inversely correlated with trisomy 12 and are associated with increased treatment-free survival. 2013 , 88, 747-53		13
986	Proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia reveals a possible role for kininogen. 2013 , 91, 478-85		11
985	LLC: physiopathologie, diagnostic et approche thérapeutique. 2013 , 2013, 61-71		
984	Molecular bases of chronic lymphocytic leukemia in light of new treatments. 2013 , 155, 51-5		10
983	"Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia". 2013 , 3, e149		29
982	Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia. <i>Blood</i> , 2013 , 122, 1621-33	2.2	52
981	Clonal evolution in chronic lymphocytic leukemia: analysis of correlations with IGHV mutational status, NOTCH1 mutations and clinical significance. 2013 , 52, 920-7		13
980	Molecular biomarkers in chronic lymphocytic leukemia. 2013 , 792, 193-214		10
979	Nouveautés sur les hémopathies lymphoïdes chroniques B matures. 2013 , 28, 174-182		
978	Chronic lymphocytic leukaemia. 2013 , 41, 278-281		
977	Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. 2013 , 6, 27		54
976	Genetic methylation and lymphoid malignancies: biomarkers of tumor progression and targeted therapy. 2013 , 1, 24		5
975	Lymphoid Malignancies: Molecular Diagnostics. 2013 , 887-928		
974	Advances in Chronic Lymphocytic Leukemia. 2013 ,		2
973	Towards targeted therapy of chronic lymphocytic leukemia. 2013 , 792, 259-91		10
972	Dielectrophoretic isolation and detection of cfc-DNA nanoparticulate biomarkers and virus from blood. 2013 , 34, 1076-84		54
971	B-cell receptor signaling in chronic lymphocytic leukemia leans on Lyn. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1125-6	1.9	3

970	T/B ratio does not reflect levels of ZAP70 expression in clonal CLL B-cells due to ZAP70 overexpression in patient T-cells. 2013 , 84, 125-32		6
969	6q deletion detected by fluorescence in situ hybridization using bacterial artificial chromosome in chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2013 , 91, 10-9	3.8	7
968	Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis. 2013 , 163, 326-33		31
967	Expression of ZAP70 in chronic lymphocytic leukaemia activates NF-B signalling. 2013 , 163, 621-30		9
966	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). 2013 , 24, 561-76		162
965	Geography, ethnicity and "roots" in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1142-50	1.9	30
964	Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. 2013 , 88, 24-31		21
963	IgD cross-linking induces gene expression profiling changes and enhances apoptosis in chronic lymphocytic leukemia cells. 2013 , 37, 455-62		7
962	Chronic lymphocytic leukemia with t(14;18)(q32;q21). 2013 , 44, 598-605		14
961	The automated monocyte count is independently predictive of overall survival from diagnosis in chronic lymphocytic leukaemia and of survival following first-line chemotherapy. 2013 , 37, 614-8		6
960	Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers. 2013 , 30, 405		13
959	Next-generation sequencing reveals the secrets of the chronic lymphocytic leukemia genome. 2013 , 15, 3-8		29
958	Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients. 2013 , 93, 161-70		13
957	Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2351-64	1.9	48
956	Chromosomal abnormalities by conventional cytogenetics and interphase fluorescence in situ hybridization in chronic lymphocytic leukemia in Taiwan, an area with low incidence--clinical implication and comparison between the West and the East. 2013 , 92, 799-806		14
955	Targeting pathological B cell receptor signalling in lymphoid malignancies. 2013 , 12, 229-43		286
954	Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study. 2013 , 31, 930-7		43
953	Etiology and Epidemiology of CLL. 2013 , 63-69		

952	Histopathology, Morphology and Immunophenotyping of CLL. 2013 , 71-89		
951	Treatment of Chronic Lymphocytic Leukemia and Related Disorders. 2013 , 103-119		
950	Pathology of Non-HodgkinĒ and HodgkinĒ Lymphomas. 2013 , 867-918		
949	Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia. 2013 , 88, 277-82		11
948	Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease. 2013 , 206, 49-62		51
947	The role of bone marrow biopsy examination at diagnosis of chronic lymphocytic leukemia: a reappraisal. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2377-84	1.9	5
946	Methylation status regulates lipoprotein lipase expression in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1844-8	1.9	13
945	Chronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy. 2013 , 162, 15-24		30
944	A protein disulfide isomerase/thioredoxin-1 complex is physically attached to exofacial membrane tumor necrosis factor receptors: overexpression in chronic lymphocytic leukemia cells. 2013 , 18, 363-75		18
943	Immunoglobulin gene rearrangements and mutational status in argentinian patients with chronic lymphocytic leukemia. 2013 , 13, 447-457.e2		13
942	Stereotyped B cell receptors in B cell leukemias and lymphomas. 2013 , 971, 135-48		18
941	Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. 2013 , 27, 2196-9		78
940	The significance of stereotyped B-cell receptors in chronic lymphocytic leukemia. 2013 , 27, 237-50		12
939	The changing paradigm of chronic lymphocytic leukemia management. 2013 , 24, 401-10		7
938	Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options. 2013 , 328, 27-35		14
937	CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes. 2013 , 98, 274-8		13
936	Genomic arrays in chronic lymphocytic leukemia routine clinical practice: are we ready to substitute conventional cytogenetics and fluorescence in situ hybridization techniques?. <i>Leukemia and Lymphoma</i> , 2013 , 54, 986-95	1.9	16
935	Structural alterations in chronic lymphocytic leukaemia. Cytogenetic and FISH analysis. 2013 , 31, 79-87		18

934 B-cell chronic lymphocytic leukemia/lymphoma. **2013**, 196-214

933 Pathologic diagnosis: molecular genetics. **2013**, 56-81

932 ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin. **2013**, 98, 1124-31 29

931 [Chronic lymphocytic leukemia]. **2013**, 138, 2153-66 4

930 Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. *Leukemia and Lymphoma*, **2013**, 54, 476-82 1.9 10

929 Quantitative detection of zeta-chain-associated protein 70 expression in chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2013**, 54, 579-86 1.9 1

928 A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. **2013**, 210, 59-70 107

927 New insights into biology, prognostic factors, and current therapeutic strategies in chronic lymphocytic leukemia. **2013**, 2013, 740615 16

926 Prevalence of ZAP-70 and CD 38 in Indian chronic lymphocytic leukemia patients. **2013**, 50, 333-6 7

925 Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia. **2013**, 19, 2893-904 52

924 Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results. **2013**, 21, 116-31 22

923 Inherited susceptibility to CLL. **2013**, 792, 293-308 8

922 Functional analysis of sucrase-isomaltase mutations from chronic lymphocytic leukemia patients. **2013**, 22, 2273-82 21

921 CIP4 controls CCL19-driven cell steering and chemotaxis in chronic lymphocytic leukemia. **2013**, 73, 3412-24 15

920 Prognostic significance of serum free light chains in chronic lymphocytic leukemia. **2013**, 2013, 359071 5

919 Igs expressed by chronic lymphocytic leukemia B cells show limited binding-site structure variability. **2013**, 190, 5771-8 18

918 Gene expression and epigenetic deregulation. **2013**, 792, 133-50 4

917 The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab. *European Journal of Haematology*, **2013**, 90, 479-85 3.8 11

916	Expression levels of Lyn, Syk, PLC β and ERK in patients with chronic lymphocytic leukemia, and higher levels of Lyn are associated with a shorter treatment-free survival. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1165-70	1.9	14
915	A method to detect differentially methylated loci with next-generation sequencing. 2013 , 37, 377-82		11
914	Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2013 , 90, 340-4	3.8	2
913	The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy. 2013 , 13, 1089-108		
912	Reverse-engineering the genetic circuitry of a cancer cell with predicted intervention in chronic lymphocytic leukemia. 2013 , 110, 459-64		19
911	ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia. 2013 , 8, 720-9		23
910	Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function. <i>Blood</i> , 2013 , 122, 2664-72	2.2	53
909	Pathology consultation on evaluating prognosis in incidental monoclonal lymphocytosis and chronic lymphocytic leukemia. 2013 , 139, 708-12		9
908	HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway. 2013 , 4, e518		99
907	Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia. 2013 , 110, 3035-40		35
906	Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling. 2013 , 110, E1500-7		37
905	Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. 2013 , 110, 6127-32		63
904	Approach to frontline therapy in elderly chronic lymphocytic leukemia patients. 2013 , 9, 331-347		
903	Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. <i>Blood</i> , 2013 , 121, 1175-83	2.2	32
902	Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells. <i>Blood</i> , 2013 , 121, 4708-17	2.2	33
901	Targeting B-cell anergy in chronic lymphocytic leukemia. <i>Blood</i> , 2013 , 121, 3879-88, S1-8	2.2	63
900	Survival of the weak (signalers): anergy in CLL. <i>Blood</i> , 2013 , 121, 3781-3	2.2	10
899	ZAP70 in B-CLL cells related to the expression in NK cells is a surrogate marker for mutational status. 2013 ,		4

898	Differential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemia. 2013 , 19, 115-23	42
897	Peptides that bind specifically to an antibody from a chronic lymphocytic leukemia clone expressing unmutated immunoglobulin variable region genes. 2013 , 19, 245-52	6
896	Temporal dynamics of clonal evolution in chronic lymphocytic leukemia with stereotyped IGHV4-34/IGKV2-30 antigen receptors: longitudinal immunogenetic evidence. 2013 , 19, 230-6	11
895	B-cell chronic lymphocytic leukemia. 786-792	
894	TLR9 signaling defines distinct prognostic subsets in CLL. 2013 , 18, 371-86	12
893	BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. 2014 , 124, 5074-84	46
892	Molecular Pathology of Chronic Lymphocytic Leukemia and Relevance to Novel Therapies. 2014 , 1664-1676	
891	Pathology of indolent B-cell neoplasms other than follicular lymphoma. 2014 , 54, 11-22	9
890	Nucleic Acids as Molecular Diagnostics in Hematopoietic Malignancies [Implications in Diagnosis, Prognosis, and Therapeutic Management. 2014 , 185-200	
889	Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling. 2014 , 5, e1439	12
888	Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells. 2014 , 28, 1158-63	44
887	Emerging roles for the FCRL family members in lymphocyte biology and disease. 2014 , 382, 29-50	29
886	The emerging role of Twist proteins in hematopoietic cells and hematological malignancies. 2014 , 4, e206	23
885	Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014 , 55, 920-8	1.9 23
884	Prognostic factors in chronic lymphocytic leukemia: a conceptual approach. 2014 , 3, 145-152	1
883	Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1274-80	1.9 3
882	Clonotypic analysis of immunoglobulin heavy chain sequences in patients with Waldenström's macroglobulinemia: correlation with MYD88 L265P somatic mutation status, clinical features, and outcome. 2014 , 2014, 809103	8
881	The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy. 2014 , 99, 1138-48	68

880	Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?. 2014 , 99, 5-6		7
879	2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation. <i>Leukemia and Lymphoma</i> , 2014 , 55, 314-9	1.9	43
878	The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. 2014 , 99, 873-80		28
877	Recent advances in the pathogenesis and treatment of chronic lymphocytic leukemia. 2014 , 35, 105-20		0
876	Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia. 2014 , 99, 881-7		25
875	Multiple productive immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukemia are mostly derived from independent clones. 2014 , 99, 329-38		28
874	Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study. 2014 , 89, 743-50		13
873	Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2085-92	1.9	25
872	Personalized lymphoma diagnosis and treatment: recent advances. 2014 , 20, 431-439		
871	Comprehensive characterization of immunoglobulin gene rearrangements in patients with chronic lymphocytic leukaemia. 2014 , 18, 979-90		3
870	Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia. 2014 , 53, 264-73		9
869	Protein kinase C in cellular transformation: a valid target for therapy?. 2014 , 42, 1556-62		16
868	Chronic lymphocytic leukaemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms?. 2014 , 142, 536-50		9
867	Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. 2014 , 167, 214-23		67
866	Amplification of B cell receptor-Erk signaling by Rasgrf-1 overexpression in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2907-16	1.9	8
865	ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. 2014 , 99, 736-42		59
864	Diagnostic moléculaire des hémopathies malignes. 2014 , 57-80		
863	Management of chronic lymphocytic leukemia. 2014 , 99, 965-72		28

862	miR-29c down-regulation is associated with disease aggressiveness and poor survival in Chinese patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1544-50	1.9	10
861	Detection of Hodgkin Transformation in a Case of Chronic Lymphocytic Leukemia by PET/CT. 2014 , 23, 67-9		1
860	Mutation status and immunoglobulin gene rearrangements in patients from northwest and central region of Spain with chronic lymphocytic leukemia. 2014 , 2014, 257517		11
859	Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis. 2014 , 89, 74-82		18
858	Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d. 2014 , 51, 168-76		27
857	Frequency analysis of HLA class I alleles in Iranian patients with progressive and non-progressive chronic lymphocytic leukemia. 2014 , 75, 170-5		3
856	The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1227-39	1.9	48
855	B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities. 2014 , 32, 22-30		19
854	Personalized medicine in CLL: current status and future perspectives. 2014 , 352, 4-14		21
853	Morphologic identification of atypical chronic lymphocytic leukemia by digital microscopy. 2014 , 36, 459-64		6
852	The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia. 2014 , 93, 361-74		34
851	Qualifying high-throughput immune repertoire sequencing. 2014 , 288, 31-8		8
850	Cryptic polyreactivity of IgG expressed by splenic marginal zone B-cell lymphoma. 2014 , 60, 54-61		9
849	Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. <i>Blood</i> , 2014 , 124, 49-62	2.2	202
848	Molecular Testing in Cancer. 2014 ,		1
847	Heterogeneous functional effects of concomitant B cell receptor and TLR stimulation in chronic lymphocytic leukemia with mutated versus unmutated Ig genes. 2014 , 192, 4518-24		19
846	A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. 2014 , 46, 56-60		136
845	GALNT11 as a new molecular marker in chronic lymphocytic leukemia. 2014 , 533, 270-9		17

- 844 Monoclonal B cell lymphocytosis and "in situ" lymphoma. **2014**, 24, 3-14 32
- 843 Stereotyped B-cell receptors in chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2014**, 55, 2252-61 19
- 842 Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. **2014**, 1, e74-84 76
- 841 Antibody modeling using the prediction of immunoglobulin structure (PIGS) web server [corrected]. **2014**, 9, 2771-83 46
- 840 Prognostic information and biological insights in chronic lymphocytic leukemia by high-resolution immunophenotypic analysis of ZAP70. **2014**, 85, 798-808 3
- 839 Proteomics-based strategies to identify proteins relevant to chronic lymphocytic leukemia. **2014**, 13, 5051-62 22
- 838 Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. *Blood*, **2014**, 123, 3790-6 2.2 82
- 837 On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort. **2014**, 28, 710-3 58
- 836 Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood. **2014**, 60, 500-9 46
- 835 B-cell receptor signaling in lymphoid malignancies and autoimmunity. **2014**, 123, 1-49 28
- 834 AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells. **2014**, 44, 3747-57 16
- 833 Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases. **2014**, 167, 224-32 22
- 832 Five important advances in hematopathology. **2014**, 138, 410-9 2
- 831 Les biomarqueurs moléculaires en oncologie. **2014**, 18
- 830 Hematopoietic stem cell aging and chronic lymphocytic leukemia pathogenesis. **2014**, 100, 335-40 18
- 829 A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. **2014**, 167, 149-61 22
- 828 Immunogenetic studies of chronic lymphocytic leukemia: revelations and speculations about ontogeny and clinical evolution. **2014**, 74, 4211-6 36
- 827 Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches?. **2014**, 32, 869-72 32

826	Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. <i>Blood</i> , 2014 , 123, 2378-88	2.2	64
825	Autoimmune cytopenias in chronic lymphocytic leukemia. 2014 , 89, 1055-62		69
824	Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. 2014 , 38, 198-203		4
823	Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. <i>Blood</i> , 2014 , 123, 3255-62	2.2	31
822	Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki limfocytowej w 2014 r. □ raport Grupy Roboczej PTHiT oraz PALG [CLL]. 2014 , 45, 221-239		3
821	Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies. 2014 , 144, 338-48		43
820	CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. 2014 , 32, 897-904		118
819	Dielectrophoretic isolation and detection of cancer-related circulating cell-free DNA biomarkers from blood and plasma. 2014 , 35, 1828-36		42
818	Evolving understanding of the CLL genome. 2014 , 51, 177-87		22
817	Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia. 2014 , 53, 612-21		32
816	The meaning and relevance of B-cell receptor structure and function in chronic lymphocytic leukemia. 2014 , 51, 158-67		30
815	ZAP70 in B-CLL cells related to the expression in NK cells is a surrogate marker for mutational status. 2014 , 86, 280-7		8
814	Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. 2014 , 4, 348-61		115
813	NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2785-92	1.9	40
812	Molecular Genetics of Chronic Lymphocytic Leukaemia. 2014 ,		
811	Chronic lymphocytic leukemia in young individuals revisited. 2014 , 99, 4-5		5
810	De Gruyter. 2014 , 22,		
809	Lyn-mediated procaspase 8 dimerization blocks apoptotic signaling in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2014 , 123, 875-83	2.2	21

808	Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. <i>Blood</i> , 2014 , 123, 3247-54	2.2	352
807	Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding. <i>Blood</i> , 2014 , 123, 1319-26	2.2	51
806	Variable induction of PRDM1 and differentiation in chronic lymphocytic leukemia is associated with anergy. <i>Blood</i> , 2014 , 123, 3277-85	2.2	26
805	Discovering Causal Patterns with Structural Equation Modeling: Application to Toll-Like Receptor Signaling Pathway in Chronic Lymphocytic Leukemia. 2015 , 555-584		
804	Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKC β subversion induces up-regulation of PKC η expression in B lymphocytes. 2015 , 100, 499-510		6
803	Chronic Lymphocytic Leukemia. 2015 , 130-144		1
802	OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. <i>Blood</i> , 2015 , 125, 284-95	2.2	15
801	Two types of BCR interactions are positively selected during leukemia development in the E μ TCL1 transgenic mouse model of CLL. <i>Blood</i> , 2015 , 125, 1578-88	2.2	35
800	Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. <i>Blood</i> , 2015 , 125, 856-9	2.2	55
799	Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8. <i>Blood</i> , 2015 , 125, 3580-7	2.2	40
798	Mutations in CHD2 cause defective association with active chromatin in chronic lymphocytic leukemia. <i>Blood</i> , 2015 , 126, 195-202	2.2	38
797	Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. <i>Blood</i> , 2015 , 125, 3297-305	2.2	107
796	Perturbation of the normal immune system in patients with CLL. <i>Blood</i> , 2015 , 126, 573-81	2.2	199
795	Prognostic relevance of MYD88 mutations in CLL: the jury is still out. <i>Blood</i> , 2015 , 126, 1043-4	2.2	29
794	So FCR, so good. <i>Blood</i> , 2015 , 126, 1872-4	2.2	2
793	Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies. 2015 , 10, 3339-3344		8
792	Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. 2015 , 13, 326-62		37
791	B-cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T-cell clonality in chronic lymphocytic leukemia. 2015 , 100, e307-10		7

790	Regulatory network reconstruction reveals genes with prognostic value for chronic lymphocytic leukemia. 2015 , 16, 1002	3
789	Gene expression and splicing alterations analyzed by high throughput RNA sequencing of chronic lymphocytic leukemia specimens. 2015 , 15, 714	13
788	Chronic Lymphocytic Leukemia in the Elderly, Which Investigations Are Necessary: A Map for the Practicing Oncologist. 2015 , 22, 7-16	3
787	Biological and clinical characteristics of patients with chronic lymphocytic leukemia with the IGHV3-21 and IGHV1-69; analysis of data from a single center. 2015 , 62, 618-26	2
786	Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival. 2015 , 6, 42130-49	27
785	Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. 2015 , 6, 1884-8	40
784	The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia. 2015 , 6, 177	14
783	Current concepts in diagnosis and treatment of chronic lymphocytic leukemia. 2015 , 19, 361-7	7
782	Developing Molecular Signatures for Chronic Lymphocytic Leukemia. 2015 , 10, e0128990	8
781	Clustering of Expression Data in Chronic Lymphocytic Leukemia Reveals New Molecular Subdivisions. 2015 , 10, e0137132	6
780	Reverse Pseudohyperkalemia: An Important Clinical Entity in Chronic Lymphocytic Leukemia. 2015 , 2015, 930379	12
779	TAC1 expression and signaling in chronic lymphocytic leukemia. 2015 , 2015, 478753	6
778	. 2015 ,	2
777	. 2015 ,	5
776	Chronic Lymphocytic Leukemia [Microenvironment and B Cells. 2015 ,	2
775	New Insights in Prognosis and Therapy of Chronic Lymphocytic Leukaemia. 2015 ,	
774	Epigenetic silencing of miR-708 enhances NF- κ B signaling in chronic lymphocytic leukemia. 2015 , 137, 1352-61	40
773	Molecular pathogenesis of CLL and its evolution. 2015 , 101, 219-28	16

772	The mystery of chronic lymphocytic leukemia (CLL): Why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology?. 2015 , 29, 205-13			39
771	Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment. 2015 , 39, 840-5			10
770	Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3031-7	1.9	7	
769	Del(20q) in patients with chronic lymphocytic leukemia: a therapy-related abnormality involving lymphoid or myeloid cells. 2015 , 28, 1130-7			6
768	ZGDHu-1 and fludarabine have a synergistic effect on apoptosis of chronic lymphocytic leukemia cells. 2015 , 34, 1239-48			4
767	Clonal evolution in chronic lymphocytic leukemia: impact of subclonality on disease progression. 2015 , 8, 71-8			5
766	DNA methylation of tumor-suppressor miRNA genes in chronic lymphocytic leukemia. 2015 , 7, 461-73			17
765	SOX11 expression in chronic lymphocytic leukemia correlates with adverse prognostic markers. 2015 , 36, 4433-40			13
764	Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212. 2015 , 54, 222-34			22
763	High-throughput sequencing using the Ion Torrent personal genome machine for clinical evaluation of somatic hypermutation status in chronic lymphocytic leukemia. 2015 , 17, 145-54			6
762	Multi-Targeted Approach to Treatment of Cancer. 2015 ,			0
761	Improved synthesis of N-benzylaminoferrocene-based prodrugs and evaluation of their toxicity and antileukemic activity. 2015 , 58, 2015-24			60
760	Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis. 2015 , 38, 93-109			28
759	Pre-malignant lymphoid cells arise from hematopoietic stem/progenitor cells in chronic lymphocytic leukemia. 2015 , 102, 528-35			4
758	IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events. 2015 , 29, 337-45			13
757	Basal Ca(2+) signaling is particularly increased in mutated chronic lymphocytic leukemia. 2015 , 29, 321-8			13
756	Incidence of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis in Calgary, Alberta, Canada. 2015 , 39, 429-34			6
755	Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase [but not SYK or BTK in chronic lymphocytic leukemia cells. 2015 , 194, 2439-46			22

754	Subjects with chronic lymphocytic leukaemia-like B-cell clones with stereotyped B-cell receptors frequently show MDS-associated phenotypes on myeloid cells. 2015 , 168, 258-67		5
753	Molecular evidence for antigen drive in the natural history of mantle cell lymphoma. 2015 , 185, 1740-8		12
752	Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia. 2015 , 15, 612-20.e1-5		19
751	A new piece to the stereotypy "puzzle" in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3008-9	1.9	
750	Surgical Pathology of Liver Tumors. 2015 ,		4
749	Non-coding recurrent mutations in chronic lymphocytic leukaemia. 2015 , 526, 519-24		565
748	Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3K inhibition. 2015 , 29, 744-7		19
747	Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia. 2015 , 112, 4322-7		31
746	Ectonucleoside triphosphate diphosphohydrolase-1 (E-NTPDase1/CD39) as a new prognostic marker in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 113-9	1.9	18
745	Przewlekła białaczka limfocytowa wysokiego ryzyka. 2015 , 46, 68-74		
744	[Chronic lymphocytic leukemia : treatment concepts in transition]. 2015 , 56, 374-80		
743	The evolving role of hematopoietic cell transplantation in chronic lymphocytic leukemia. 2015 , 10, 18-27		1
742	KLKB1 mRNA overexpression: A novel molecular biomarker for the diagnosis of chronic lymphocytic leukemia. 2015 , 48, 849-54		23
741	Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential. 2015 , 15, 11		7
740	Higher gene expression variability in the more aggressive subtype of chronic lymphocytic leukemia. 2015 , 7, 8		29
739	Hypermorphic mutation of phospholipase C, β acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. <i>Blood</i> , 2015 , 126, 61-8	2.2	106
738	Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma. 2015 , 165, 147-75		10
737	A canadian perspective on the first-line treatment of chronic lymphocytic leukemia. 2015 , 15, 303-13		1

736 Molecular Pathogenesis of B Cell Lymphomas. **2015**, 399-416

735 Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells. **2015**, 194, 101-12 11

734 The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia. **2015**, 34, 22-35 30

733 IGHV gene usage and mutational status in follicular lymphoma: Correlations with prognosis and patient age. **2015**, 39, 702-8 6

732 Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy. **2015**, 19, 941-55 26

731 The biology behind PI3K inhibition in chronic lymphocytic leukaemia. **2015**, 6, 25-36 7

730 Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2015**, 56, 3150-8 1.9 17

729 Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia. **2015**, 14, 933-45 25

728 Chronic lymphocytic leukemia/small lymphocytic lymphoma: another neoplasm related to the B-cell follicle?. *Leukemia and Lymphoma*, **2015**, 56, 3378-86 1.9 5

727 The rate of in vitro fludarabine-induced peripheral blood and bone marrow cell apoptosis may predict the chemotherapy outcome in patients with chronic lymphocytic leukemia. **2015**, 71, 1121-7 2

726 ARResT/AssignSubsets: a novel application for robust subclassification of chronic lymphocytic leukemia based on B cell receptor IG stereotypy. **2015**, 31, 3844-6 23

725 Characterization of a new human plasma cell leukemia cell line UHKT-944. *European Journal of Haematology*, **2015**, 95, 352-60 3.8

724 Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. **2015**, 2, 572-82 34

723 Enhanced Chemokine Receptor Recycling and Impaired S1P1 Expression Promote Leukemic Cell Infiltration of Lymph Nodes in Chronic Lymphocytic Leukemia. **2015**, 75, 4153-63 32

722 PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL). **2016**, 393, 123-142 38

721 Soluble CD163 as a prognostic biomarker in B-cell chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2015**, 56, 3219-21 1.9 7

720 Applied Protein and Molecular Techniques for Characterization of B Cell Neoplasms in Horses. **2015**, 22, 1133-45 9

719 The genomic landscape of chronic lymphocytic leukaemia: biological and clinical implications. **2015**, 169, 14-31 22

718	Immunoglobulin heavy variable (IGHV) genes and alleles: new entities, new names and implications for research and prognostication in chronic lymphocytic leukaemia. 2015 , 67, 61-6		19
717	Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1626-35	1.9	
716	A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. 2015 , 29, 598-605		92
715	B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. <i>European Journal of Haematology</i> , 2015 , 94, 193-205	3.8	121
714	Systemic eosinophilia with skin and pulmonary infiltrates in a patient with chronic lymphocytic leukemia: A case report. 2016 , 3,		
713	Chronic Lymphocytic Leukemia, the Prototypic Chronic Leukemia for Flow Cytometric Analysis. 2016 , 226-234		
712	. 2016 ,		2
711	11. Chronic lymphocytic leukemia. 2016 , 205-228		
710	Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy. 2016 , 8, e2016047		5
709	Editorial (Thematic Issue: Pathogenetic Mechanisms of CLL - A Target in Therapy). 2016 , 16, 651		
708	A Novel Assay for the Identification of NOTCH1 PEST Domain Mutations in Chronic Lymphocytic Leukemia. 2016 , 2016, 4247908		4
707	Regulation of Autophagy in Chronic Lymphocytic Leukemia. 2016 , 221-240		
706	Chronic lymphocytic leukaemia. 2016 , 104, 169-82		85
705	Double IGHV DNA gene rearrangements in CLL: influence of mixed-mutated and -unmutated rearrangements on outcomes in CLL. 2016 , 6, e440		3
704	The prognostic significance of surface dipeptidylpeptidase IV (CD26) expression in B-cell chronic lymphocytic leukemia. 2016 , 47, 166-71		9
703	Issues in diagnosis of small B cell lymphoid neoplasms involving the bone marrow and peripheral blood. Report on the Bone Marrow Workshop of the XVIIth meeting of the European Association for Haematopathology and the Society for Hematopathology. 2016 , 69, 349-73		2
702	Early generated B1 B cells with restricted BCRs become chronic lymphocytic leukemia with continued c-Myc and low Bmf expression. 2016 , 213, 3007-3024		34
701	SLP76 integrates into the B-cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with an aggressive disease course. 2016 , 101, 1553-1562		10

700	High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2016 , 128, 2931-2940	2.2	75
699	Prognostication of chronic lymphocytic leukemia in the era of new agents. 2016 , 2016, 149-155		24
698	Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. 2016 , 101, 959-67		41
697	The clinical implications of gene mutations in chronic lymphocytic leukaemia. 2016 , 114, 849-54		25
696	Mimicking the tumour microenvironment of chronic lymphocytic leukaemia in vitro critically depends on the type of B-cell receptor stimulation. 2016 , 114, 704-12		3
695	Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease. 2016 , 30, 1301-10		32
694	Secondary autoimmune cytopenias in chronic lymphocytic leukemia. 2016 , 43, 300-10		16
693	What does it mean I have a monoclonal B-cell lymphocytosis?: Recent insights and new challenges. 2016 , 43, 201-8		13
692	B Cell Energy Modulated by TLR1/2 and the miR-17~92 Cluster Underlies the Indolent Clinical Course of Chronic Lymphocytic Leukemia Stereotyped Subset #4. 2016 , 196, 4410-7		20
691	Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression. 2016 , 11, 335-43		17
690	Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia. 2016 , 37, 11947-11957		20
689	Chronic lymphocytic leukemia and proteomics: protein profiles and links with disease progression still need validation. <i>Leukemia and Lymphoma</i> , 2016 , 57, 985-6	1.9	
688	Loss of a chromosomal region with synteny to human 13q14 occurs in mouse chronic lymphocytic leukemia that originates from early-generated B-1 B cells. 2016 , 30, 1510-9		16
687	El estado mutacional de las inmunoglobulinas en pacientes con leucemia linfocítica crónica: significado y pronóstico. 2016 , 15, 86-92		
686	CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. 2016 , 30, 2011-2018		33
685	Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. 2016 , 60, 154-65		16
684	An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. 2016 , 17, 779-790		379
683	Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. <i>Blood</i> , 2016 , 127, 208-15	2.2	442

682	Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. <i>Blood</i> , 2016 , 127, 1752-60	2.2	53
681	Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL. <i>Blood</i> , 2016 , 128, 816-26	2.2	39
680	The genetics of mature B-cell malignancies. 2016 , 265-311		
679	Chronic lymphocytic leukemia immunoglobulins display bacterial reactivity that converges and diverges from auto-/poly-reactivity and IGHV mutation status. 2016 , 172, 44-51		8
678	Hypomethylation coordinates antagonistically with hypermethylation in cancer development: a case study of leukemia. 2016 , 10 Suppl 2, 18		25
677	lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome. 2016 , 6, e468		33
676	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia. 2016 , 714-726		
675	The metabolomic signature of hematologic malignancies. 2016 , 49, 22-35		14
674	Lipoprotein lipase in chronic lymphocytic leukemia: function and prognostic implications. <i>European Journal of Haematology</i> , 2016 , 97, 409-415	3.8	6
673	Molecular Pathology: Predictive, Prognostic, and Diagnostic Markers in Lymphoid Neoplasms. 2016 , 9, 489-521		3
672	The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. 2016 , 91, 1090-1095		43
671	Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed?. 2016 , 279, 347-57		34
670	Small nucleolar RNA expression profiles refine the prognostic impact of IGHV mutational status on treatment-free survival in chronic lymphocytic leukaemia. 2016 , 172, 819-23		6
669	CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status. 2016 , 172, 48-55		16
668	Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study. <i>European Journal of Haematology</i> , 2016 , 96, 36-45	3.8	6
667	Breed Distribution and Clinical Characteristics of B Cell Chronic Lymphocytic Leukemia in Dogs. 2016 , 30, 215-22		20
666	Metaphase Cytogenetics in Chronic Lymphocytic Leukemia. 2016 , 4, 65-73		
665	Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers. 2016 , 29, 79-89		22

664	Molecular Biomarkers in Hematopoietic Neoplasms. 2016 , 187-223		
663	Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. 2016 , 197, 2522-31		23
662	Molecular Cytopathology. 2016 ,		1
661	Genetic evolution in chronic lymphocytic leukaemia. 2016 , 29, 67-78		1
660	Present and future of personalized medicine in CLL. 2016 , 29, 100-110		8
659	Key Molecular Drivers of Chronic Lymphocytic Leukemia. 2016 , 16, 593-606		14
658	Rewired NFB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2016 , 97, 499-510	3.8	14
657	t(14;18)(q32;q21) in chronic lymphocytic leukemia patients: Report of two cases and a literature review. 2016 , 12, 4351-4356		6
656	Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. 2016 , 38, 346-357		17
655	NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome. 2016 , 175, 43-54		32
654	Assembly-based inference of B-cell receptor repertoires from short read RNA sequencing data with V'DJer. 2016 , 32, 3729-3734		39
653	IL-4 enhances expression and function of surface IgM in CLL cells. <i>Blood</i> , 2016 , 127, 3015-25	2.2	55
652	Integration of innate into adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia. <i>Blood</i> , 2016 , 127, 436-48	2.2	20
651	IL-4 rescues surface IgM expression in chronic lymphocytic leukemia. <i>Blood</i> , 2016 , 128, 553-62	2.2	25
650	Toll-like receptors signaling: A complex network for NF- κ B activation in B-cell lymphoid malignancies. 2016 , 39, 15-25		48
649	Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks. 2016 , 7, 11938		95
648	Real-world clinical experience in the Connect chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. 2016 , 175, 892-903		37
647	The mutational signature of chronic lymphocytic leukemia. 2016 , 473, 3725-3740		3

646	Global DNA methylation profiling reveals new insights into epigenetically deregulated protein coding and long noncoding RNAs in CLL. 2016 , 8, 106	34
645	The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia. 2016 , 9, 1177-1187	2
644	UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?. 2016 , 101, e63-5	10
643	Integrating multiple immunogenetic data sources for feature extraction and mining somatic hypermutation patterns: the case of "towards analysis" in chronic lymphocytic leukaemia. 2016 , 17 Suppl 5, 173	1
642	Determination of HLA-G Expression and Evaluation of Its Role as a Prognostic Factor in Chronic Lymphocytic Leukemia. 2016 , 30, 399-403	4
641	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 2016 , 140, 1228-1230	3
640	Neue Therapiekonzepte bei der chronisch-lymphatischen Leukämie. 2016 , 22, 283-294	3
639	Profiling B cell chronic lymphocytic leukemia by reverse phase protein array: Focus on apoptotic proteins. 2016 , 100, 1061-1070	9
638	A ribosome-related signature in peripheral blood CLL B cells is linked to reduced survival following treatment. 2016 , 7, e2249	20
637	SF3B1 and IGHV gene mutation status predict poor prognosis in Japanese CLL patients. 2016 , 103, 219-26	4
636	Transformation in Low-grade B-cell Neoplasms. 2016 , 9, 79-92	12
635	Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century. 2016 , 9, 28	32
634	Role of precision medicine in the treatment of chronic lymphocytic leukaemia. 2016 , 1, 145-154	
633	The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with . 2016 , 173, 127-36	12
632	Clonality Analysis of Immunoglobulin Gene Rearrangement by Next-Generation Sequencing in Endemic Burkitt Lymphoma Suggests Antigen Drive Activation of BCR as Opposed to Sporadic Burkitt Lymphoma. 2016 , 145, 116-27	26
631	Pitting new treatments for chronic lymphocytic leukemia against old ones: how do they fare?. 2016 , 9, 245-54	1
630	A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. 2016 , 30, 1440-3	21
629	Analysis of clinical prognostic variables for Chronic Lymphocytic Leukemia decision-making problems. 2016 , 60, 342-51	12

628	Differential methylation tests of regulatory regions. 2016 , 15, 237-51	3
627	Chronic lymphocytic leukemia (CLL)-Then and now. 2016 , 91, 330-40	83
626	Humanized mouse G6 anti-idiotypic monoclonal antibody has therapeutic potential against IGHV1-69 germline gene-based B-CLL. 2016 , 8, 787-98	6
625	Prognostic factors and risk stratification in chronic lymphocytic leukemia. 2016 , 43, 233-40	48
624	Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia. 2016 , 39, 34-40	3
623	The molecular pathogenesis of chronic lymphocytic leukaemia. 2016 , 16, 145-62	170
622	The clinical significance of 8q24/MYC rearrangement in chronic lymphocytic leukemia. 2016 , 29, 444-51	15
621	Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting. 2016 , 11, 61-70	5
620	Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors. 2016 , 101, e99-102	21
619	Immunoglobulin heavy chain variable region gene repertoire and B-cell receptor stereotypes in Indian patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2389-400	1.9 4
618	Catalog of genetic progression of human cancers: non-Hodgkin lymphoma. 2016 , 35, 109-27	7
617	Prognostic Factors for Chronic Lymphocytic Leukemia. 2016 , 11, 37-42	17
616	B Cell Receptor Signaling. 2016 ,	
615	CD126 and Targeted Therapy with Tocilizumab in Chronic Lymphocytic Leukemia. 2016 , 22, 2462-9	14
614	Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders. 2016 , 32, 175-89	6
613	mRNA overexpression of kallikrein-related peptidase 14 (KLK14) is an independent predictor of poor overall survival in chronic lymphocytic leukemia patients. 2016 , 54, 315-24	11
612	CTLA-4 affects expression of key cell cycle regulators of G0/G1 phase in neoplastic lymphocytes from patients with chronic lymphocytic leukaemia. 2016 , 16, 317-32	8
611	Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances. 2016 , 22, 134-45	4

610	Antigen Selection Shapes the T-cell Repertoire in Chronic Lymphocytic Leukemia. 2016 , 22, 167-74	28
609	Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. 2016 , 30, 346-50	61
608	Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. 2016 , 1863, 401-413	125
607	COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status. <i>Leukemia and Lymphoma</i> , 2017 , 58, 70-79	1.9 9
606	Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. 2017 , 7,	16
605	Chronic lymphocytic leukaemia. 2017 , 3, 16096	219
604	Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia. 2017 , 31, 1348-1354	18
603	From genome to proteome: Looking beyond DNA and RNA in chronic lymphocytic leukemia. 2017 , 155, 73-84	5
602	Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. 2017 , 92, 375-380	60
601	What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?. 2017 , 18, 12	6
600	Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. 2017 , 4, e114-e126	149
599	The PTPROt tyrosine phosphatase functions as an obligate haploinsufficient tumor suppressor in vivo in B-cell chronic lymphocytic leukemia. 2017 , 36, 3686-3694	7
598	Current Treatment of Chronic Lymphocytic Leukemia. 2017 , 18, 5	14
597	Early stages in the ontogeny of small B-cell lymphomas: genetics and microenvironment. 2017 , 282, 395-414	8
596	Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia. 2017 , 10, 83	28
595	Cyclin D1 overexpression in proliferation centres of small lymphocytic lymphoma/chronic lymphocytic leukaemia. 2017 , 70, 899-902	10
594	Milestones in 'Chronic Lymphocytic Leukemia: An exciting decade of progress-10th anniversary of. 2017 , 10, 8-12	
593	High-Throughput Immunogenetics for Clinical and Research Applications in Immunohematology: Potential and Challenges. 2017 , 198, 3765-3774	46

592	Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Clinical Pharmacology and Therapeutic Results. 2017 , 99-122		
591	Venetoclax for the treatment of patients with chronic lymphocytic leukemia. 2017 , 13, 1223-1232		7
590	Clinical, histopathological, and molecular features of mucosa-associated lymphoid tissue (MALT) lymphoma carrying the t(X;14) (p11;q32)/GPR34-immunoglobulin heavy chain gene. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1-4	1.9	4
589	Numerous Ontogenetic Roads to Mantle Cell Lymphoma: Immunogenetic and Immunohistochemical Evidence. 2017 , 187, 1454-1458		9
588	Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations. 2017 , 31, 1477-1481		75
587	MicroRNA: Defining a new niche in Leukemia. 2017 , 31, 129-138		12
586	IGHV mutational status testing in chronic lymphocytic leukemia. 2017 , 92, 1393-1397		15
585	Role and timing of new drugs in CLL. 2017 , 35 Suppl 1, 30-32		2
584	Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. 2017 , 23, 5292-5301		20
583	Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. 2017 , 102, e352-e355		7
582	Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification. 2017 , 102, 968-971		17
581	Lymphoid Leukaemias of Mature B, T and Natural Killer Cells. 2017 , 417-524		1
580	FcγRIIb expression in early stage chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2642-2648	1.9	5
579	Molecular Analysis of Genetic Markers for Non-Hodgkin Lymphomas. 2017 , 93, 10.14.1-10.14.29		1
578	Genomic data integration in chronic lymphocytic leukemia. 2017 , 19, e2936		13
577	Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2017 , 98, 363-370	3.8	8
576	Chronic Lymphocytic Leukemia Patient Clustering Based on Somatic Hypermutation (SHM) Analysis. 2017 , 988, 127-138		3
575	Venetoclax for the treatment of chronic lymphocytic leukemia. 2017 , 26, 1307-1316		39

574	Detection of monoclonal B cells in general population from two different regions of Mexico. 2017 , 44, 279-285		
573	B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. 2017 , 15, 1692-1703		23
572	MicroRNAs and Cancer: A Long Story for Short RNAs. 2017 , 135, 1-24		68
571	Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes. 2017 , 409, 42-48		5
570	Flow Cytometry of B-Cell Neoplasms. 2017 , 37, 697-723		8
569	The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells. 2017 , 19, 762-771		21
568	Molecular Diagnostics. 2017 ,		4
567	MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia. 2017 , 7, e585		11
566	Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia. 2017 , 102, e394-e396		8
565	New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia. 2017 , 12, 1041-1052		2
564	Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its Idiotope. 2017 , 21, 3243-3255		9
563	Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia. 2017 , 31, 837-845		33
562	Modeling the chronic lymphocytic leukemia microenvironment in vitro. <i>Leukemia and Lymphoma</i> , 2017 , 58, 266-279	1,9	11
561	Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia. 2017 , 23, 165-171		5
560	The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based Study. 2017 , 109,		15
559	Antigen receptor stereotypy in chronic lymphocytic leukemia. 2017 , 31, 282-291		74
558	Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. 2017 , 23, 735-745		62
557	Pathology and Molecular Pathology of Hematologic Malignancies. 2017 , 571-590		

556	Dynamic variation of CD5 surface expression levels within individual chronic lymphocytic leukemia clones. 2017 , 46, 31-37.e10	6
555	Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia. 2017 , 35, 664-670	24
554	IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus. 2017 , 31, 1686-1694	20
553	EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. 2017 , 31, 1547-1554	34
552	Identification of key miRNA-gene pairs in chronic lymphocytic leukemia through integrated analysis of mRNA and miRNA microarray. 2018 , 15, 361-367	9
551	The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. 2017 , 8, 2185	99
550	Preferential Usage of Specific Immunoglobulin Heavy Chain Variable Region Genes With Unmutated Profile and Advanced Stage at Presentation Are Common Features in Patients With Chronic Lymphocytic Leukemia From Senegal. 2017 , 148, 545-554	4
549	Early progression of disease as a predictor of survival in chronic lymphocytic leukemia. 2017 , 1, 2433-2443	7
548	Somatic Hypermutational Status and Gene Repertoire of Immunoglobulin Rearrangements in Chronic Lymphocytic Leukemia. 2017 ,	1
547	The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. 2017 , 2017, 329-337	39
546	Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia: New Insights into Leukemic Progression. 2017 , 22,	8
545	Telomere protein complexes and their role in lymphoid malignancies. 2017 , 9, 17-30	2
544	Altered N-Linked Glycosylation in Follicular Lymphoma and Chronic Lymphocytic Leukemia: Involvement in Pathogenesis and Potential Therapeutic Targeting. 2017 , 8, 912	11
543	The role of B cell antigen receptors in mantle cell lymphoma. 2017 , 10, 164	12
542	Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome. 2017 , 7, 16784	9
541	Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons. 2017 , 8, 71234-71248	18
540	Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia. 2017 , 10, 1909-1914	5
539	Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia. 2017 , 35, 984-993	37

538	Chronic lymphocytic leukaemia. 2018 , 391, 1524-1537		142
537	The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker. 2018 , 18, 319-329		15
536	Prognostic Factors in the Era of Targeted Therapies in CLL. 2018 , 13, 78-90		7
535	Small cell lymphocytic variant of marginal zone lymphoma: A distinct form of marginal zone lymphoma derived from naïve B cells as a cutaneous counterpart to the naïve marginal zone lymphoma of splenic origin. 2018 , 34, 116-121		1
534	Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. <i>Blood</i> , 2018 , 131, 2283-2296	2.2	59
533	Morphology and Immunophenotype of Chronic Lymphocytic Leukemia. 2018 , 79-98		
532	Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation. 2018 , 18, 13		2
531	Pathology of Non-Hodgkin and Hodgkin Lymphomas. 2018 , 773-826		
530	Lymphoid Leukemias in Adults. 2018 , 422-433		1
529	Targeting B cell receptor signalling in cancer: preclinical and clinical advances. 2018 , 18, 148-167		159
528	Epigenetic deregulation in chronic lymphocytic leukemia: Clinical and biological impact. 2018 , 51, 1-11		26
527	Chronic Lymphocytic Leukemia. 2018 ,		2
526	Imprecision and DNA Break Repair Biased towards Incompatible End Joining in Leukemia. 2018 , 16, 428-438		8
525	Double sword role of EZH2 in leukemia. 2018 , 98, 626-635		13
524	Disease characteristics and clinical outcomes in patients aged less than 40 with chronic lymphocytic leukemia. 2018 , 65, 80-85		2
523	Critical molecular pathways in CLL therapy. 2018 , 24, 9		23
522	Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity. 2018 , 200, 4180-4189		24
521	iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. <i>Blood</i> , 2018 , 131, 2745-2760	2.2	607

520	Treatment of Chronic Lymphocytic Leukemia and Related Disorders. 2018 , 117-134		
519	Elevated IL-17A and IL-22 regulate expression of inducible CD38 and Zap-70 in chronic lymphocytic leukemia. 2018 , 94, 143-147		6
518	Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV and IgHV subgroups. 2018 , 32, 332-342		30
517	Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 59-68	1.9	5
516	Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 633-642	1.9	6
515	Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1614-1623	1.9	11
514	Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1338-1347	1.9	5
513	The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. 2018 , 180, 33-40		23
512	A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. 2018 , 180, 259-266		33
511	What is the optimal management of older CLL patients?. 2018 , 31, 83-89		3
510	Advances in chronic lymphocytic leukemia pharmacotherapy. 2018 , 97, 349-358		5
509	Using prognostic models in CLL to personalize approach to clinical care: Are we there yet?. 2018 , 32, 159-166		8
508	Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. 2018 , 2, e39		9
507	Current trends in the management of Richter's syndrome. 2018 , 7, IJH09		28
506	On the architecture of translational research designed to control chronic lymphocytic leukemia. 2018 , 2018, 1-8		6
505	From Mice to Men: How B Cell Immunology Helped the Understanding of Leukemia Development. 2018 , 9, 2402		1
504	Notch Signaling in T-Cell Acute Lymphoblastic Leukemia and Other Hematologic Malignancies. 2018 , 199-225		
503	Syndecan-1 (sCD138) levels in chronic lymphocytic leukemia: clinical and hematological correlations. 2018 , 53, 205-209		3

502	Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation. 2018,		3
501	MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL. 2019, 184, 925-936		7
500	Chronic lymphocytic leukemia treatment algorithm 2018. 2018, 8, 93		46
499	Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies. 2018, 78, 1653-1663		25
498	Identification of Distinct Unmutated Chronic Lymphocytic Leukemia Subsets in Mice Based on Their T Cell Dependency. 2018, 9, 1996		6
497	Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation. 2018, 97, 2269-2278	18	
496	Role of Natural Compounds in Prevention and Treatment of Chronic Lymphocytic Leukemia. 2018, 195-203		8
495	The Ins and Outs of Autophagy and Metabolism in Hematopoietic and Leukemic Stem Cells: Food for Thought. 2018, 6, 120		12
494	Chronische Lymphatische Leukämie. 2018, 47, 412-417		
493	Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-CLL 2017. 2018, 57, 190-215		4
492	Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemia. <i>Blood</i> , 2018, 132, 2375-2388	2.2	31
491	The Genomic Landscape of Chronic Lymphocytic Leukaemia: Clinical Implications. 2018, 18, S112-S115		1
490	Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. 2018, 12, 2577-2590		38
489	Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). 2018, 2, 1705-1718		9
488	BCL2 Inhibitors: Insights into Resistance. 2018, 23-43		
487	Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. 2018, 15, 510-527		73
486	The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia. 2018, 24, 868-880		103
485	Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma. 2018, 23, 111-122		14

484	Elevated serum BDNF levels are associated with favorable outcome in CLL patients: Possible link to CXCR4 downregulation. 2018 , 63, 17-21.e1	8
483	The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index. 2018 , 2018, 9506979	15
482	Immunoglobulin gene analysis as a tool for investigating human immune responses. 2018 , 284, 132-147	18
481	The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study. 2018 , 24, 5048-5057	21
480	Altered Metabolism of Leukemic Cells: New Therapeutic Opportunity. 2018 , 336, 93-147	6
479	Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia. 2018 , 11, 601-611	8
478	Bioinformatics of Epigenomic Data Generated From Next-Generation Sequencing. 2018 , 65-106	2
477	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. 2018 , 93, E216-E219	9
476	A History of the Chronic Leukemias. 2018 , 3-8	
475	Update on Fc receptor-like (FCRL) family: new immunoregulatory players in health and diseases. 2018 , 22, 487-502	21
474	Chronic Lymphocytic Leukemia: Diagnosis and Treatment. 2018 , 93, 651-664	18
473	Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients. 2018 , 7, 2621-2628	4
472	Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia?. 2018 , 140, 51-54	12
471	The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. 2018 , 18, 973-982	7
470	ZAP70 expression enhances chemokine-driven chronic lymphocytic leukemia cell migration and arrest by valency regulation of integrins. 2018 , 32, 4824-4835	11
469	Preferential use of unmutated immunoglobulin heavy variable region genes in Boxer dogs with chronic lymphocytic leukemia. 2018 , 13, e0191205	3
468	MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019 , 60, 658-667	1.9 13
467	Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment. 2019 , 291, 190-213	40

466	Predicting the outcome of patients with chronic lymphocytic leukemia: Progress and uncertainty. 2019 , 125, 3699-3705		8
465	High-resolution melting analysis for rapid and sensitive screening in chronic lymphocytic leukemia. 2019 , 18, 814-821		2
464	Deregulation of Ikaros expression in B-1 cells: New insights in the malignant transformation to chronic lymphocytic leukemia. 2019 , 106, 581-594		5
463	Advances in drug-based therapies in chronic lymphocytic leukemia and future prospects. 2019 , 2, e51		
462	Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. <i>Blood</i> , 2019 , 134, 688-698	2.2	16
461	Constitutive Activation of the B Cell Receptor Underlies Dysfunctional Signaling in Chronic Lymphocytic Leukemia. 2019 , 28, 923-937.e3		5
460	Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. 2019 , 19, 715-722.e6		22
459	Molecular pathogenesis of chronic lymphocytic leukaemia. 2019 , 186, 668-684		7
458	Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. 2019 , 187, 307-318		19
457	Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. 2019 , 6, e366-e374		36
456	Chronic lymphocytic leukaemia: from genetics to treatment. 2019 , 16, 684-701		85
455	Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma. 2019 , 33, 553-574		1
454	A practical guide for mutational signature analysis in hematological malignancies. 2019 , 10, 2969		73
453	Detection of Differentially Methylated Regions Using Bayes Factor for Ordinal Group Responses. 2019 , 10,		1
452	Lymphoma genetics. 2019 , 101-110		
451	PET/Computed Tomography in Chronic Lymphocytic Leukemia and Richter Transformation. 2019 , 14, 405-410		6
450	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. 2019 , 94, 1353-1363		152
449	Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia. 2019 , 14, 551-561		5

448	Venetoclax for the Treatment of Chronic Lymphocytic Leukemia. 2019 , 14, 469-476	7
447	Refining prognosis after first-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy in chronic lymphocytic leukaemia. 2019 , 20, 1478-1479	1
446	New roles for B cell receptor associated kinases: when the B cell is not the target. 2019 , 33, 576-587	14
445	Another step forward in the 20-year history of mutations in chronic lymphocytic leukemia. 2019 , 104, 219-221	5
444	Computational Methods for Detection of Differentially Methylated Regions Using Kernel Distance and Scan Statistics. 2019 , 10,	1
443	Precision Medicine in Cancer Therapy. 2019 ,	1
442	The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia. 2019 , 121, 150-156	17
441	Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas. 2019 , 9, 52	4
440	Genomics-Enabled Precision Medicine for Cancer. 2019 , 178, 137-169	6
439	Hedgehog activation in CLL. <i>Blood</i> , 2019 , 133, 2628-2630	2.2
438	Distinct immunoglobulin heavy chain variable region gene repertoire and lower frequency of del(11q) in Taiwanese patients with chronic lymphocytic leukaemia. 2019 , 187, 82-92	2
437	Growth dynamics in naturally progressing chronic lymphocytic leukaemia. 2019 , 570, 474-479	47
436	Combined analysis of ZAP-70 and CD38 expression in sudanese patients with B-cell chronic lymphocytic leukemia. 2019 , 12, 282	1
435	Laboratory Diagnosis of Chronic Lymphocytic Leukaemia. 2019 , 21-35	2
434	Chronic Lymphocytic Leukemia: Who, How, and Where?. 2019 , 3-17	2
433	Study of gene expressions' correlation structures in subgroups of Chronic Lymphocytic Leukemia Patients. 2019 , 95, 103211	2
432	Prognostic Markers. 2019 , 53-65	
431	Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of Chronic Lymphocytic Leukemia: The 2018 Update. 2019 , 69-77	

430	Analysis of basal chromosome instability in patients with chronic lymphocytic leukaemia. 2019 , 34, 245-252	2
429	Chronic Lymphocytic Leukemia. 2019 ,	
428	Molecular Diagnostics in Non-Hodgkin Lymphoma. 2019 , 103-127	
427	Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments. 2019 , 19, 678-685.e4	12
426	The B-cell receptor in control of tumor B-cell fitness: Biology and clinical relevance. 2019 , 288, 198-213	9
425	p66Shc deficiency in the E μ CL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape. 2019 , 104, 2040-2052	9
424	New advances in chronic lymphocytic leukemia treatment: Biodegradable ZnO hybrid cluster nanoparticle as antineoplastic agents. 2019 , 409-430	
423	Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia. 2019 , 10, 60-75	5
422	The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma. 2019 , 9, 9-17	4
421	High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance. 2019 , 104, 2249-2257	2
420	Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. 2019 , 185, 852-864	14
419	Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: CALGB 70603 (Alliance). <i>Leukemia and Lymphoma</i> , 2019 , 60, 2580-2583	1.9
418	Dissecting CLL through high-dimensional single-cell technologies. <i>Blood</i> , 2019 , 133, 1446-1456	2.2 1
417	Time to Treatment Prediction in Chronic Lymphocytic Leukemia Based on New Transcriptional Patterns. <i>Frontiers in Oncology</i> , 2019 , 9, 79	5.3 5
416	Case 7-2019: A 73-Year-Old Woman with Swelling of the Right Groin and Fever. 2019 , 380, 859-868	0
415	Stereotyped B Cell Receptor Immunoglobulins in B Cell Lymphomas. 2019 , 1956, 139-155	9
414	Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials. 2019 , 2019, 476-481	2
413	New Protein Markers of Chronic Lymphocytic and Acute Lymphocytic Leukemia. 2019 ,	

412	Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials. <i>Blood</i> , 2019 , 134, 1796-1801	2.2	8
411	Recurrent somatic mutations reveal new insights into consequences of mutagenic processes in cancer. 2019 , 15, e1007496		6
410	Application of Genomics to Clinical Practice in Haematological Malignancy. 2019 , 7, 236-252		
409	The evolving treatment landscape of chronic lymphocytic leukemia. 2019 , 31, 568-573		7
408	In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment. <i>Cancers</i> , 2019 , 11,	6.6	21
407	Bendamustine alone or with rituximab modifies expression of apoptosis-regulating genes and proteins of CLL cells, depending on IGVH mutational status. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1409-1419		
406	AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival. 2019 , 25, 1574-1587		9
405	The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia. 2019 , 33, 287-298		22
404	Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. <i>Blood</i> , 2019 , 133, 1205-1216	2.2	94
403	Acalabrutinib and its use in treatment of chronic lymphocytic leukemia. 2019 , 15, 579-589		18
402	Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia. 2019 , 144, 2695-2706		12
401	Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1438-1446	1.9	11
400	Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. <i>Blood</i> , 2019 , 133, 494-497	2.2	18
399	Molecular and cellular genetics of non-Hodgkin lymphoma: Diagnostic and prognostic implications. 2019 , 106, 44-51		13
398	Altered expression of metabolic pathways in CLL detected by unlabelled quantitative mass spectrometry analysis. 2019 , 185, 65-78		3
397	Sex-related DNA methylation differences in B cell chronic lymphocytic leukemia. 2019 , 10, 2		17
396	Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis. 2019 , 125, 135-143		15
395	Chronic Lymphocytic Leukemia. 2019 ,		

394	High-Throughput Sequencing of the T-Cell Receptor Beta Chain Gene Repertoire in Chronic Lymphocytic Leukemia. 2019 , 1881, 355-363		0
393	Immunoglobulin Gene Analysis in Chronic Lymphocytic Leukemia. 2019 , 1881, 51-62		0
392	Activation-induced deaminase and its splice variants associate with trisomy 12 in chronic lymphocytic leukemia. 2019 , 98, 423-435		2
391	Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients. 2019 , 25, 2503-2512		14
390	Accumulation of DNA damage and alteration of the DNA damage response in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019 , 60, 795-804	1.9	6
389	SLAMF6 in health and disease: Implications for therapeutic targeting. 2019 , 204, 3-13		8
388	Overview of non-coding mutations in chronic lymphocytic leukemia. 2019 , 13, 99-106		6
387	TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib. 2019 , 79, 360-371		23
386	Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development. 2019 , 33, 957-968		10
385	Prognostic relevance of CD69 expression in B cell chronic lymphocytic leukemia. 2019 , 28, 33-40		2
384	Chronic Myelogenous Leukemia Diagnosed in the Setting of Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 2020 , 28, 216-224		1
383	Multidisciplinary diagnostics of chronic lymphocytic leukemia: European Research Initiative on CLL - ERIC recommendations. 2020 , 42, 269-274		6
382	The Impact and Prognostic Significance of Chronic Lymphocytic Leukemia Upregulated 1 (CLLU1) Gene Expression in Patients with Chronic Lymphocytic Leukemia: A Single Center Experience. 2020 , 51, 259-264		
381	Mature lymphoid neoplasms. 2020 , 603-625		
380	Involvement of P2 receptors in hematopoiesis and hematopoietic disorders, and as pharmacological targets. 2020 , 16, 1-15		10
379	98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia. 2020 , 9, 999-1007		2
378	High frequency of chronic lymphocytic leukemia-like low-count monoclonal B-cell lymphocytosis in Japanese descendants living in Brazil. 2020 , 105, e298-e301		2
377	Pathophysiology of chronic lymphocytic leukemia and human B1 cell development. 2020 , 111, 634-641		5

376	Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia. 2020 , 13, 31-38		3
375	Chronic Lymphocytic Leukemia. 2020 , 1850-1871.e5		1
374	Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO). 2020 , 4, e473		9
373	DAP Kinase-Related Apoptosis-Inducing Protein Kinase 2 (DRAK2) Is a Key Regulator and Molecular Marker in Chronic Lymphocytic Leukemia. 2020 , 21,		2
372	SOHO State of the Art Updates and Next Questions: Clonal Evolution in Chronic Lymphocytic Leukemia. 2020 , 20, 779-784		2
371	Educational Updates in Hematology Book: 25th Congress of the European Hematology Association, Virtual Edition 2020. 2020 , 4, e444		1
370	Aspartic Aminopeptidase Is a Novel Biomarker of Aggressive Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2020 , 12,	6.6	2
369	Driver Mutations and Single Copy Number Abnormalities Identify Binet Stage A Patients with Chronic Lymphocytic Leukemia with Aggressive Progression. 2020 , 9,		2
368	Evolution of Advanced Chronic Lymphoid Leukemia Unveiled by Single-Cell Transcriptomics: A Case Report. <i>Frontiers in Oncology</i> , 2020 , 10, 584607	5.3	
367	The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations. 2020 , 95, 1361-1367		7
366	High CXCR3 on Leukemic Cells Distinguishes from in Chronic Lymphocytic Leukemia: Evidence from CD5 and CD5 Clones. 2020 , 2020, 7084268		1
365	Chemokine Receptors CCR1 and CCR2 on Peripheral Blood Mononuclear Cells of Newly Diagnosed Patients with the CD38-Positive Chronic Lymphocytic Leukemia. 2020 , 9,		0
364	Treatment of Chronic Lymphocytic Leukemia. 2020 , 383, 460-473		75
363	MNDA controls the expression of MCL-1 and BCL-2 in chronic lymphocytic leukemia cells. 2020 , 88, 68-82.e5		2
362	Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia. 2020 , 190, 901-908		8
361	Assessing prognosis of chronic lymphocytic leukemia using biomarkers and genetics. 2020 , 8, 329-342		2
360	Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. 2020 , 10, 86		5
359	Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia. 2020 , 8, 40		10

358	Whole-exome and whole-genome sequencing in chronic lymphocytic leukemia: new biomarkers to target. 2020 , 21, 957-962		
357	Importance of Crosstalk Between Chronic Lymphocytic Leukemia Cells and the Stromal Microenvironment: Direct Contact, Soluble Factors, and Extracellular Vesicles. <i>Frontiers in Oncology</i> , 2020 , 10, 1422	5.3	11
356	A reduced panel of eight genes (ATM, SF3B1, NOTCH1, BIRC3, XPO1, MYD88, TNFAIP3, and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia. 2021 , 43, 683-692		3
355	The prevalence and characterisation of TRAF3 and POT1 mutations in canine B-cell lymphoma. 2020 , 266, 105575		1
354	Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome. 2020 , 11, 594841		6
353	Chronic Lymphocytic Leukemia-Induced Humoral Immunosuppression: A Systematic Review. 2020 , 9,		7
352	Unsupervised machine learning and prognostic factors of survival in chronic lymphocytic leukemia. 2020 , 27, 1019-1027		9
351	Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies. <i>Cancers</i> , 2020 , 12,	6.6	15
350	Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. <i>Blood</i> , 2020 , 135, 2402-2412	2.2	43
349	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020 , 135, 1859-1869	2.2	45
348	Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients. 2020 , 11, 854		5
347	Evaluation of Somatic Hypermutation Status in Chronic Lymphocytic Leukemia (CLL) in the Era of Next Generation Sequencing. 2020 , 8, 357		3
346	Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing. 2020 , 34, 2545-2551		15
345	Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape. 2020 , 21, 24		22
344	Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived. 2020 , 22, 36		14
343	Educational Case: Small Lymphocytic Lymphoma: Diagnostic Features and Prognosis. 2020 , 7, 2374289519898859		
342	Tracing CLL-biased stereotyped immunoglobulin gene rearrangements in normal B cell subsets using a high-throughput immunogenetic approach. 2020 , 26, 25		9
341	Precision Medicine Management of Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2020 , 12,	6.6	16

340	Prognostic and Predictive Molecular Biomarkers in Chronic Lymphocytic Leukemia. 2020 , 22, 1114-1125		8
339	IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms. 2020 , 11, 3390		8
338	B cell signalling pathways-New targets for precision medicine in chronic lymphocytic leukaemia. 2020 , 92, e12931		4
337	Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. 2020 , 105, 2205-2217		21
336	Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients. 2020 , 10, 14		3
335	Is There a Role for Chemotherapy in the Era of Targeted Therapies?. 2020 , 15, 72-82		2
334	Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). 2020 , 105, 2598-2607		20
333	B Cell Receptor Immunogenetics in B Cell Lymphomas: Immunoglobulin Genes as Key to Ontogeny and Clinical Decision Making. <i>Frontiers in Oncology</i> , 2020 , 10, 67	5.3	12
332	is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. 2020 , 117, 4320-4327		24
331	Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group. 2020 , 34, 1038-1051		14
330	Do we need to analyse everything at diagnosis in chronic lymphocytic leukaemia?. 2020 , 189, 603-604		1
329	Genomic and Epigenomic Alterations in Chronic Lymphocytic Leukemia. 2020 , 15, 149-177		8
328	Impact of using leader primers for IGHV mutational status assessment in chronic lymphocytic leukemia. 2020 , 34, 2257-2259		2
327	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. <i>Blood</i> , 2020 , 135, 1204-1213	2.2	81
326	An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy. <i>Cancers</i> , 2020 , 12,	6.6	13
325	Diagnose und Behandlung der chronischen lymphatischen Leukämie. 2020 , 15, 8-16		
324	DAPK3 participates in the mRNA processing of immediate early genes in chronic lymphocytic leukaemia. 2020 , 14, 1268-1281		0
323	CLL intracлонаl fractions exhibit established and recently acquired patterns of DNA methylation. 2020 , 4, 893-905		1

322	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. 2020 , 105, 1613-1620		6
321	Prognosis Assessment of Early-Stage Chronic Lymphocytic Leukemia: Are We Ready to Predict Clinical Evolution Without a Crystal Ball?. 2020 , 20, 548-555.e4		5
320	Chronic Lymphocytic Leukemia. 2021 , 11,		11
319	Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia. 2021 , 106, 1608-1615		4
318	Pseudohyperkalemia in Serum and Plasma: The Phenomena and Its Clinical Implications. 2021 , 36, 235-238		0
317	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. <i>Blood</i> , 2021 , 137, 1365-1376	2.2	26
316	Reading the B-cell receptor immunome in chronic lymphocytic leukemia: revelations and applications. 2021 , 93, 14-24		2
315	Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia. 2021 , 124, 474-483		3
314	An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia. 2021 , 17, 371-387		0
313	IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics. <i>Blood</i> , 2021 , 137, 2935-2946	2.2	12
312	Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. 2021 , 2, 54-69		6
311	ER Stress and Unfolded Protein Response in Leukemia: Friend, Foe, or Both?. 2021 , 11,		5
310	T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword. 2020 , 11, 612244		10
309	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021 , 106, 493-499	3.8	1
308	Molecular Genetics in Indolent Lymphomas. 2021 , 5-20		
307	Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia. 2021 , 12, 665		3
306	HELQ and EGR3 expression correlate with IGHV mutation status and prognosis in chronic lymphocytic leukemia. 2021 , 19, 42		
305	Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. 2021 , 14, 17		4

304	Assessing technical and biological variation in SWATH-MS-based proteomic analysis of chronic lymphocytic leukaemia cells. 2021 , 11, 2932		2
303	The utility and limitations of B- and T-cell gene rearrangement studies in evaluating lymphoproliferative disorders. 2021 , 53, 157-165		1
302	Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review. 2021 , 13, 1459-1476		0
301	Prognostic factors and effectiveness of the first-line therapy for chronic lymphocytic leukemia: results of 10-year follow-up. 2021 , 27, 80-96		1
300	A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. 2021 , 39, 380-393.e8		7
299	mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies. 2021 , 4, 424		5
298	MARCKS affects cell motility and response to BTK inhibitors in CLL. <i>Blood</i> , 2021 , 138, 544-556	2.2	2
297	T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective. 2021 , 106, 1234-1243		2
296	References. 2021 , 301-427		
295	B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation. <i>Blood</i> , 2021 , 138, 1053-1066	2.2	6
294	Extracellular vesicles and their associated miRNAs as potential prognostic biomarkers in chronic lymphocytic leukemia. 2021 , 23, 66		1
293	From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct. <i>Cancers</i> , 2021 , 13,	6.6	1
292	Subgroup-specific gene expression profiles and mixed epistasis in chronic lymphocytic leukemia.		1
291	The future of laboratory testing in chronic lymphocytic leukaemia. 2021 , 53, 377-384		0
290	Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia. 2021 , 9, 37		2
289	The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment. 2021 , 11,		2
288	Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective. 2021 , 2, 628-634		0
287	Clinical outcome and prognostic factors in dogs with B-cell chronic lymphocytic leukemia: A retrospective study. 2021 , 35, 1918-1928		2

286	Reliable IGHV status assessment by next generation sequencing in routine practice for chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2800-2803	1.9	0
285	Challenges with Approved Targeted Therapies against Recurrent Mutations in CLL: A Place for New Actionable Targets. <i>Cancers</i> , 2021 , 13,	6.6	1
284	Identification of Clinically Relevant Subgroups of Chronic Lymphocytic Leukemia Through Discovery of Abnormal Molecular Pathways. 2021 , 12, 627964		0
283	Immune Gene Rearrangements: Unique Signatures for Tracing Physiological Lymphocytes and Leukemic Cells. 2021 , 12,		0
282	The complex karyotype landscape in chronic lymphocytic leukemia allows to refine the risk of Richter syndrome transformation. 2021 ,		8
281	Predominant VH1-69 IgBCR Clones Show Higher Expression of CD5 in Heterogeneous Chronic Lymphocytic Leukemia Populations. <i>Frontiers in Oncology</i> , 2021 , 11, 703254	5.3	0
280	Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?. <i>Cancers</i> , 2021 , 13,	6.6	1
279	Acalabrutinib in treatment-naive chronic lymphocytic leukemia. <i>Blood</i> , 2021 , 137, 3327-3338	2.2	18
278	Exploring the pathways to chronic lymphocytic leukemia. <i>Blood</i> , 2021 , 138, 827-835	2.2	3
277	Resistance Mutations to BTK Inhibitors Originate From the NF-B but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway. 2021 , 12, 689472		6
276	An Updated Review of Chronic Lymphocytic Leukemia. 2021 , 96, 195-208		
275	Towards Control Of Chronic Lymphocytic Leukemia With Targeted Agents. 2021 , 39,		1
274	Multivariate transcriptome analysis identifies networks and key drivers of chronic lymphocytic leukemia relapse risk and patient survival. 2021 , 14, 171		1
273	Proteomics-based identification of cancer-associated proteins in chronic lymphocytic leukaemia. 2021 , 52, 1-12		0
272	Repertoire of Rearranged Immunoglobulin Heavy Chain Genes in Russian Patients With B-Cell Lymphoproliferative Diseases. 2021 , 21, e938-e945		1
271	Temporal variation in lymphocyte proteomics.		
270	Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPPOS activity in chronic lymphocytic leukemia. 2021 , 2, 853-864		2
269	ENDOG Impacts on Tumor Cell Proliferation and Tumor Prognosis in the Context of PI3K/PTEN Pathway Status. <i>Cancers</i> , 2021 , 13,	6.6	2

- 268 The Biology of Chronic Lymphocytic Leukemia: Diagnostic and Prognostic Implications. **2021**, 27, 266-274 ○
- 267 Perspectives on Precision Medicine in Chronic Lymphocytic Leukemia: Targeting Recurrent Mutations-NOTCH1, SF3B1, MYD88, BIRC3. **2021**, 10, ○
- 266 Potential Relevance of B-cell Maturation Pathways in Defining the Cell(s) of Origin for Chronic Lymphocytic Leukemia. **2021**, 35, 665-685 1
- 265 Altered DNA Methylation Profiles in Mutated CLL Patients. **2021**, 22, ○
- 264 Immunoglobulin Variable Heavy Chain Somatic Hypermutation Testing in a Patient with Small Lymphocytic Lymphoma and Multiple Myeloma. **2021**, 6, 1665-1670
- 263 The Significance of B-cell Receptor Stereotypy in Chronic Lymphocytic Leukemia: Biological and Clinical Implications. **2021**, 35, 687-702 ○
- 262 SAMHD1 in cancer: curse or cure?. **2021**, 1 ○
- 261 CRIS: complete reconstruction of immunoglobulin sequences from RNA-seq data. **2021**, 1, vbab021 ○
- 260 The road to chemotherapy-free treatment in chronic lymphocytic leukaemia. **2021**, 33, 670-680 ○
- 259 From Descriptive to Functional Genomics of Leukemias Focusing on Genome Engineering Techniques. **2021**, 22, 2
- 258 Molecular Pathology of Mature Lymphoid Malignancies. **2021**, 14, 529-547
- 257 Old Prognostic Markers Still Have a Role in CLL Management. **2021**, 21, S139-S141
- 256 Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM). **2021**, 16, e0257353
- 255 Chronic lymphocytic leukemia in a young population. **2021**, 110, 106668 ○
- 254 Immunomolecular evaluation of dihydroartemisinin effects on apoptosis in chronic lymphocytic leukemia cell lines. **2021**, 110, 106702
- 253 The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients. **2021**, 110, 106686
- 252 Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study. **2021**, 36, 194-204 3
- 251 Incorporating molecular biomarkers into the continuum of care in chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2021**, 62, 1289-1301 1.9 ○

250 Mature B-Cell Neoplasms. **2021**, 339-359

249	Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative. 2021 , 100, 825-830	1
248	Lymphoid Malignancies.	3
247	Chronic Lymphocytic Leukemia. 211-227	1
246	Chronic lymphocytic leukaemia: clinical translations of biological features. 2005 , 294, 165-85	6
245	New insights into the phenotype and cell derivation of B cell chronic lymphocytic leukemia. 2005 , 294, 31-49	27
244	Clinical and laboratory parameters that define clinically relevant B-CLL subgroups. 2005 , 294, 109-33	10
243	The indolent B-cell lymphomas. 2006 , 131, 89-120	2
242	Gene expression profiling in malignant lymphomas. 2007 , 593, 134-46	5
241	B cell receptor and antigens in CLL. 2013 , 792, 1-24	6
240	Determining the Origin of Human Germinal Center B Cell-Derived Malignancies. 2017 , 1623, 253-279	1
239	Staging of Chronic Lymphocytic Leukemia. 2004 , 193-199	1
238	Guidelines for Clinical Management of CLL. 2004 , 219-240	1
237	Young Patients With Chronic Lymphocytic Leukemia. 2004 , 401-413	3
236	Molecular Biology of Chronic Lymphocytic Leukemia. 2004 , 77-94	1
235	Cutaneous B-Cell Lymphomas. 2011 , 247-262	2
234	CD5 and other superantigens may select and maintain rabbit self-renewing B-lymphocytes and human B-CLL cells. 2000 , 252, 87-96	5
233	Chronic lymphocytic leukemia/small lymphocytic lymphoma. 81-102	1

232	Historical aspects of chronic lymphocytic leukaemia. 2000 , 111, 1023-34		2
231	Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia. 2000 , 111, 230-8		25
230	Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia. 2000 , 111, 608-17		33
229	Association of CD38 Antigen Expression with Other Prognostic Parameters in Early Stages of Chronic Lymphocytic Leukemia. <i>Leukemia and Lymphoma</i> , 2001 , 42, 1315-1321	1.9	24
228	Pathological RANK signaling in B cells drives autoimmunity and chronic lymphocytic leukemia. 2021 , 218,		3
227	Molecular/Cytogenetic Education for Hematopathology Fellows. 2020 , 154, 149-177		2
226	The diagnostic chronic lymphocytic leukaemia genome by nanopore sequencing.		1
225	Impact of Genetics on Mature Lymphoid Leukemias and Lymphomas. 2020 , 10,		1
224	Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations. 2020 , 189, 853-859		6
223	Immunoglobulin heavy variable somatic hyper mutation status in chronic lymphocytic leukaemia: on the threshold of a new era?. 2020 , 189, 809-810		4
222	Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. 2004 , 113, 1008-16		162
221	Ig V region restrictions in human chronic lymphocytic leukemia suggest some cases have a common origin. 2004 , 113, 952-4		8
220	In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. 2005 , 115, 755-64		453
219	HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. 2005 , 115, 1644-50		58
218	Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients. 2008 , 118, 306-15		19
217	Implications of new prognostic markers in chronic lymphocytic leukemia. 2012 , 2012, 76-87		38
216	Mutational Status of Ig VH Genes Provides Clinically Valuable Information in B-Cell Chronic Lymphocytic Leukemia. <i>Blood</i> , 1999 , 94, 1837-1839	2.2	1
215	Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia. <i>Blood</i> , 1999 , 94, 1840-1847	2.2	34

214	Immunoglobulin V genes and CD38 expression in CLL. <i>Blood</i> , 2000 , 95, 2455-2457	2.2	4
213	Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. <i>Blood</i> , 2000 , 96, 377-379	2.2	4
212	High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. <i>Blood</i> , 2000 , 96, 1505-1511	2.2	1
211	Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. 2012 , 7, e35178		56
210	IGHV1-69-encoded antibodies expressed in chronic lymphocytic leukemia react with malondialdehyde-acetaldehyde adduct, an immunodominant oxidation-specific epitope. 2013 , 8, e65203		10
209	VDJSeq-Solver: in silico V(D)J recombination detection tool. 2015 , 10, e0118192		11
208	Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemia. 2015 , 10, e0118801		12
207	The Number of Overlapping AID Hotspots in Germline IGHV Genes Is Inversely Correlated with Mutation Frequency in Chronic Lymphocytic Leukemia. 2017 , 12, e0167602		2
206	HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis. 2017 , 12, e0172978		2
205	Dysregulation of H/ACA ribonucleoprotein components in chronic lymphocytic leukemia. 2017 , 12, e0179883		7
204	Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. 2018 , 13, e0193249		5
203	Use of V H, D and J H immunoglobulin gene segments in Brazilian patients with chronic lymphocytic leukaemia (CLL). 2008 , 31, 643-648		3
202	Specificity and biologic activities of novel anti-membrane IgM antibodies. 2016 , 7, 74701-74723		1
201	The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. 2017 , 8, 25942-25954		19
200	Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients. 2017 , 8, 25455-25468		7
199	What are genome-wide association studies telling us about B-cell tumor development?. 2010 , 1, 367-372		8
198	CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia. 2017 , 8, 42571-42587		31
197	Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling. 2017 , 8, 71981-71995		14

196	Efficient lysis of B-chronic lymphocytic leukemia cells by the plant-derived sesquiterpene alcohol Bisabolol, a dual proapoptotic and antiautophagic agent. 2018 , 9, 25877-25890	5
195	Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans. 2015 , 6, 5426-34	40
194	Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. 2015 , 6, 29833-46	25
193	Comprehensive assessment of potential multiple myeloma immunoglobulin heavy chain V-D-J intraclonal variation using massively parallel pyrosequencing. 2012 , 3, 502-13	16
192	Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. 2016 , 7, 4598-610	34
191	Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia. 2016 , 7, 20520-31	24
190	Assessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia. 2016 , 7, 32846-53	32
189	ZAP-70 and CD38 expression are independent prognostic factors in patients with B-cell chronic lymphocytic leukaemia and combined analysis improves their predictive value. 2008 , 46, 147-52	7
188	THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT. 2018 , 23, 283-301	2
187	Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. 2021 , 106, 87-97	17
186	Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV- Unmutated Chronic Lymphocytic Leukemia. 2020 , 10,	2
185	Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies. 2020 , 60, 146-158	2
184	Chronic lymphocytic leukaemia in Norway--incidence and prognostic markers at diagnosis. 2012 , 132, 2056-9	7
183	Recent advances in chronic lymphocytic leukemia therapy. 2020 , 55, S72-S82	3
182	Expression of miR-15a and miR-16-1 in patients with chronic lymphocytic leukemia. 2013 , 157, 284-93	12
181	ZAP70 Expression Within del6q21, del11q13 and del17p13 Cytogenetic Subgroups of Iranian Patients with Chronic Lymphocytic Leukemia. 2014 , 16, e22528	1
180	FISH Analysis for del6q21 and del17p13 in B-cell Chronic Lymphocytic Leukemia in Iranians. 2013 , 15, 107-12	5
179	Molecular diagnostics on lymphoid malignancies. 2004 , 128, 1379-84	3

- 178 A case of chronic lymphocytic leukemia with unmutated variable region of the immunoglobulin heavy chain gene with markedly high lactate dehydrogenase responding to ibrutinib. **2021**, 12, 172
- 177 The Hydropathy Index of the HCDR3 Region of the B-Cell Receptor Identifies Two Subgroups of IGHV-Mutated Chronic Lymphocytic Leukemia Patients With Distinct Outcome. *Frontiers in Oncology*, **2021**, 11, 723722 5.3
- 176 Molecular pathogenesis of B-cell chronic lymphocytic leukemia: analysis of 13q14 chromosomal deletions. **2000**, 252, 275-84 8
- 175 Somatic mutation of bcl-6 genes can occur in the absence of VH mutations in chronic lymphocytic leukemia. *Blood*, **2000**, 95, 3534-3540 2.2 3
- 174 Chronic Lymphocytic Leukemia. **2002**, 497-503
- 173 La Leucémie Lymphoïde Chronique : une maladie unique ou deux maladies distinctes ?. **2002**, 186, 1251-1268
- 172 Chronisch lymphatische Leukämie vom B-Zell-Typ (B-CLL). **2003**, 393-410
- 171 The Heterogeneous Origin of the B-CLL Cell. **2004**, 95-107
- 170 Prognostic Indicators of Chronic Lymphocytic Leukemia. **2004**, 201-215 1
- 169 Autologous and Allogeneic Transplantations for Chronic Lymphocytic Leukemia. **2004**, 255-268
- 168 Autoimmune and Hypersplenic Cytopenias. **2004**, 361-376
- 167 Genetics of B-Cell Chronic Lymphocytic Leukemia. **2004**, 57-75
- 166 Molecular Diagnostics in Neoplastic Hematopathology. **2004**, 233-259
- 165 Molecular and Pathological Characterization of Human Tumors. **2004**, 215-232
- 164 New Applications of Flow Cytometry in Cancer Diagnosis and Therapy. **2004**, 199-232
- 163 Chronische lymphatische Leukämie. **2004**, 1975-2000
- 162 Molecular Pathology of Hematological Malignancies. **2004**, 239-277
- 161 Common Cytogenetic Abnormalities. **2004**, 163-171

- 160 Nodal B-Cell Lymphoma. **2004**, 19-120 3
- 159 Chronische lymphatische Leukämie/lymphoplasmozytoides Lymphom. **2006**, 2845-2886
- 158 Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia. **2006**, 406-414
- 157 Gene expression profiling data in lymphoma and leukemia: review of the literature and extrapolation of pertinent clinical applications. **2006**, 130, 483-520 24
- 156 Leucémie lymphoïde chronique. **2007**, 339-346
- 155 Flow cytometric detection of ZAP-70 in chronic lymphocytic leukemia: correlation with immunocytochemistry and Western blot analysis. **2007**, 131, 50-6 12
- 154 Chronic Lymphocytic Leukaemia.
- 153 Molecular Diagnostics of Lymphoid Malignancies. **2008**, 655-674
- 152 Chronic Lymphoid Leukemias. **2008**, 2293-2308
- 151 Chronic Lymphocytic Leukemia and the B-Cell Receptor. **2008**, 45-67
- 150 Origin and Nature of Chronic Lymphocytic Leukemia B Cells. **2008**, 1-18 1
- 149 Stem Cell Transplantation in CLL. **2008**, 185-200
- 148 Gene Expression Profiling in the Study of Chronic Lymphocytic Leukemia. **2008**, 19-33
- 147 CLL-Specific Complications. **2008**, 231-260
- 146 Differential Diagnosis, Staging and Prognostic Factors. **2008**, 103-119 2
- 145 Stem Cells in Leukemia and Other Hematological Malignancies. **2009**, 111-136
- 144 Gene Expression Profiling. **2010**, 177-189
- 143 Prognostic Markers. **2010**, 65-72

- 142 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. **2010**, 211-220
- 141 Myelodysplastic Syndromes and Chronic Myeloproliferative Neoplasms. **2010**, 293-312
- 140 Genesis and consequences of genetic lesions in lymphoid neoplasms. **2010**, 361-379
- 139 MicroRNAs in Leukemia. **2011**, 269-285
- 138 Diagnosis of Leukemias: New Diagnostic Modalities and Implications for Classification. 43-55
- 137 The Role of Stem-Cell Transplantation in Chronic Lymphocytic Leukemia. 315-326
- 136 Encyclopedia of Cancer. **2011**, 351-356
- 135 Lymphomas of the Bone Marrow. **2011**, 341-393
- 134 Molecular Diagnosis of Hematopoietic Neoplasms. **2011**, 1415-1440
- 133 Chronic Lymphocytic Leukemia: Pathophysiology, Diagnosis and Manifestations, and Prognostic Markers. 297-307
- 132 T(11;18)(q21;q21)-positive gastrointestinal MALT lymphomas are heterogeneous with respect to the V(H) gene mutation status. **2011**, 3, 24-32
- 131 Special Situations: Management of Elderly Patients and Chronic Lymphocytic Leukemia in Transformation. 327-337
- 130 Molecular Biology of Chronic Lymphoproliferative Disorders. 191-210
- 129 Lymphoid Leukaemias of Mature T, B and Natural Killer Cells. 301-376
- 128 Diseases. 160-300
- 127 High-dose therapy with autologous stem cell transplantation for patients with chronic lymphocytic leukaemia.
- 126 B-Cell Leukemias of Mature Lymphocytes. **2012**, 387-402
- 125 Cutaneous lymphoproliferative diseases and related disorders. **2012**, 1311-1420

- 124 Kapitel E1 Literaturverzeichnis zu Peter, Pichler, Müller-Ladner (Hrsg.): Klinische Immunologie. **2012**, e1-e80
- 123 Chronic Lymphocytic Leukemia: From Pathobiology to Targeted Therapy. **2012**, 43-52
- 122 Bone Marrow Involvement in Primary Mature B and T Cell Leukemias. **2012**, 171-189
- 121 Tumours of the Immune System.
- 120 Where Do We Stand in the Genomics of Lymphomas?. **2013**, 495-541
- 119 Prognostic Factors in B-Cell Lymphomas. **2013**, 101-139
- 118 Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia. **2013**, 65-82
- 117 Chronic Lymphocytic Leukaemia.
- 116 Molecular Diagnostics of Lymphoid Neoplasms. **2014**, 521-555 1
- 115 MicroRNAs in Hematologic Malignancies. **2014**, 67-95
- 114 Chronische lymphatische Leukämie. **2014**, 1-10
- 113 Lymphoma, Non-Hodgkin's. **2014**,
- 112 Molecular Testing in Hematologic Malignancies. **2014**, 135-167
- 111 Chronic Lymphocytic Leukemia. **2014**, 1958-1978.e7
- 110 Encyclopedia of Cancer. **2014**, 1-6
- 109 High-dose therapy with autologous stem cell transplantation for patients with chronic lymphocytic leukaemia.
- 108 Apoptosis Pathways in Chronic Lymphocytic Leukemia: Role of the Microenvironment and Therapeutic Strategies. **2015**, 73-98
- 107 Chronic Lymphocytic Leukemia at the Genomic Level. **2015**, 57-72

106 Hematolymphoid Lesions. **2015**, 323-388

105 ZAP-70 protein expression in B-cell chronic lymphoid leukemia: a single center experience from Pakistan. **2015**, 16, 1587-90

4

104 Cytogenetics: Applications. **2016**, 67-82

103 Somatic Mutation in Immunoglobulin Gene Variable Region in Patients With Chronic Lymphoid Leukemia and Its Influence on Disease Prognosis. **2016**, 3,

102 Encyclopedia of Cancer. **2017**, 441-446

101 Molecular Diagnostics of Lymphoid Malignancies. **2017**, 103-129

100 Effect of IGHV Gene Mutation Status and BCR Structure Stereotypy on Effectiveness of BR Regimen in First-Line Therapy of Chronic Lymphocytic Leukemia. **2017**, 10, 141-149

99 Chronic Myeloid Leukemia (CML) and Chronic Lymphocytic Leukemia (CLL). **2017**,

98 B-Cell Leukemias of Mature Lymphocytes. **2018**, 397-413.e2

97 Prognostic Indicators in CLL: Clinical, Cytogenetics, Novel Mutations, MicroRNAs, Hierarchal Classification. **2018**, 35-60

1

96 Treatment of repeatedly relapsing chronic lymphocytic leukemia. **2018**, 12, 139-143

95 Clinical Evaluation and Management of Chronic Lymphocytic Leukemia. **2019**, 401-409

94 Telomere dynamics in adult hematological malignancies. **2019**, 163, 1-7

3

93 HSP90 overexpression potentiates the B-cell receptor and fibroblast growth factor receptor survival signals in chronic lymphocytic leukemia cells. **2020**, 11, 2037-2046

1

92 HLA allele repertoire in Russian chronic lymphocytic leukemia patients with an unfavorable prognosis. **2020**, 65, 312-320

91 Why is amyloidosis not multiple myeloma?. *Blood*, **2021**, 138, 1514-1515

2.2

90 Profiling of biological and environmental risk factors in immunogenetic subgroups of chronic lymphocytic leukemia - Czech national study. **2020**, 164, 425-434

89 An overlapping case of in situ mantle cell neoplasia and leukemic non-nodal mantle cell lymphoma. **2020**, 60, 169-173

88	EXPRESSION OF LIPOPROTEIN LIPASE AND c-MYC ONCOGENE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AFFECTED BY THE CHORNOBYL ACCIDENT. 2020 , 25, 421-429		
87	Small B-Cell Lymphomas With and Without Plasmacytic Differentiation. 2020 , 87-121		
86	Distinctive Signaling Profiles With Distinct Biological and Clinical Implications in Aggressive CLL Subsets With Stereotyped B-Cell Receptor Immunoglobulin. <i>Frontiers in Oncology</i> , 2021 , 11, 771454	5.3	3
85	Chronic Lymphocytic Leukemia and Related Chronic Leukemias. 2006 , 1210-1228		
84	Targeted Therapy in Chronic Lymphocytic Leukemia. 2008 , 61-86		
83	Non-Hodgkin-Lymphome niedriger Malignität. 342-384		
82	Lymph nodes and spleen. 688-812		1
81	Understanding Monoclonal B Cell Lymphocytosis: An Interplay of Genetic and Microenvironmental Factors. <i>Frontiers in Oncology</i> , 2021 , 11, 769612	5.3	0
80	How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen.. 2021 , 28, 4611-4633		0
79	B-cell receptor isotypes differentially associate with cell signaling, kinetics, and outcome in chronic lymphocytic leukemia. 2021 ,		1
78	Role of Par-4 in B-Cell Hematological Malignancies. 2021 , 133-148		
77	Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.. <i>Leukemia and Lymphoma</i> , 2022 , 1-12	1.9	2
76	Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia.. 2022 ,		0
75	B cell receptor antigen expression and phosphatidylinositol 3-kinase signaling regulate genesis and maintenance of mouse chronic lymphocytic leukemia.. 2022 ,		1
74	Biological and Clinical Insight from Analysis of the Tumor B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia.. <i>Cancers</i> , 2022 , 14,	6.6	1
73	InterTADs: integration of multi-omics data on topologically associated domains, application to chronic lymphocytic leukemia.. 2022 , 4, lqab121		0
72	[Chronic lymphocytic leukemia].. 2022 ,		
71	Druggable Molecular Pathways in Chronic Lymphocytic Leukemia.. 2022 , 12,		

70	TGF- β /SMAD Pathway Is Modulated by miR-26b-5p: Another Piece in the Puzzle of Chronic Lymphocytic Leukemia Progression.. <i>Cancers</i> , 2022 , 14,	6.6	0
69	Proteogenomics refines the molecular classification of chronic lymphocytic leukemia.		0
68	Unmutated IGHV1-69 CLL Clone Displays a Distinct Gene Expression Profile by a Comparative qRT-PCR Assay.. 2022 , 10,		0
67	The Immune Microenvironment Shapes Transcriptional and Genetic Heterogeneity in Chronic Lymphocytic Leukemia.. 2022 ,		0
66	Memory B-cell like chronic lymphocytic leukaemia is associated with specific methylation profile of promoter and undetectable expression of gene.. 2022 , 1-8		0
65	CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia.. <i>Leukemia and Lymphoma</i> , 2022 , 1-7	1.9	0
64	Up to 8 Years Follow-up From RESONATE-2: First-Line Ibrutinib Treatment for Patients With Chronic Lymphocytic Leukemia.. 2022 ,		8
63	Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective.. <i>Frontiers in Oncology</i> , 2021 , 11, 790004	5.3	2
62	Molecular pathology of lymphoma. 257-276		
61	Network analysis reveals a major role for 14q32 cluster miRNAs in determining transcriptional differences between IGHV-mutated and unmutated CLL.		
60	Lower access to risk stratification tests and drugs, and worse survival of chronic lymphocytic leukaemia patients treated in public as compared to private hospitals in Brazil: A retrospective analysis of the Brazilian registry of chronic lymphocytic leukaemia.		
59	Modeling the B-cell receptor signaling on single cell level reveals a stable network circuit topology between non-malignant B cells and chronic lymphocytic leukemia cells and between untreated cells and cells treated with kinase inhibitors.. 2022 ,		
58	Activated CLL cells regulate IL17F producing Th17 cells in miR155 dependent and outcome specific manners.. 2022 ,		0
57	B-cell Receptor Signaling Induced Metabolic Alterations in Chronic Lymphocytic Leukemia Can Be Partially Bypassed by TP53 Abnormalities. 2022 , 6, e722		0
56	TRAF3 alterations are frequent in del-3'IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features.. 2022 ,		0
55	Neoantigens - the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders.. 2022 , 100969		0
54	ROR1 - An Orphan Becomes Apparent.. <i>Blood</i> , 2022 ,	2.2	4
53	Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL.		1

52	Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. <i>Blood</i> ,	2.2	4
51	Immunoglobulin Gene Mutational Status Assessment by Next Generation Sequencing in Chronic Lymphocytic Leukemia. 2022 , 153-167		0
50	High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in CLL patients.		0
49	Molecular Basis and Role of Siglec-7 Ligand Expression on Chronic Lymphocytic Leukemia B Cells. 13,		1
48	T-helper cell regulation of CD45 phosphatase activity by galectin-1 and CD43 governs chronic lymphocytic leukaemia proliferation.		
47	Immunoglobulin Gene Sequence as an Inherited and Acquired Risk Factor for Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2022 , 14, 3045	6.6	
46	Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group. <i>Leukemia and Lymphoma</i> , 1-14	1.9	0
45	Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench. <i>Cancers</i> , 2022 , 14, 3345	6.6	
44	Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 12,	5.3	0
43	Low CD49d Expression in Newly Diagnosed Chronic Lymphocytic Leukaemia May be Associated with High-Risk Features and Reduced Treatment-Free-Intervals .. <i>European Journal of Haematology</i> ,	3.8	
42	Left truncation in linked data: A practical guide to understanding left truncation and applying it using SAS and R. <i>Pharmaceutical Statistics</i> ,	1	
41	Myeloma and Leukemia. 2023 , 503-528		
40	The molecular biology and therapeutic potential of Nrf2 in leukemia. 2022 , 22,		0
39	Genetic Testing at Diagnosis Has Prognostic Value in Patients with Chronic Lymphocytic Leukemia including at Early Stages. 2022 , 12, 1802		
38	Genomic and transcriptional profiling stratifies VQ myeloma lines into two clusters with distinct risk signatures and drug responses.		
37	Spatial organization and early signaling of the B-cell receptor in CLL. 13,		
36	Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms.		1
35	A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression.		

- 34 Integrative epigenomics in chronic lymphocytic leukaemia: Biological insights and clinical applications. ○
- 33 PKC δ facilitates leukemogenesis in chronic lymphocytic leukaemia by promoting constitutive BCR-mediated signaling. ○
- 32 EXABS-176-CLL Clinical Significance of B-Cell Receptor Stereotype in CLL. **2022**, 22, S78-S80 ○
- 31 Loss of AID exacerbates the malignant progression of CLL. **2022**, 36, 2430-2442 ○
- 30 5'Rapid amplification of cDNA ends (5'RACE): A simpler method to analyze immunoglobulin genes and discover the value of the light chain in chronic lymphocytic leukemia. **2022**, 106952 ○
- 29 Management of front line chronic lymphocytic leukemia. **2022**, 97, 1
- 28 Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of TP53 and TP53 mutation. ○
- 27 Clinical and economic burden of first-line chemoimmunotherapy by risk status in chronic lymphocytic leukemia. 1-13 ○
- 26 Proteogenomics refines the molecular classification of chronic lymphocytic leukemia. **2022**, 13, ○
- 25 Chronic Lymphocytic Leukemia. 1-11 ○
- 24 Modern Approach to Prognostication and Therapy of Chronic Lymphocytic Leukemia. **2022**, ○
- 23 CD160 receptor in CLL: Current state and future avenues. 13, ○
- 22 Biological relevance of ZNF224 expression in chronic lymphocytic leukemia and its implication IN NF-kB pathway regulation. 9, ○
- 21 Old and New Facts and Speculations on the Role of the B Cell Receptor in the Origin of Chronic Lymphocytic Leukemia. **2022**, 23, 14249 1
- 20 Hematopoietic and Lymphoid Tumors. **2021**, 377-521 ○
- 19 Distinct Immunogenetic Profiles of Chronic Lymphocytic Leukemia in Asia: A Taiwan Cooperative Oncology Group Registry Study. **2022**, 6, e803 ○
- 18 Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. ○
- 17 Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. 1-12 ○

- 16 Evidence of somatic hypermutation in the antigen binding sites of patients with CLL harboring IGHV genes with 100% germline identity. 12, ○
- 15 PKC δ Facilitates Leukemogenesis in Chronic Lymphocytic Leukaemia by Promoting Constitutive BCR-Mediated Signalling. **2022**, 14, 6006 ○
- 14 High-throughput proteomics identifies THEMIS2 as independent biomarker of treatment-free survival in untreated CLL. ○
- 13 Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. ○
- 12 A novel next-generation sequencing capture-based strategy to report somatic hypermutation status using genomic regions downstream to immunoglobulin rearrangements. ○
- 11 Recent revelations and future directions using single-cell technologies in chronic lymphocytic leukemia. 13, ○
- 10 STEREOTYPED CASES IN UKRAINIAN COHORT OF CHRONIC LYMPHOCYtic LEUKEMIA PATIENTS DEPENDING ON THE IONIZING RADIATION EXPOSURE. **2022**, 27, 307-323 ○
- 9 Prediction of Clinical Outcomes with Explainable Artificial Intelligence in Patients with Chronic Lymphocytic Leukemia. **2023**, 30, 1903-1915 ○
- 8 Next-CLL. **2023**, ○
- 7 Expert consensus on the management of chronic lymphocytic leukaemia in Asia. ○
- 6 Genetic Lesions in Russian CLL Patients with the Most Common Stereotyped Antigen Receptors. **2023**, 14, 532 ○
- 5 B cell M-CLL clones retain selection against replacement mutations in their immunoglobulin gene framework regions. 13, ○
- 4 CLL stereotyped B-cell receptor immunoglobulin sequences are recurrent in the B-cell repertoire of healthy individuals: Apparent lack of central and early peripheral tolerance censoring. 13, ○
- 3 Precision diagnostics in chronic lymphocytic leukemia: Past, present and future. 13, ○
- 2 Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. **2023**, ○
- 1 Effectiveness of pegfilgrastim prophylaxis in preventing febrile neutropenia during R-FC chemoimmunotherapy for chronic lymphocytic leukemia: A multicenter prospective phase II study. 13, ○